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C'est pourquoi la meilleure part de notre memoire est hors de noun, 
dans un souffle pluvieux, dans l'odeur de renferme d'une chambre ou 
dans l'odeur d'une premiere flambee, partout oü nous retrouvons de 
nous-meme ce que notre intelligence, n'en ayant pas l'emploi, avait 
dedaigne, la deniere reserve du passe, la meilleure, celle qui, quand 
toutes nos larmes semblent taries, sait noun faire pleurer encore. Hors 
de nous? En nous pour mieux dire, mais derobee ä nos propres regards, 
dans un oubli plus ou moins prolonge. C'est grace ä cet oubli seul que 
nous pouvons de temps ä autre retrouver 1'etre que nous fumes, nous 
placer vis-ä-vis des choses comme cet eire 1'etait, souffrir a nouveau, 
parce que nous ne sommes plus nous, mais lui, et qu'il aimait ce qui 
nous est maintenant indifferent 
Marcel Proust 
"Ä 1 'ombre des jeunes filles enFleur" 
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The cannabinoid system is involved in many functions of mammalian brain, such as 
learning and memory, pain perception and 
'locomotion. The "brain type" cannabinoid 
receptor CB 1 is one of the key elements of the cannabinoid system. In this Thesis, some 
aspects of the neurobiology of mouse CB 1 are described. 
CB 1 mRNA distribution was analysed by single and double in situ hybridization 
(ISH), revealing the expression of the receptor in specific neuronal subpopulations. This 
expression pattern suggests many putative functional cross-talks between the 
cannabinoid system and other signalling molecules in the brain, such as glutamate, 
GABA, cholecystokinin and nitric oxide (NO). 
The putative functional interactions of the cannabinoid system with the NO 
pathway was studied by pharmacological treatment of neuronal NO synthase (nNOS) 
mutant mice with the CBI agonist A9-tetrahydrocannabinol (A9-THC). The results 
showed that nNOS is necessary for some central effects of A9-THC. Moreover, ISH 
analysis revealed. that nNOS-deficient mice contain levels of CBI lower than normal in 
selected brain regions. 
A "conditional" targeting approach was developed to gain insights into the specific 
functions of CB 1 in mouse brain. By gene targeting experiments, two mutant lines were 
obtained. The "Flox CB 1" mouse line, containing the whole open reading frame of CB I 
flanked by two loxP sites will be the key tool for the generation of mouse mutants with a 
spatiotemporal-restricted deletion of CB I. The "CBN" mice, carrying a "null" mutation 
of CB 1, were used for a study aimed to clarify some aspects of the in vitro 
neuroprotective activity of cannabinoids and, in particular, the involvement of CB 1. 
In vitro oxidative stress assays were performed on cell lines and on primary 
neuronal cultures derived from homozygous CBN/CBN mice and wild type littermates. 
The results indicate a differential protective activity of cannabinoids on cell lines and 
)rilnary cultures. However, CBI does not appear to be involved in the in vitro 
leuroprotective effects of cannabinoids. 
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Chapter 1 
Introduction. Overview of the cannabinoid system 
1.1 Historical aspects of Cannabis sativa: origin, diffusion and uses 
Cannabis sativa (C. S. ), also known as Marihuana, is one of the oldest cultivated 
plants and is considered one of the very first plants grown not specifically for their food 
content (reviewed by Peters & Nahas, 1999). C. S. was cultivated for two purposes: 
fibres for tissues and extracts for therapeutic and recreative purposes. First historical 
reports of the use of C. S. were found in China nearly 5000 years ago, where it was 
grown rather for fibers than for production of psychoactive extracts. From China, the use 
of C. S. moved to India, where it was mentioned as a sacred plant in the Atharva Veda 
(one of the holy books of hindu religion, 2000 BC). Herodotus reported the use of hemp 
among populations along the coasts of Caspian and Aral Seas (Historiae III, 440 BC). 
Romans and Greeks did not use C. S. as a pleasure-inducing drug as they preferred 
alcohol, but they cultivated the plant to obtain fibers to make ropes and sails. Some 
medical uses were described by the Greek physicians Dioscorides (De materia medica, 
ca. 60 AD) and Galen (129-210 AD). C. S. became very widespread in the Islamic world 
during the Middle Age. Through the Arab invasions (ninth to twelfth century AD) its use 
was diffused to all the southern Mediterranean coast, from Egypt to Morocco (Nahas, 
1982). Arab physicians such as al-Razi (900 AD) and al-Badri (1251 AD) described 
many details of medical uses of C. S. and recommended it for the ear, for dissolving 
flatulence, to cure epilepsy and to induce appetite (references from Peters & Nahas, 
1999). 
In the first half of the 18th century, the British physician O'Shaughnessy 
introduced C. S. into British medicine, after observing its use in India. He and other 
British physicians prescribed C. S. extracts for the treatment of rabies, rheumatism, 
2 
epilepsy, tetanus and as antialgesic (Nahas, 1973). In 1840, Jacques-Joseph Moreau, 
considered as the father of modern psychopharmacology, observed experimentally the 
properties of C. S. (Moreau, 1845). He compared the effects of C. S. extracts on himself 
to the symptoms observed with his mental patients. He described eight symptoms present 
either after C. S. intoxication or in mental illness: feeling of bliss, dissociation of ideas, 
errors of time and space appreciation, exacerbation of the sense of hearing, fixed ideas, 
disturbances of emotions, irresistible impulses and illusions. Interestingly, from such 
observations, he became convinced of the organic nature of mental illness and that 
"hashish [is] a unique powerful tool to deeply explore the mental pathologies". 
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Fig. 1.1. Schematic representation of the propagation of Cannabis sativa, through the ages. 
Marihuana smoking for recreational purposes reached the Americas via the 
African slaves deported to Brazil in the 17th century by the Portuguese. From Brazil, the 
use of "grass" (the translation of the Arabic word hashish) spread to central America and 
from there reached the U. S. A., where it was first the typical drug of black jazz musicians 
in the early 20th century. In the 1960s, it became widely diffused among university 
students and was then returned eastwards to Europe (Fig. 1.1). Today, C. S. extracts are 
ýýýý ýý 
ýý 
ýý 
1960.70 
the most widely used illicit drugs in western world. However, the therapeutic potential, 
3 
after many decades of oblivion, are again the focus of attention of scientific as well as 
social and political communities. 
1.2 Hallmarks in cannabinoid research 
Despite the long history, the mechanisms of action of C. S. derived drugs have not 
yet been completely understood. However, in the last decades, an impressive body of 
studies has led to many and important clarifications. An indicative progression of the 
scientific interest in C. S. can be obtained by a simple counting of the publications during 
the last three decades (Fig. 1.2). 
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Fig 1.2. Number of publications produced in recent decades, in relation to cannabinoid research. 
The values were obtained with a Medline search (http: //www. ncbi. nhn. nih. gov/entrez/query), 
using as keywords "cannabinoid OR marihuana" and limiting the search to two years' periods. 
Key discoveries are indicated. 
One of the first and most important steps in recent marihuana research was the 
purification of the major psychoactive compound in C. S., (-)-A9-tetrahydrocannabinol 
(A9-THC; Mechoulam & Gaoni, 1965; Petrzilka & Sikemeier, 1967). Since those 
pioneering studies, the number of published papers increased exponentially, indicating a 
high interest in the chemistry, biochemistry, biology and pharmacology of C. S. 
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derivatives (Fig 1.2). During the late 70s and the early 80s the number of publications 
seemed to decrease slightly, likely reflecting major difficulties in defining precise 
mechanisms of action of 09-THC and natural and synthetic cannabinoids. Due to the high 
lipophilicity of cannabinoid compounds, two mechanisms were postulated: a direct 
interaction with the cell membranes (Hillard et al., 1985) or an interaction mediated 
through still undiscovered membrane receptors (Howlett et al., 1986). Indicative data 
were present for both hypotheses. However, in 1988, the availability of new potent 
synthetic cannabinoid compounds, such as CP-55,940 (Johnson & Melvin, 1986), led to 
the discovery of a typical receptor-mediated interaction between cannabinoid compounds 
and biological tissues (Howlett et al., 1988). Such a finding, even though far from 
explaining all the effects of cannabinoids, represented a new impulse to the research. 
Two years later, Matsuda et al. (1990) cloned the first cannabinoid receptor (CBI) and 
opened the way to the molecular approach to the biology of cannabinoids. CB 1 was 
described as aG protein coupled receptor and was found to be expressed mainly in the 
brain, indicating a function in central effects of cannabinoids. Later, Munro et al. (1993) 
cloned a second receptor, named CB2, also able to bind cannabimimetic compounds, 
whose expression is limited to cells and tissues of the immune system. In this way, the 
early 90s paved the way towards the understanding of the mechanism(s) of action of 
exogenously administered C. S. derivatives and synthetic cannabinoids. However, one 
important piece of the puzzle was still missing: the endogenous ligands of the receptors, 
the so-called "endocannabinoids". One did not have a long time to wait to get such an 
answer. Devane et al. (1992) purified from porcine brains a novel compound that was 
able to bind and stimulate cannabinoid receptors. This compound is an amide of 
arachidonic acid and was named "anandamide", from the Sanskrit word for "bliss", 
ananda. Later, another endogenous ligand was described, 2-arachidonyl glycerol 
(Mechoulam et al., 1995; Sugiura et al., 1995). Furthermore, an active system for 
5 
anandamide uptake was uncovered in cells (Hillard et al., 1997; Beltramo et al., 1997; 
Bisogno et al., 1997a), and specific pathways were found that produce and degrade the 
endocannabinoids (Di Marzo et al., 1994). Such an impressive efflux of new data and 
discoveries led the "cannabinoid researchers" to postulate the existence of a new 
signalling system, made by endogenous compounds, their specific receptors and their 
specific mechanisms for production, release, uptake and degradation (reviewed by Di 
Marzo et al., 1998). Moreover, the functional interactions of the "cannabinoid system" 
with other physiological systems appear to be more and more relevant, participating in 
the maintenance of the physiological status and possibly being disregulated in 
pathophysiological conditions. As mentioned before, CB 1 and CB2 are expressed mainly 
in the brain and in the immune system, respectively. Therefore, it appears that two 
distinct (although likely interacting) "cannabinoid systems" exist, one related to brain 
function and the other to immunological activities. 
1.3 CB1, the "brain type" cannabinoid receptor 
1.3.1 Mechanisms of action 
Despite the possibility that cannabinoids could exert some of their actions 
through non receptor-mediated mechanisms, there is general agreement that most of such 
actions are mediated by specific receptors. At the moment, two "cannabinoid receptors" 
have been cloned: the "brain type" CB 1, expressed in the central nervous system, but 
also in many peripheral organs (Matsuda et al., 1990; Shire et al., 1995) although at 
lower levels and CB2, whose expression is limited to cells and organs of the immune 
system (Munro et al., 1993). Both CB 1 and CB2 are seven transmembrane G protein 
coupled receptors, generally coupled to Gi/o proteins. CB2 was cloned from a leukaemic 
cell line and has a relatively low sequence identity with CB 1 (44% overall the whole 
protein, 68% in the transmembrane regions) (Munro et al., 1993). CB 1 has been 
extensively characterised. In vitro studies, using primary neuronal cultures, neuronal cell 
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lines that endogenously express CB 1, heterologous expression of the receptor in other 
cell lines, or brain slices, have revealed that the intracellular signal transduction pathways 
stimulated by CB 1 activation are dependent on the system used. However, CB 1 is 
believed to exert its functions presumably through two main intracellular pathways: 
inhibition of adenylate cyclase and alterations of ion channels activity. However, in the 
recent years, also other intracellular pathways have been shown to be triggered by CB 1. 
1.3.1.1 Inhibition of adenylate cyclase 
A reversible, dose-dependent and stereoselective inhibitory action of A9-THC on 
adenylate cyclase activity in neuroblastoma cells was one of the key observations that led 
to the discovery of the existence of cannabinoid receptors (Howlett & Fleming, 1984; 
Howlett et al., 1986; Bidaut-Russell et al., 1990). Such an inhibition is mediated by 
inhibitory G proteins (G; /. ), because this effect can be blocked by pertussis toxin in 
neuroblastoma cells, in membranes derived from mammalian brain and in primary 
neuronal cultures (Howlett et al., 1986; Bidaut-Russel et al., 1990; Bouaboula et al., 
1995). Pertussis toxin is able to prevent the dissociation of the a and 0/7 subunits of Giro, 
thereby blocking the G protein-mediated inhibition of adenylate cyclase. Activation of 
G proteins was also shown by receptor-stimulated [31S]GTPyS binding to brain-derived 
membranes and to brain sections (Sim et al., 1995; Breivogel et al., 1997). Interestingly, 
the regional distribution of CB 1 receptor as revealed by radioligand binding, and the 
activation of G proteins by cannabinoid agonists are very similar, indicating that 
presumably all CB 1 receptors are able to activate G proteins. However, quantitative 
differences suggest that the receptor can have different coupling efficiencies in various 
brain regions (Sim et al, 1995; Childers & Breivogel, 1998; Ameri, 1999). The adenylate 
cyclase-cAMP-protein kinase A (PKA) pathway is one of the key mechanisms in 
neuronal physiology. As an example, cAMP-dependent gene expression appears to be 
universally required for establishing long-term memory (Silva et al., 1998; Alberini, 
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1999). Therefore, the inhibition of this pathway by cannabinoids acting at CBI can 
explain many of the pharmacological effects of cannabinoids, such as the inhibition of 
memory formation (Hampson & Deadwyler, 1998). The coupling of CB 1 to Gi/o proteins 
is considered one of the main mechanisms of action of the receptor, but evidence also 
exists indicating that different G protein subtypes are involved in CB 1 signal 
transduction. As an example, coupling with GS proteins was described in primary striatal 
neurons, after a simultaneous stimulation of CB 1 and D2 dopamine receptors (Glass & 
Felder, 1997). Another important element of the CB 1 signal transduction pathways is the 
ability of the receptor to sequester G proteins, rendering them unavailable for the action 
of other G protein coupled receptors (Vasquez & Lewis, 1999). 
1.3.1.2 Modulation of ion channels 
Gi/. is able to couple seven transmembrane receptors not only to adenylate 
cyclase, but also to ion channels. Studies on neuroblastoma cell lines and on primary 
neurons expressing CBI revealed that cannabinoid receptor activation inhibits voltage- 
activated inward calcium currents (Caulfield & Brown, 1992; Mackie & Hille, 1992). 
This effect appears to be mediated by Gi/., because it is blocked by pertussis toxin. In 
experiments using inhibitors of different calcium channel subtypes, it was shown that N- 
type and P/Q-type calcium channels are mainly involved in this effect of CB 1 (Mackie & 
Hille, 1992). Moreover, the addition of non-hydrolysible analogues of cAMP or 
inhibitors of phosphodiesterase did not alter the inhibitory effect of CB 1 onto calcium 
channels, thus indicating an adenylate cyclase-independent mechanism. CB 1 was shown 
to regulate also the actions of potassium channels. Early studies revealed that 
cannabinoids acting at CBI can modulate two potassium channels, the inwardly 
rectifying potassium (Kir) channel and the voltage-dependent A-type potassium channel. 
Inwardly rectifying potassium currents are enhanced by cannabinoids in a dose- and 
pertussis toxin-dependent manner, thus indicating a G; o-dependent process (Henry & 
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Chavkin, 1995; Mackie et al., 1995). Interestingly, a recent report by Garcia et al. (1998) 
showed that cannabinoid actions on Kir and on P/Q-type calcium channels can be 
strongly attenuated by phosphorylation of CB 1 at a single serine residue (S317) in the 
third cytoplasmic loop of the receptor by the action of protein kinase C (PKC), thus 
constituting a putative regulatory system of CB I. Deadwyler et al. (1993) have shown 
that the voltage-dependent potassium A currents (KA) are significantly enhanced in a 
concentration-dependent manner by CB 1 agonists in primary hippocampal cells. 
Fig. 1.3. Schematic representation of the main effects of CBI on ion channels. Activation of 
CB 1 leads to the stimulation of Gj1o proteins that, in turn, inhibits the adenylate cyclase-mediated 
conversion of ATP into cAMP. cAMP molecules can bind the regulatory subunits of protein 
kinase A (PKA) and cause the liberation of the catalytic subunits. Active PKA can phosphorylate 
A-type potassium channels (K+A), causing a decrease of the current. Given the negative effect of 
CB I on adenylate cyclase, the final result is an activation of A-type potassium channels. Gi/0 
activated by CB 1 can also directly inhibit N- or P/Q-type calcium channels and activate inwardly 
rectifying potassium channels (Kir). These last two effects are controlled by protein kinase C 
(PKC), that, when activated, can phosphorylate CBI in the third cytoplasmic loop and uncouple 
the receptor from the ion channels. 
The activation of A-type potassium channels (KA) by CB 1 is dependent on the 
inhibition of cAMP synthesis with the subsequent inhibition of a protein kinase A (PKA)- 
mediated phosphorylation of the channel, but not on a direct coupling of Gi/. proteins to 
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the A-type potassium channel (Deadwyler et al., 1993; Hampson et al., 1995; Childers 
and Deadwyler, 1996). 
Thus, cannabinoids acting at CB 1 are able to decrease the Ca`- influx by 
inhibiting N- and P/Q-type calcium channels and to increase the efflux of iC ions by 
activating inwardly rectifying potassium currents and A-type potassium channels (Fig. 3). 
Considering that i) the calcium channels are mainly located presynaptically and are 
necessary for evoked neurotransmitter release in the CNS (Takahashi & Momiyama, 
1993; Wheeler et al., 1994; Ameri, 1999), ii) the activation of potassium channels can 
amplify a presynaptic inhibition of calcium channels by reducing the duration of the 
action potential (Ameri, 1999), and iii) CB 1 is highly expressed in the presynaptic 
terminals (Herkenham et al., 1990,1991; Tsou et al., 1998a), it appears likely that CB 1 
plays a major role in the modulation of neurotransmitter release at synapses. Indeed, 
cannabinoids acting at CB 1 have been shown to inhibit the release of glutamate in 
cultured rat hippocampal cells (Shen et al., 1996), acetylcholine release in superfused rat 
hippocampal slices (Gifford et al., 1997), noradrenaline release in slices from human, 
guinea pig and rat hippocampus (Schlicker et al., 1997), and GABA release from rat 
hippocampal slices (Katona et al., 1999). Thus, the presynaptic inhibition of several 
neurotransmitters by cannabinoids can be considered as a plausible cellular mechanism 
underlying the psychoactive actions of cannabinoids. 
1.3.1.3 Other pathways triggered by CBI 
Inhibition of adenylate cyclase, stimulation of A-type and inwardly rectifying 
potassium currents, and inhibition of N- and P/Q-type calcium channels are considered as 
the main intracellular events induced by CB 1 in neurons. However, recent observations 
revealed additional regulatory mechanisms. In electrophysiological experiments on rat 
hippocampal slices, Schweitzer (2000) showed that cannabinoids acting at CB 1 are able 
to decrease the activity of postsynaptic potassium-persistent voltage-dependent M- 
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currents in CAI hippocampal pyramidal cells. This would indicate that cannabinoids may 
specifically increase the excitability of postsynaptic cells. Moreover, using microdialysis 
techniques, very recent results from Acquas et al. (2000) indicate an increase of 
acetylcholine release in hippocampus and frontal cortex of freely moving rats after in 
vivo treatment with low doses of cannabinoid agonists. It is therefore possible that 
cannabinoids acting at CB 1 can exert different intracellular effects in different brain areas 
or at different concentrations. Netzeband et al. (1999) showed that in primary cerebellar 
granule cells, CB 1 is able to enhance the peak amplitude of the Ca. 2+ response elicited by 
stimulation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors 
(NMDARs). This effect appears to involve pertussis toxin-sensitive G proteins (Gi/o) and 
the phopspholipase C (PLC)/inositol 1,4,5-trisphosphate (IP3) pathway, and finally 
results in an increased Ca 2+ release from intracellular stores. These data are very 
interesting in light of the facts that i) PLC and IP3 can trigger the activation of PKC 
(Schwartz & Kandel, 1991) and ii) PKC can inhibit, by phosphorylation of the third 
intracellular loop, the effects of CB 1 on calcium channels and inwardly rectifying 
potassium channels (Garcia et al., 1998). Therefore, it can be speculated that, in certain 
conditions (i. e. upon NMDAR activation by glutamate), cannabinoids acting at CB1 
might "switch" their effects on calcium mobility, by enhancing the release of Ca 2+ from 
intracellular stores, and by inhibiting, following PKC phosphorylation, their own effects 
on calcium channels and inwardly rectifying potassium channels. The involvement of IP3 
in the signal transduction cascade of CB 1 was also very recently shown by Gomez Del 
Pulgar et al. (2000). Using CB 1-transfected Chinese hamster ovary cells (CHO) and 
human glioma cells, these authors showed that cannabinoids can stimulate protein kinase 
B/Akt (PKB) in a CBI-, Gi/. - and IP3-dependent manner, thus, indicating a novel 
potential mechanism of cannabinoid action. Another potentially very interesting 
intracellular cascade triggered by CB 1 is the mitogen activated protein kinase (MAPK) 
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pathway. Bouaboula et al. (1995) showed that cannabinoid treatment of CB 1 transfected 
CHO cells was able to stimulate the phosphorylation of MAPKs in a receptor-dependent, 
pertussis toxin-sensitive and cAMP-independent manner. MAPKs pathway is very 
important in many aspects of neurophysiology, from differentiation and survival of 
neurons (Fukunaga & Miyamoto, 1998), to the induction of important forms of neuronal 
plasticity, such as long-term memory (Orban et al., 1999). However, thus far, the 
activation of MAPK by CBI receptor has only been found in non-neuronal cell lines 
artificially transfected with CB 1. Therefore, it is still uncertain whether it plays role in the 
CNS under physiological conditions. 
In conclusion, the inhibition of adenylate cyclase, the activation of A-type and 
inwardly rectifying potassium channels and the inhibition of N- and P/Q-type calcium 
channels appear as the prominent mechanisms through which cannabinoids acting at CB 1 
exert their intracellular effects. Nevertheless, other pathways can be, in different 
conditions, activated by CB1, and the direction of the research in the near future will 
likely focus not only on finding novel mechanisms of action, but also on defining the 
cellular status leading to the activation by cannabinoids of either of the intracellular 
pathways. Already the CB 1 signal transduction changes caused by simultaneous 
dopamine D2 receptors (Glass & Felder, 1997) and NMDAR activation (Netzeband et 
al., 1999) represent very interesting functional receptor cross talks that might contribute 
to the understanding of the different, and sometimes apparently divergent, effects of 
cannabinoids. 
1.3.2 Distribution of CB1 in the mammalian brain 
After the discovery of the existence of a cannabinoid receptor in the brain, the 
cannabinoid receptor distribution was first shown by autoradiography of ligand-receptor 
binding on slide-mounted rat brain sections, with the radiolabeled agonist [3H]CP 55,940 
(Herkenham et al., 1990,1991). Autoradiographic experiments using another radioligand 
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in rats, [3H] WIN 55,212-2, and [3H]CP 55,940 in humans, confirmed the general 
distribution of the receptor (Jansen et al., 1992; Glass et al., 1997a). It became quickly 
apparent that the quantity of receptor in the brain is very high, thus, CBI can be 
considered one of the most abundant G-protein coupled receptors in mammalian brain 
(Herkenham et al., 1990), comparable in quantity and density with glutamate receptors. 
After the cloning of CBI (Matsuda et al., 1990), the distribution of CBI was 
investigated at the mRNA level, by in situ hybridization (ISH) in rodents (e. g. Matsuda 
et al., 1993; Marsicano & Lutz, 1999) and in humans (Mailleaux et al., 1992; Westlake 
et al., 1994). More recently, anti-CBI antibodies became available, thus the 
immunohistochemical (IHC) distribution of the receptor was determined (Tsou et al., 
1998a; Pettit et al., 1998). Agonist-stimulated [35S]GTPYS binding to slide-mounted 
sections (Sim et al., 1995) is another interesting method that has been used to define the 
functional neuroanatomy of the brain type cannabinoid receptor (Breivogel & Childers, 
1998). 
The highest density of cannabinoid receptors has been demonstrated in basal 
ganglia (substantia nigra, globus pallidus, enteropeduncular nucleus and dorsolateral 
caudate putamen) and in the cerebellum. In these areas, discrepancies between mRNA 
(ISH) and protein (IHC and ligand binding) expression were observed, thus indicating 
the presence of the receptor on distal neuronal projections. As an example, substantia 
nigra pars reticulata does not contain CB1 mRNA, but is one of the most densely stained 
regions in immunohistochemical and ligand binding experiments (Mailleux & 
Vanderhaeghen, 1992; Westlake et al., 1994; Matsuda et al., 1993; Tsou et al., 1998a). 
High densities of binding were also described in the CA pyramidal cell layers of 
hippocampus (Herkenham et al. 1990). Such binding was shown by 
immunohistochemistry to be due to a dense plexus of immunoreactive fibres surrounding 
the cell bodies of pyramidal cells which appear per se devoid of CB 1 protein (Tsou et al., 
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1998a). However, pyramidal cells of hippocampus have been shown to express low but 
significant levels of CB 1 mRNA (Matsuda et al., 1993; Marsicano & Lutz, 1999; 
Chapter 2), thus again indicating the possibility that CB 1 protein is localised on distal 
projections of pyramidal CA hippocampal neurons. In hippocampus, neocortex (layers II, 
III, V and VI), entorhinal cortex, amygdaloid region (basomedial and basolateral 
amygdala), anterior olfactory nucleus, olfactory tubercle and piriform cortex, CB 1 is 
expressed (at mRNA and protein levels) both in scattered cells containing very high 
levels of the receptor and in more diffuse low-expressing neurons (Matsuda et al., 1993; 
Tsou et al., 1998a). In these cortical regions, scattered highly expressing cells are likely 
to be GABAergic interneuroris, while diffuse low-expressing cells are probably principal 
glutamatergic neurons (Katona et al., 1999; Marsicano & Lutz, 1999; Chapter 2). Other 
forebrain areas that contain low levels of CB1, generally uniformly distributed, are the 
ventromedial hypothalamic area and some thalamic nuclei. In the hindbrain, beside the 
molecular and granular layers of cerebellum expressing high levels of the receptor, CB 1 
is present at low levels in some nuclei of brain stem, such as the periaqueductal gray 
(Matsuda et al., 1993; Tsou et al., 1998a). 
Functional mapping by agonist-stimulated [35S]GTPYS binding using different 
CBI agonists, revealed that cannabinoid activation of G-proteins occurs with the same 
regional distribution as the receptors (Breivogel et al., 1997; Breivogel & Childers, 
1998). However, in some regions, the ratio between estimated amount of receptor and 
the G protein activation is not always constant, thus indicating regional differences in 
receptor coupling efficiencies (Breivogel & Childers, 1998). This is important to be 
considered, because sometimes cannabinoids seems to exert pharmacological effects that 
involve regions where the density of CB1 is very low (e. g. pain modulation mediated in 
the periaqueductal gray). Therefore, the activity of cannabinoids at CB 1 cannot be 
predicted solely based on relative receptor density, but other factors, such as receptor 
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coupling efficiency or different functional conditions of the receptor (e. g. 
phosphorylation, see above, 1.3.1 "Mechanisms of action") must be taken in account. 
1.3.3 CB1 ligands 
1.3.3.1 The problem of nomenclature. 
C. sativa contains more than 60 compounds belonging to the chemical family of 
"cannabinoids" (Iversen, 2000). Among them, A9-THC was described as the most 
psychoactive one and was shown to bind and activate CB 1 (Mechoulam and Gaoni, 
1965; Howlett et al., 1986; Matsuda et al., 1990). Considering this aspect, some 
problems arise for the nomenclature of cannabinoid compounds. Classically (and more 
correctly), the term "cannabinoid" should be referred to a class of compounds sharing 
some structural characteristics as three ring structure, the lack of nitrogen atoms and the 
presence of a pentyl side chain regardless whether derived from C. S. (Nahas et al., 
1999). However, with the discovery of the cannabinoid receptors and the development of 
new synthetic agonists and antagonists, the term "cannabinoid" has inevitably extended 
its meaning. In its general use, it names all the compounds derived from Cannabis sativa 
possessing the above mentioned structural characteristics and all the molecules (agonists 
or antagonists, natural or synthetic) that are able to bind to CB 1 and/or CB2 receptors. 
The discovery of endogenous ligands for CB1 and CB2 with the related mechanisms for 
synthesis, release, uptake and degradation (see below), have further increased the 
complexity of the "cannabinoid" nomenclature. Again, commonly, "endocannabinoids" 
are called the endogenous ligands of CBI and CB2 (Di Marzo et al., 1998), and, in a 
general sense, "cannabimimetic" compounds are all the chemicals (natural or synthetic) 
that are able to interfere with the metabolism of endocannabinoids, therefore increasing 
or decreasing the activity of these compounds. This classification is, of course, 
conventional and limited for many aspects, but it is the most common nomenclature used 
in the recent literature. Therefore, this will be the adopted convention, in this thesis. 
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1.3.3.2 CBI agonists 
From the chemical point of view, CBI agonists can be classified into four groups 
(Pertwee, 1997; Fig 1.4): (i) "classical cannabinoids", that are dibenzopyran derivatives 
and include A9-THC. (ii) "nonclassical cannabinoids", developed by Pfizer (USA), which 
contain bicyclic and tricyclic analogues of A9-THC that lack a pyran ring (Johnson and 
Melvin, 1986). The most important compound of this family is CP 55,940, used for the 
demonstration of the existence of the cannabinoid receptors (Howlett et al., 1986). (iii) 
Aminoalkylindoles, developed by Sterling Winthrop (USA) (Pacheco et al., 1991). The 
members of this group are structurally quite different from "classical" and "nonclassical" 
cannabinoids. The prototype of this group is WIN 55,212-2. (iv) "Eicosanoids", that are 
derivatives of arachidonic acid and were discovered as endogenous ligands of the 
cannabinoid receptors (Devane et al., 1992). Prototypes of this group are anandamide 
(arachidonylethanolamide, AEA) and 2-arachidonylglycerol, the two major 
endocannabinoids so far discovered in mammals. 
1.3.3.3 CBI antagonists 
As soon as cannabinoid receptors were discovered, several newly synthesised 
compounds were tested as putative specific antagonists of CBI or CB2. The first 
compounds to be shown to have some antagonistic properties at cannabinoid receptors 
were members of the aminoalkylindoles group, WIN 56,098 (Pacheco et at., 1991) and 
6-bromopravadoline (WIN 54,461; Casiano et al., 1991). However, the initial compound 
is rather weak antagonist (K1 in the order of micromolar), while the latter compound, 
even though more potent, has been shown to act, in some cannabinoid tests, as a partial 
agonist (Pertwee, 1997). Another aminoalkylindole compound, AM630 (6- 
iodopravadoline; Pertwee et al., 1995) has good potency, but again can act as partial 
agonist in some preparations and is not effective in vivo (Eissenstat et al., 1995). 
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Fig 1.4. Structures of CB 1 ligands. 
By far, the most potent and well-characterised CB1 antagonist is SR141716A 
(Rinaldi-Carmona et al., 1994; Fig 1.4). This compound is able to displace 
[3H]CP 55,940 from specific binding sites (Ka= ca. 2 nM) and is a potent antagonist of 
several of the typical effects of cannabinoids, both in vitro and in vivo. Another 
interesting property of SR141716A is the high specificity for CBI, having little or no 
affinity for CB2 and for a wide range of other membrane receptors (Rinaldi-Carmona et 
al. 1994; Compton et al., 1996). More recently, a CB2 specific antagonist was developed 
by the same group, SR 144528 (Rinaldi-Carmona, 1998). Both these antagonists were 
shown to act, in some conditions, in an opposite way as cannabinoid receptor agonists 
(inverse agonism) (Rinaldi-Carmona, 1998; Portier et al., 1999). SR141716A, in 
particular, is able to increase locomotor activity in mice (Compton et al., 1996), improve 
some forms of short-term memory in rats and mice (Terranova et al., 1996), and enhance 
the forskolin-induced production of cAMP in cells transfected with CBI (Felder et al., 
1995). Two different mechanisms could explain these observations. First, cannabinoid 
receptors might be tonically stimulated by endogenous ligands, whose action is blocked 
"Nonclassical" cannabinoids: 
CP 55,940 
Aminoalkylindoles: 
WIN 55,212-2 
CB1 antagonist: 
SR 141716A 
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by the addition of the antagonist. Second, the receptor might be present in two different 
conformational state, one precoupled to and the other uncoupled from the effector 
system(s). In this case, the SR compounds could produce their effects in absence of other 
drugs, because they bind preferentially to the receptor in the uncoupled state, thus 
shifting the equilibrium away from the precoupled status (Pertwee, 1997; Shire et al., 
1999). This second mechanism is very interesting, also in view of the regional differences 
in receptor coupling efficiencies of CB 1 (Breivogel & Childers, 1998), once more 
pointing to the importance of the functional status of the receptor in different anatomical 
regions and in different cellular conditions. 
1.4 The cannabinoid system 
With the discovery of cannabinoid receptors (Matsuda et al., 1990; Munro, 
1993), it became clear that natural and synthetic cannabinoids were likely to interfere 
with an endogenous neuronal system, in analogy, for example, to the opiates with the 
endogenous opioid system. In 1992, the first endogenous ligand of CB 1 was purified 
from porcine brain (Devane et al., 1992). The compound is an amide of arachidonic acid 
with ethanolamine and was named anandamide from the Sanskrit word "ananda" meaning 
"bliss". Early studies showed that anandamide (also called arachidonylethanolamide, 
AEA) is able to induce behavioural effects typical for A9-THC and other CB1 agonists in 
rodents, i. e. inhibition of locomotor activity, catalepsy, analgesia on a hot plate and rectal 
hypothermia (Fride & Mechoulam, 1993). After the discovery of anandamide, other 
metabolites were characterised in the brain with similar agonistic effects at cannabinoid 
receptors. These are all polyunsaturated fatty acid derivatives with no higher efficacy 
than anandamide and comprise docosatetraenoylethanolamide, di-homo-y- 
lineoylethanolamide (Hanus et al., 1993), and 2-arachidonylglycerol (2-AG, Mechoulam 
et al., 1995; Sugiura et al., 1995). 
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1.4.1 Synthesis of endocannabinoids 
Studies carried out in rat neurons demonstrated that synthesis and release of 
anandamide, whose basal levels in the brain are low as compared to most 
neurotransmitters, could be stimulated by treatment with depolarising agents such as 
ionomycin, 4-aminopyridine, kainate and high extracellular K+ concentrations (Di Marzo 
et al., 1994). 
EXTRACELLULAR 
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Fig. 1.5. Schematic representation of the main mechanisms involved in the synthesis, release, re- 
uptake and degradation of anandamide. AA, arachidonic acid; AC, adenylate cyclase; ArAPC, 
sn-1,2-di-arachidonoyl-phosphatidylcholine; AT, "anandamide transporter"; FAAH, fatty acid 
amide hydrolase; NArPE, N-arachidonoyl-phosphatidylcholine; NO, nitric oxide; PE, 
phosphatidyl-ethanolamine; PKA, cAMP-dependent protein kinase; PLD, N-acyl-phosphatidyl- 
ethanolamine-selective phospholipase D. 
Neurons and astrocytes are also able to rapidly uptake and degrade anandamide, 
,z ýý ý_,; _, '=h 
forming arachidonic acid and ethanolamine (Di Marzo et al., 1994; Deutsch & Chin, 
1993). In this view, anandamide appears to act as a classical neurotransmitter, with 
depolarisation-induced release, action at specific receptors, (re)-uptake by cells and 
intracellular degradation. However, differently from classical neurotransmitters, 
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anandamide and other endocannabinoids are not stored in presynaptic vesicles, but are 
thought to be synthesised "on demand" from membranous precursors. Anandamide, in 
particular, is likely to originate from the phospholipase D (PLD)-catalysed hydrolysis of 
a phospholipid precursor, N-arachidonyl-phosphatidyl-ethanolamine (NArPE; Di Marzo 
et al., 1994; 1998). NArPE is produced by the transfer of an arachidonate moiety from 
1,2-sn-di-arachidonyl-phosphatidylcholine (ArAPC) to phosphatidyl-ethanolamine (PE), 
catalysed by a Ca 2+-dependent trans-acylase (Sugiura et al., 1996; Cadas et al., 1996). 
Interestingly, it was shown that stimulation of adenylate cyclase and cAMP-dependent 
protein kinase (PKA) leads to an enhancement of the activity of the trans-acylase, thus, 
presumably increasing the final amount of produced anandamide (Cadas et al., 1996) (Fig 
1.5). 
Whereas the main metabolic pathway leading to the synthesis of anandamide is 
likely as above described, several pathways may contribute to the biosynthesis of the 
other important endocannabinoid, 2-arachidonylglycerol (2-AG). 2-AG was shown in 
several neuronal and non-neuronal cells to be produced after the stimulation of the 
phosphoinositide-phospholipase C (PI-PLC) pathway (Di Marzo et al., 1996). According 
to this pathway, 2-AG would be formed by the sequential hydrolysis of phosphatidyl 
inositols and diacylglycerols (DAGs) catalyzed by the G-protein-coupled PI-PLC and sn- 
1-selective DAG lipase, respectively (Di Marzo, 1999). However, also other pathways 
were proposed, where 2-AG is the result of a depolarisation-induced process. After 
stimulation with ionomycin, DAGs serving as 2-AG precursor can be produced by 
cortical neurons through the PI-PLC pathway (Stella et al., 1997) and by mouse 
neuroblastoma cells through the hydrolysis of phopsphatidic acid (PA) (Bisogno et al., 
1997b). In both cases, the sn-l-selective DAG lipase catalyses DAG hydrolysis to 2-AG. 
Moreover, precursors other than DAGs, such as 1-lyso-phosphoglycerides (Ueda et al., 
1993) can also generate 2-AG. 
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1.4.2 Inactivation of endocannabinoids 
Anandamide and 2-AG can diffuse through the cell membrane quite rapidly (Di 
Marzo, 1999). However, recently, a selective, temperature-sensitive, saturable and Na+- 
independent "anandamide transporter" protein was described in several primary neuron 
cultures and cell lines (Hillard et al., 1997; Beltramo et al., 1997; Bisogno et al., 1997a). 
Interestingly, the "anandamide transporter" was recently shown to be significantly 
stimulated by nitric oxide donors, thus, indicating a putative regulatory pathway for the 
inactivation of endocannabinoids (Maccarrone et al., 1998; 2000) (Fig. 1.5). No evidence 
has been yet presented for a similar uptake mechanism for 2-AG. Once inside the cells, 
anandamide and 2-AG are degraded to arachidonic acid and ethanolamine (Fig. 1.5) and 
glycerol, respectively. In 1996, the complete cDNA encoding for an enzyme able to 
specifically hydrolyse anandamide and other fatty acid amides was cloned (Cravatt et al., 
1996). This enzyme, generally referred to as fatty acid amide hydrolase (FAAH), is 
present in brain areas where high levels of CBI are also present (Thomas et al., 1997; 
Tsou et al., 1998b; Marsicano & Lutz, unpublished observations). While FAAH is the 
major anandamide-degrading enzyme (Katayama et al., 1997), FAAH is also able to 
hydrolyse 2-AG (Goparaju et al., 1998), but evidence also exists that other hydrolases 
also contribute to 2-AG breakdown in the CNS (Bisogno et al., 1997b; Di Marzo et al., 
1998; Goparaju et al., 1999). Interestingly, both the "anandamide transporter" and 
FAAH are able to transport and degrade, respectively, also other fatty acid amides 
different from anandamide, such as N-linoleoyl-ethanolamide (Maurelli et al., 1995; 
Maccarrone et al., 1998) or cis-9-octadecenoamide, also called oleamide (Cravatt et al., 
1996). These and other similar compounds have no direct cannabinoid activity, but are 
often released from neurons in higher amounts than anandamide (Di Marzo et al., 1994). 
Considering that the "anandamide transporter" and FAAH are likely to be very important 
for the physiological inactivation of anandamide in vivo (Beltramo et al., 1997; Compton 
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& Martin, 1997), it is therefore possible that these naturally occurring compounds 
contribute to the elevation of the endogenous levels of anandamide and 2-AG, by 
competing at transport and degradation sites. 
In conclusion, despite many still open questions regarding various aspects of the 
biology of cannabinoids, it is now accepted that the entity of endocannabinoids with their 
release, transport and degradation systems, and the CB 1 receptor, with its intracellular 
signal transduction mechanisms, constitute a novel neuronal system that could be 
involved in several important functions of the CNS. 
1.5 Proposed roles of the cannabinoid system in the CNS 
As mentioned above (1.3 "CBI, the `brain type' cannabinoid receptor"), the 
intracellular pathways triggered by CB 1, together with the anatomical distribution of the 
receptor, can account for most of the effects induced by pharmacological treatment of 
animals with cannabinoids (Breivogel & Childers, 1998). However, the recent discovery 
of endocannabinoids and the partial elucidation of the mechanisms involved in their 
regulation, allowed the researchers to hypothesise some of the physiological and/or 
pathophysiological functions which the cannabinoid system might be involved in. Here, I 
will briefly summarise the present evidence regarding the roles of the endocannabinoid 
system in various CNS functions and some of the potential therapeutic applications. 
1.5.1 Nociception 
In mammals, A9-THC and synthetic CB 1 agonists exert strong analgesic effects in 
several pain paradigms and through different administration routes, including local spinal 
and supraspinal applications (for recent reviews, see Martin and Lichtman, 1998; 
Chaperon & Thiebot, 1999). Exogenous cannabinoid analgesia appears to be partly 
connected with the opioid system (reviewed by Manzanares et al., 1999). Experiments 
using different opioid receptor antagonists administered either intrathecally (i. t. ) or 
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intracerebroventricularly (i. c. v. ) indicated that K-opioid receptors and µ-opiod receptors 
are involved in the spinal and supraspinal analgesic effects of cannabinoids, respectively 
(Reche et al., 1996). When pharmacologically administered, endogenous cannabinoids, 
such as anandamide, are also able to induce analgesia (Stein et al., 1996; Compton & 
Martin, 1997; Adams et al., 1998). However, the opioid system does not appear to be 
involved in the analgesic effect of exogenously administered anandamide (Welch et al., 
1995), thus, pointing to pharmacological differences between endocannabinoids and 
exogenous cannabinoid compounds. Recent studies have suggested that the endogenous 
cannabinoid system may modulate pain perception. Intrathecal administration of either 
the CBI antagonist SR 141716A or antisense oligonucleotides complementary to CBI 
mRNA, which resulted in a 60% decrease in CB 1 binding sites, elicited significant 
hyperalgesia in rats (Richardson et al., 1998; Edsall et al., 1996). Analgesia induced by 
anandamide administration was reversed by N-methyl-D-aspartate receptor antagonists, 
thus, indicating the involvement of glutamate transmission in the analgesic effects of 
endogenous cannabinoids. Moreover, in a peripheral pain model, Calignano et al. (1998) 
showed that endogenous cannabinoids can produce analgesic effects also at CB 1-like and 
CB2-like receptors located in the periphery, and, given the hyperalgesic properties of SR 
141716A in the same tests, suggested a tonic activation of the endogenous cannabinoid 
system directed to "buffer" the noxious stimuli. Furthermore, recently, Walker et al. 
(1999) demonstrated that peripheral pain stimuli were able to induce a significant release 
of anandamide in the periaqueductal grey, a brain area mainly devoted to the processing 
of nociceptive information. Discrepant results were obtained in genetic approaches. In 
1999, two CB 1-deficient mouse lines were established by two different groups (Zimmer 
et al., 1999; Ledent et al., 1999). Unexpectedly, regarding pain perception, the mouse 
line generated by Zimmer and co-workers showed a marked hypoalgesia. On the other 
hand, Ledent et al. (1999) were not able to detect any changes in basal pain perception in 
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their mutant mice. Besides the reasons putatively at the basis of such discrepancy 
(discussed in Introduction of Chapter 4), both mouse lines did not show the exogenous 
cannabinoid-induced analgesia. Interestingly, in further studies, the mouse line generated 
by Ledent et al. (1999), despite showing a normal antinociceptive response to opioid 
administration, did not possess the so-called "stress-induced" analgesia, which is believed 
to depend on the endogenous opioid system (Valverde et al., 2000). Moreover, the 
mouse line from Zimmer et al. (1999) presented a significant increase in the expression of 
some endogenous opioids, such as dynorphin and enkephalin (Steiner et al., 1999). 
Although, as discussed in the Introduction of Chapter 4, these phenotypic aspects of CB 1- 
mutant mice can be due to interactions between cannabinoid and opioid systems occurring at 
embryonic stages, nevertheless, such interaction might be reconsidered as an important point 
for the nociceptive functions of the endogenous cannabinoid system. 
In rodents, a combination of morphine with A9-THC or CP 55,940 resulted in 
greater than additive antinociceptive effects in several pain models (Reche et al., 1996; 
Smith et al., 1998; Pugh et al., 1996). This suggests the use of cannabinoids as potential 
analgesic drugs that could be used in combination with other analgesics, with the 
advantage of reducing potentially negative side effects. Particularly interesting appears 
the possibility that the endocannabinoid system is involved in particular 
pathophysiological conditions, such as chronic and inflammatory neuropathic pain 
(Herzberg et al., 1997). This would imply that drugs able to modulate the activity of 
endogenous cannabinoids might be used in order to increase their "natural" analgesic 
effect. However, the direct participation of endocannabinoids to these pathological 
conditions has still to be confirmed and discrepant results have recently been presented 
(Bealieu et al., 2000; Piomelli et al., 2000; Di Marzo et al., 2000). 
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1.5.2 Locomotion 
Exogenous cannabinoids profoundly affect locomotion in animals, in a dose- 
related biphasic manner. Large doses of natural and synthetic CB 1 agonists (including 
anandamide) strongly reduce motor activity and can induce catalepsy, while low doses 
could stimulate motor activity (Smith et al., 1994; Sulcova et al., 1998; Rodriguez de 
Fonseca et al., 1998; Sanudo-Pena et al., 1999; Sakurai et al., 1985). The CBI 
antagonist SR 141716A is able to reverse the locomotor inhibitory effects of CB 1 
agonists (Rinaldi-Carmona, 1994; Compton et al., 1996). When administered alone, the 
antagonist could induce hyperactivity in drug-naive mice, however larger doses than 
those necessary to counteract the effects of cannabinoid agonists were required 
(Compton et al., 1996). As for nociception, discrepant results were gained in the CB 1- 
deficient mice. Ledent et al. (1999) saw a modest stimulation of locomotor activity, 
while Zimmer et al. (1999) observed a severe hypomotility. CB 1 is highly expressed in 
the basal ganglia, a brain region that plays a crucial role in motor-related processes, with 
a high density of CB 1 protein in outflow nuclei, such as the entopeduncular nucleus 
(internal globus pallidus in primates), substantia nigra pars reticulata and external globus 
paffidus (Herkenham et al, 1990; Tsou et al., 1998a). Dorsolateral caudate putamen and 
subthalamic nucleus contain CB 1 mRNA, thus indicating GABAergic striatonigral and 
glutamatergic subthalamonigral axons as the main CB 1-containing subcellular structures 
(Mailleux & Vanderhaegen, 1992; Matsuda et al., 1993). A modulation of dopaminergic, 
GABAergic and glutamatergic transmission in these regions has been proposed for the 
cannabinoid-induced motor deficits (Glass et al., 1997b; Sanudo-Pena & Walker, 1997). 
Indeed, the potent synthetic CB 1 agonist WIN 55,212-2 was shown to be able to reduce 
the spontaneous firing rate of neurons in the globus pallidus (Miller & Walker, 1996), 
and exogenously administered anandamide and CP 55,940 decreased the electrically- 
evoked release of dopamine in striatal slices (Cadogan et al., 1997). A cannabinoid- 
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mediated reduction of GABA uptake was shown in substantia nigra and globus pallidus 
(Romero et al., 1998; Maneuf et al., 1996). 
In recent years, the endogenous cannabinoid system has been proposed to play an 
important role in locomotion, both in physiological and pathophysiological conditions 
(Rodriguez de Fonseca et al., 1998). Anandamide was found in microdialysates from the 
dorsal striatum of freely moving rats (Giuffrida et al., 1999). Its level was increased by 
depolarisation and was enhanced by stimulation of dopamine D2 receptors, whereas 
counteraction of its possible action at CBI with SR 141716A enhanced the motor- 
stimulatory effect of the D2 agonist quinpirole. Therefore, the authors proposed that the 
endocannabinoid system may act as a feedback mechanism inhibiting dopamine-mediated 
stimulatory activity. Anandamide and 2-AG were also shown to be present at high levels 
in the substantia nigra and external layer of the globus pallidus (Di Marzo et al., 2000). 
Interestingly, in the same study, the authors revealed a net increase of pallidal 2-AG in 
reserpine-treated animals, a model of Parkinson's disease, whereas DI or D2 receptor 
stimulation, respectively, in the same animals were able to decrease the levels of both 
endocannabinoids. Finally, full restoration of locomotion in the reserpine-treated animals 
was obtained by coadministration of the CB 1 antagonist SR 141716A and the D2 agonist 
quinpirole, thus indicating a link between the endocannabinoid signalling in the globus 
pallidus and symptoms of Parkinson's disease. Indeed, clinical studies have shown that 
cannabinoid agonists can be used to reduce the levodopa-induced dyskinesia in 
Parkinson's disease (Muller-Vahl et al., 1999; reviewed in Sevcik & Masek, 2000). Also 
other neurological disorders connected with altered locomotor function have been 
proposed to involve a dysfunctional cannabinoid system. Therefore, cannabinoid-related 
therapy might be beneficial. As examples, in human brain derived from Huntington's 
chorea patients, specific CBI binding appeared to be decreased in the basal ganglia at 
very early stages of the disease (Glass et al., 1993; Glass et al., 2000). Similar results 
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were obtained in a transgenic mouse model of the disease, with a net decrease of the 
CB I mRNA levels in subsets of neurons of striatum, cortex and hippocampus before the 
onset of the signs of the disease (Denovan-Wright & Robertson, 2000). The Gilles de la 
Tourette syndrome has also been proposed as a target of cannabinoid therapy (Muller- 
Vahl et al., 1997). Of particular interest is a recent report concerning the ability of 
cannabinoids to control spasticity and tremor in a mouse model of multiple sclerosis 
(Baker et al., 2000). The authors showed not only that pharmacological treatment with 
CB 1 agonists were able to drastically reduce these signs, but also that treatment of the 
animals with CB 1 and CB2 antagonists were able to exacerbate them. Therefore, they 
concluded that the endogenous cannabinoid system may be tonically active in the control 
of tremor and spasticity in multiple sclerosis. This and others studies indicate that 
therapeutic uses of cannabinoids should rely more on the modulation of the endogenous 
cannabinoid system (by, for example, the use of drugs able to reduce the uptake or the 
degradation of endocannabinoids) rather than on the administration of exogenous 
cannabinoid agonists and antagonists (for recent reviews, see Di Marzo et al., 2000; 
Piomelli et al., 2000). 
1.5.3 Learning and memory 
Synthetic and natural cannabinoids are able to inhibit memory formation in animals 
as assessed by various paradigms and generally exhibit their actions at doses that do not 
decrease locomotor activity (Heyser et al., 1993; Nakamura et al., 1991 Ferrari et al., 
1999). These effects are inhibited by the specific CBI antagonist SR 141716A, thus 
indicating the involvement of the receptor. CB 1 is highly expressed in brain areas that are 
considered as central elements for various kinds of memory formation, that are related to 
structures such as hippocampus, retrohippocampal areas (entorhinal and perirhinal 
cortex), amygdaloid nuclei and septal nuclei (Herkenham et al., 1990; Matsuda et al., 
1993; Tsou et al., 1998a). CBI is expressed in various subtypes of cells in these areas. 
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Both GABAergic interneurons and glutamatergic pyramidal cells express CB 1 at various 
levels (Matsuda et al., 1993; Tsou et al., 1998a; Katona et al., 1999; Marsicano & Lutz, 
1999; see also Chapter 2). Therefore, the mechanism of action of cannabinoids in these 
areas can be different depending on the cell types involved, but in most cases it appears 
to include a presynaptic inhibition of neurotransmitter release. In the hippocampus, 
cannabinoids were shown, to decrease the release of glutamate, acetylcholine, 
noradrenaline and GABA (Shen et al., 1996; Gifford et al., 1997; Schlicker et al., 1997; 
Katona et al., 1999). Such inhibitory effects on neurotransmitter release are considered 
to be the basis of the CB 1-mediated blockade of long term potentiation (LTP) in 
hippocampal slices, an electrophysiological model of synaptic plasticity (Nowicky & 
Teyler, 1987; Terranova et al., 1995; Misner & Sullivan, 1999). Interestingly, a recent 
report by Nava et al. (2000a) showed that memory impairment caused by A9-THC and 
the associated reduction of hippocampal acetylcholine concentrations were inhibited not 
only by the CB 1 antagonist SR 141716A, but also by the dopamine receptor D2 
antagonist sulpiride. This would indicate that cannabinoid-induced memory impairment 
are mediated by a concomitant D2 and CB 1 stimulation, thus pointing to an involvement 
of a cannabinoid dopamine cross-talk also in learning and memory processes. The 
endocannabinoids anandamide and 2-AG are also present in hippocampus and are able to 
inhibit LTP in a CB 1-mediated manner (Stella et al., 1997; Felder et al., 1996; Terranova 
et al., 1995). In particular, 2-AG production appears to be enhanced by electrical 
stimulation of hippocampal slices (Stella et al., 1997). In early experiments, exogenously 
administered anandamide failed to impair memory processes (Crawley et al., 1993; 
Lichtman et al., 1995), likely due to the metabolic instability of the compound. Indeed, 
anandamide impaired memory in rats pre-treated with the protease inhibitor 
phenylmethylsulphonyl fluoride (Mallet & Beninger, 1998) and the metabolically stable 
analogue R-methanandamide impaired memory in rats (Brodkin and Moerschbaecher, 
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1997). The endogenous cannabinoid system has been proposed to be tonically stimulated 
during active forgetting processes in which less important information is deleted from 
memory storage (Hampson & Deadwyler, 1998; Collin et al., 1995). This notion is 
supported by several experiments. Treatment with the CB 1 antagonist SR 141716A was 
shown to enhance social recognition (Terranova et al., 1996) and, more recently, to 
increase spatial memory in a delay version of the radial-arm maze task (Lichtman, 2000). 
Moreover, CB 1-KO mice showed also enhanced memory in a paradigm of object 
recognition (Reibaud et al., 1999) and increased hippocampal LTP (Bohnre et al., 2000). 
However, in contrast to the apparent memory enhancing effects of SR 141716A in some 
forms of memory, these results were not confirmed in a variety of different operant tasks 
(Brodkin & Moerschbaecher, 1997; Mallet and Beninger, 1998; Mansbach et al., 1996). 
These apparent discrepancies can indicate a tonic role of endocannabinoids in the 
modulation of some forms of memory and not in others. It is interesting to note that in 
both tasks where SR 141716A was shown to improve performances (Terranova et al., 
1996; Lichtman, 2000), the animals had to retain the information for substantially longer 
periods of time than in the tasks where no improving effects were observed. This would 
indicate that the endocannabinoid tone is involved more in a long-lasting active 
forgetting than in the immediate erasing of "unwanted information". 
The negative effects of cannabinoids on memory performance and the apparent 
enhancing effects of CBI antagonists suggest cannabinoid-related treatment in 
pathologies with alterations of various forms of memory. As an example, the use of the 
CB1 antagonist SR 141716A has been proposed in the pathological conditions marked 
by memory deficits, as in traumatic brain injury or neurodegenerative disease, such as 
Alzheimer's disease (Lichturan, 2000). 
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1.5.4 Reward and motivational systems 
Cannabis sativa derivatives have been known for millennia for their recreational 
and pleasure-inducing effects (Mechoulam, 1986). Among the many pharmacological 
effects produced by cannabinoid preparations is the dose-dependent "high", which is 
mainly due to the presence of A9-THC. On this basis, many studies in recent decades 
have attempted to clarify the mechanisms involved in these reward-inducing effects of 
cannabinoids by using animal models. In animals, motivational properties of drugs can be 
approached by three main behavioural procedures. 1) Intravenous self-administration 
(Goudie, 1991). 2) Drug-induced alterations of intracranial electrical self-stimulation, 
which occurs at a variety of electrode placements (the medial forebrain bundle being one 
of the more reward-relevant sites) (Stellar & Rice, 1989) 3) Place conditioning 
procedures, which are based on the principle that animals would learn to approach or 
avoid previously neutral environmental stimuli which have been paired with rewarding or 
aversive events, respectively (Carr et al., 1989). Numerous attempts to establish 
cannabinoids as reinforcers or self-administered drugs in näive or drug-experienced rats 
or monkeys were unsuccessful (e. g. Leite & Carlini, 1974). Moreover, several studies 
gave evidence that synthetic and natural cannabinoids behave as negative reinforcers in 
rodents (McGregor et al., 1996; Parker & Gillies, 1995). However, in different 
experimental conditions, cannabinoids were shown to possess some reinforcing effect. As 
examples, 09-THC was able to reduce the current threshold intensity for intracranial self- 
stimulation in the medial forebrain bundle in some strains of rats (Lepore et al., 1996), 
was self-administered at low concentrations in rats, after previous food deprivation 
(Takahashi & Singer, 1979), and supported place preference in rats at doses that differed 
depending on the time interval between injections (Lepore et al., 1995). Self- 
administration of cannabinoids was more consistently observed in mice. WIN 55,212-2 
was self-injected by CD 1 mice at moderate concentrations and became aversive at higher 
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doses. Such effects were likely CB 1-mediated, as they were abolished by SR 141716A 
and were absent in CB 1-knock out mice obtained in the same CD 1 genetic background 
(Martellotta et al., 1998; Ledent et al., 1999). Genetically determined strain differences 
could account for the discrepant results in drug preference, self-administration and 
intracranial self-stimulation obtained in rodents. Indeed, in the same experimental 
paradigm, A9-THC facilitated intracranial self-stimulation in the medial forebrain bundle 
at highest levels in Lewis rats, at half values in Sprangue-Dawley rats, but had no effect 
in Fisher 344 rats (Lepore et al., 1996). However, cannabinoids were shown to increase 
responding for palatable drinking, such as beer, near-beer and sucrose solutions, in a 
CB 1-dependent manner (Gallate et al., 1999) and to facilitate electrical self-stimulation in 
lateral hypothalamus, an area involved in feeding behaviour (Trojniar & Wise, 1991). 
These results would indicate that cannabinoids (although not consistently reinforcers per 
se and in some cases even producing aversion) may be active in facilitating the 
motivational effects of other positive reinforcers (Chaperon & Thiebot, 1999). This 
hypothesis is supported also by experiments in which the CB 1 antagonist SR 141716A 
was shown to block the establishment of conditioned place preference generated by 
classical reinforcers, such as cocaine, morphine and food (Chaperon & Thiebot, 1999). 
Moreover, morphine self-administration was highly reduced in CB 1-knock out mice 
(Ledent at al., 1999). SR 141716A also reduced motivation for sucrose solution, beer 
and alcohol consumption (Gallate & McGregor, 1999; Arnone et al., 1997; Colombo et 
al., 1998). Taken together, these results suggest that the endocannabinoid system is 
likely to be required for the perception of the motivational value of positive reinforcers, 
even if these reinforcers do not directly interact with the cannabinoid system itself 
(Chaperon & Thiebot, 1999). 
From the anatomo-functional point of view, the main circuits related to reward 
appear to consist of a synaptically interconnected series of neuronal tracts closely 
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associated with the medial forebrain bundle (reviewed in Gardner, 1997). Three stages 
can be individuated in the neuronal transmission connected with the reward circuits 
(Gardner & Vogel, 1998). 1) From various external reinforcing stimuli, a "first stage" of 
reward circuits originate diffusely in the ventral anterior forebrain, from different anterior 
bed nuclei of the medial forebrain bundle. Among these, CB 1 mRNA is present in the 
anterior lateral hypothalamus, in the horizontal limb of the diagonal band of Broca, in the 
lateral preoptic area, in the magnocellular preoptic nucleus and in the olfactory tubercle 
(Matsuda et al., 1993). From these and other nuclei of the medial forebrain bundle, 
projecting axons run posteriorly within the medial forebrain bundle and synapse on 
dopaminergic cells in the ventral tegmental area. These projections are believed to 
encode for information critical to the set point of hedonic tone (Gardner & Vogel, 1998). 
2) Dopaminergic neurons project anteriorly, always within the medial forebrain bundle to 
the nucleus accumbens and constitute the "second stage" of reward-related transmission. 
It is on this "second stage" dopaminergic convergence that addictive and abusable 
substances appear to increase brain reward functions and produce the pleasurable and 
euphoric effects at the basis of addiction (Gardner & Vogel, 1998; Kornetsky & 
Duvauchelle, 1994). 3) "Third stage" neurons appear to carry reward-relevant 
information from nucleus accumbens to the ventral pallidum, using as primary 
neurotransmitter the endogenous opioid peptide enkephalin (Gardner & Vogel, 1998). In 
order to complicate the picture, a number of additional circuits coming from several 
distinct anatomical regions such as prefrontal cortex, amygdala, locus ceruleus, raphe 
nucleus and others, synapse onto the above neuronal "stages", apparently to regulate and 
modulate the overall set point of hedonic tone (Gardner & Vogel, 1998). In this complex 
situation, cannabinoids acting at CBI are likely to interact at different stages with 
reward-related circuits. However, the mesolimbic dopaminergic system is considered as 
the common neuronal substrate for the motivational and rewarding effects of drugs and 
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for related physiological functions of the brain. Therefore, cannabinoids have been 
extensively studied in regard of their influence on this system. Ventrotegmental 
dopaminergic neurons are likely to be devoid of CB1, but anatomical and functional 
interactions between CBI and dopamine receptors were described in dorsolateral 
striatum (e. g. Glass & Felder, 1997; Giuffrida et al., 1999; Hermann, Marsicano & Lutz, 
in preparation). Even in absence of direct experimental evidence, given the fact that 
nucleus accumbens is coexentensive with the ventral striatum and that there is extensive 
homology between the afferents, efferents and internal neuroanatomical organisation of 
the nucleus accumbens and those of the dorsal striatum (Gerfen, 1988; 1993), it can be 
assumed that the anatomofunctional interactions between dopaminergic and cannabinoid 
systems found in dorsolateral striatum may also hold at some extent in the nucleus 
accumbens (Gardner & Vogel, 1998). However, A9-THC has been reported to enhance 
dopamine outflow in nucleus accumbens and medial prefrontal cortex of rats (Chen et al., 
1990a; 1990b). More recently, A9-THC and WIN 55,212-2 were shown to induce 
dopamine release selectively in the shell, but not in the core, of nucleus accumbens. Such 
an effect was completely prevented by SR 141716A (Tanda et al., 1997). These 
cannabinoid actions were also strongly reduced by the aspecific opioid receptor 
antagonist naloxone and by the µn opioid specific antagonist naloxonazine, thus 
indicating that CB 1 stimulation may facilitate mesolimbic dopamine transmission by 
activating the endogenous opioid system (Tanda et al., 1997; Chen at al., 1990a). In vivo 
electrophysiological studies have also shown that cannabinoids acting at CB 1 are able to 
activate mesolimbic and meso-prefrontal dopaminergic neurons (Diana et al., 1998; 
Gessa et al., 1998; French, 1997). On the other hand, SR 141716A did not change the 
spontaneous firing rate of mesolimbic dopaminergic cells, thus presumably excluding that 
these neurons are under the control of a tonically activated cannabinoid system (Gessa et 
al., 1998). 
33 
In conclusion, despite the fact that behavioural data are at some extent 
contradictory in revealing positive reinforcing properties of cannabinoids per se, an 
involvement of the cannabinoid system exists in many aspects of reward-related brain 
functions, mostly mediated by interactions with the dopaminergic and the opioid systems. 
In this respect, CB 1 antagonists treatment has been proposed for the management of 
opioid addiction (Ledent et al., 1999). On the other hand, cannabinoids or drugs aimed 
to enhance endogenous cannabinoid tone might be useful in the treatment of dysphoric 
states (Gardner & Vogel, 1998). 
1.5.5 Neuroprotection 
Natural and synthetic exogenous cannabinoids were shown to exert 
neuroprotective effects in several in vivo and in vitro neurotoxicity models (Hampson et 
al., 1998a; Nagayama et al., 1999; Sinor et al., 2000). Also endocannabinoids and related 
compounds have been proposed to exert neuroprotective activity (Di Marzo et al., 
1998). Anandamide is able to inhibit NMDA-receptor-mediated Ca 2+ influx (Hampson et 
al., 1998b) and has been shown to be released following glutamate stimulation or cell 
injury (Schmid et al., 1996; Cadas et al., 1996; Hansen et al., 1998). However, the exact 
mechanism(s) of these neuroprotective effects have not yet been clarified. "Classical" and 
"non-classical" cannabinoids such as A9-THC and CP 55,940 contain a phenolic ring 
(Fig. 1.4) which has been proposed as an important lead structure for protection against 
oxidative stress, regardless of any specific receptor-mediated action (Moosmann & Behl, 
1999). Therefore, the presence of a phenolic ring in many exogenous cannabinoids could 
account for their neuroprotective effects. Indeed, A9-THC, but also another constituent 
of C. Sativa, cannabidiol, which has a very low affinity for CB 1, were both shown to act 
as neuroprotective antioxidant (Hampson et al., 1998a). However, other mechanisms 
appear to be also involved. Aminoalkylindole compounds, such as WIN 55,212-2, and 
endocannabinoids do not contain the phenolic ring and, indeed, do not show antioxidant 
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properties (Marsicano, Moosmann, Behl & Lutz, in preparation; see also Chapter 5). 
However, WIN 55,212-2 was shown to be a potent neuroprotectant in a rat model of 
global and focal ischaemia (Nagayama et al., 1999). Interestingly, in the same report, the 
neuroprotective action of WIN 55,212-2 appeared to be CBI-mediated in vivo, but is 
CB 1-independent in vitro, thus indicating differences in the mechanisms of action in the 
whole animal or in isolated neuronal cultures. Recently, endocannabinoids were also 
shown to protect cortical neurons from in vitro 02 deprivation, in a CB 1- and CB2- 
independent way (Sinor et al., 2000). Moreover, palmitoylethanolamide, a non-CB 1- 
binding eicosanoid member of the same family of anandamide (Di Marzo et al., 1998), 
was shown to protect cerebellar granule cells from glutamate toxicity (Skaper et al., 
1996). Finally, CB 1 expression was recently shown to be increased in experimental 
stroke (Jin et al., 2000), thus indicating a likely involvement of CB 1-mediated 
endogenous cannabinoid signalling pathways in self-protecting mechanisms of the brain. 
Taken together, these data suggest complex mechanisms underlying the neuroprotective 
effects of cannabinoids and the putative neuroprotective role of the endogenous 
cannabinoid system, ranging from chemical antioxidant properties of "classical" and 
"non-classical" cannabinoids to the receptor-mediated effects of aminoalkylindoles and 
endocannabinoids. 
Whatever the underlying mechanism(s) are, these properties of exogenous and 
endogenous cannabinoids have been considered as promising in respect of possible 
therapeutic applications. Regulation of glutamate transmission, antioxidant properties 
and inhibition of Ca 2+ permeability can constitute a "cocktail" of positive effects in 
neurodegenerative pathologies. In this context, cannabinoids or drugs aimed to increase 
the endocannabinoid tone might emerge as potentially very useful therapeutic agents in 
neurotoxic diseases, such as brain ischaemia or Alzheimer's disease (Piomelli et al., 
2000). 
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1.5.6 Other proposed central roles of the cannabinoid system 
Besides the roles mentioned above, exogenous and endogenous exert also other 
effects in animals and humans. 
Natural and synthetic cannabinoids, as well as endocannabinoids produce a typical 
decrease of body temperature in animals (Pertwee, 1997). This effect is probably due to 
the presence of cannabinoid receptors in hypothalamic and caudal brainstem areas 
(Breivogel & Childers, 1998). Interestingly, recent results have shown that hypothermic 
effects induced by 09-THC are mediated by a coactivation of CB 1 and dopamine D2-like 
receptors (Nava et al., 2000b), underlying the importance of a functional cross-talk 
between cannabinoid and dopaminergic systems. An active cannabinoid tone was never 
shown to exist in the control of basal temperature, either by CB 1 antagonist treatment 
(Compton et al., 1996) nor in CB 1-knock out mice (Zimmer et al., 1999; Ledent et al., 
1999). However, given the facts that endocannabinoids are released in cellular stress 
conditions and that the cannabinoid system has been proposed to play a role in immune 
system and in inflammation (reviewed by Di Marzo et al., 1998), a role of the 
cannabinoid system in the modulation of body temperature in stress conditions might be 
hypothesized. 
The central endogenous cannabinoid system has also been proposed to have a role 
in sleep (Murillo-Rodriguez et al., 1998). The mechanism through which anandamide and 
other cannabinoids are able to induce sedation have not yet been clearly understood. 
However, very interestingly, the hypnotic actions of oleamide, a non-canriabimimetic 
fatty acid amide that accumulates in cerebrospinal fluids under conditions of sleep 
deprivation and that induces sleep in animals (Boger et al., 1998), were shown to be 
blocked by the CB 1 antagonist SR 141716A (Mendelson & Basile, 1999), thus 
indicating a central role of the cannabinoid system in sleep-inducing mechanisms. 
Appetite stimulation, relief of anxiety and sedation are three of the typical effects 
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described by Cannabis sativa extract users and have been correlated with the presence of 
cannabinoid receptors in the hypothalamus and limbic system (Di Marzo et al., 1998). 
The endogenous cannabinoid system has been proposed to play a tonic modulatory role 
in the sucrose and ethanol intake (Annone et al., 1997), in the inhibition of anxiety-like 
responses (Navarro et al., 1997) and in the decrease of arousal (Santucci et al., 1996) in 
rodents. Taken together, the main central effects of cannabinoids and the proposed roles 
of the endocannabinoid system could be related to a general stress-recovery system (Di 
Marzo et al., 1998). "Feel less pain, control your movement, relax, eat, forget, sleep and 
protect" might be some of the signals that are mediated by the activation of the 
endogenous cannabinoid system. 
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1.6 Aims of the Thesis 
Exploring some of the physiological and pharmacological aspects of the 
cannabinoid system was the major aim of this thesis. Several different methodological 
means were applied to investigate the biology of the mouse cannabinoid system and of 
the "brain type" cannabinoid receptor CB 1 in particular. 
In Chapter 2 and partly in Chapter 3, single and double in situ hybridization 
experiments were performed to determine the CB 1-expressing neuronal populations in 
the forebrain at the cellular level that are expressing the receptor. There were two 
purposes for these studies. First, to better understand the mechanisms through which the 
cannabinoid system might modulate neural activity in the brain; second, to describe genes 
that are coexpressed with CB 1 in the adult mouse brain in the light of defining which Cre 
recombinase-expressing transgenic mouse lines could be used to generate "conditional" 
mouse mutants (see "Discussion" of Chapter 4). Both aims were reached, with a detailed 
description of the expression pattern of CB 1 at cellular level and the definition of two 
genes, cholecystokinin and glutamic acid decarboxylase, whose regulatory sequences 
appear optimal candidates for spatially restricted expression of Cre recombinase in 
transgenic mouse lines. 
Neuroanatomical experiments constitute a good tool to get a deeper insight into 
possible physiological functions of a protein. However, it was also my interest to 
investigate some more functional aspects of the cannabinoid system. From the results 
described in Chapter 2, it was possible to hypothesise an involvement of CB 1 in the 
modulation of GABAergic and glutamatergic neurons. It is known that glutamatergic 
transmission is strictly connected with the nitric oxide pathway. Therefore, the 
availability of mutant mice for the gene nNOS (neuronal nitric oxide synthase) 
represented a good opportunity to explore in details one of the putative functional 
connections of the cannabinoid system with other neurotransmitter systems. With this 
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aim, in Chapter 3, the functional cross-talk between cannabinoid system and nitric oxide 
(NO) pathway was analysed. nNOS-knock out mice were behaviourally assayed for 
cannabinoid-induced pharmacological effects. Moreover, nNOS mutants were 
characterised for the expression of CB 1 in selected brain areas by in situ hybridization 
and coexpression between CBI and nNOS was analysed by double in situ hybridization 
in wild type mice. Results indicate that nNOS is necessary for some behavioural effects 
of A9-THC, that nNOS mutant mice express lower levels of CB 1 mRNA in selected brain 
areas and that CB 1 and nNOS are coexpressed in some regions of mouse forebrain. 
Chapter 4 constituted the central part of this thesis. It describes a sophisticated 
genetic approach to investigate very specifically and precisely the physiological functions 
of CB 1. The most important steps for the generation of a "conditional" CB 1-mutant 
mouse line are presented, with the obtaining of the "Floxed CB V" line and of the 
cannabinoid receptor null mice ("CBN" line). Several techniques were used for the 
preparation of this Chapter, ranging from molecular biology, to cell culture and mouse 
breeding methods. The "Floxed CB I" line will represent a powerful tool during the next 
years for the genetic analysis of the functions of CB I, whereas the "CBN" line represents 
an interesting model for the investigations on the activity of CB 1 at cellular level. 
One example of these investigations is described in Chapter 5. In the last Chapter 
of my thesis, I analysed some aspects of the neuroprotective properties of cannabinoids, 
by the use of in vitro neurotoxicity assays. Cannabinoids were shown to possess 
neuroprotective potentialities, but the exact mechanism(s) of these effects is still unclear. 
Therefore, several cannabinoids were tested in in vitro neurotoxicity assays and the 
involvement of CB I in cannabinoid-mediated neuroprotection was analysed. Cell lines 
were permanently transfected with CB 1 and neuroprotective effects of various 
cannabinoids were tested on such cell clones in comparison to the parental wild type cell 
clones. Moreover, primary cerebellar granule cells derived from wild type mice and from 
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CB I -knock out mice (CBN mouse line, as generated in Chapter 4) were also used to 
determine the role of CB 1 in cannabinoid-induced in vitro neuroprotection. Results seem 
to indicate that CB 1 is not necessary for cannabinoid-mediated neuroprotection in vitro. 
In conclusion, the overall strategy of the Thesis tried to cover several aspects of 
physiological roles of the cannabinoid system and of CB 1 in the mouse brain. 
Neuroanatomical and neurochemical results, as obtained in Chapter 2 and 3, represented 
the rationale for a functional analysis (cross-talk between cannabinoids and nitric oxide 
pathway in Chapter 3) and for the future spatial deletion of CB 1 (see the Discussion of 
Chapter 4). The generation of CB 1-mutant mice and in particular the "conditional" 
deletion of CB 1 (Chapter 4) will represent a powerful tool for understanding in details 
the physiological roles of the cannabinoid system in mouse physiology and behaviour. 
Moreover, null CB 1-deficient animals were used in this Thesis as a source of neurons to 
analyse the roles of CBI in in vitro neuroprotection of cannabinoids (Chapter 5). 
Although much work is still to be done in the future, the work described in this Thesis 
led to new insights into the roles of CB 1 and the cannabinoid system. 
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Chapter 2 
Expression of the cannabinoid receptor CB1 in distinct 
neuronal subpopulations in the adult mouse forebrain 
This work is published as Marsicano & Lutz, European Journal of Neuroscience, Vol. 
11, pp. 4213-4225,1999. 
2.1 Introduction 
The characteristic behavioural effects of cannabinoids are mediated by CB 1, the 
"brain type" cannabinoid receptor, a seven transmembrane G-protein-coupled receptor 
(Matsuda et al., 1990). Biochemical studies showed that G; io proteins transduce the 
cannabimimetic inhibition of adenylate cyclase (Howlett, 1995). CB 1 causes a cAMP- 
independent inhibition of N- and Q-type voltage-dependent Ca 2+ channels (Mackie & 
Hille, 1992; Felder et al., 1995) and a cAMP-dependent stimulation of inwardly 
rectifying K+ channels (Deadwyler et al., 1993; Mackie et al., 1995). These signal 
transduction pathways can explain some effects of cannabinoids in the central nervous 
system, such as inhibition of acetylcholine, noradrenaline and glutamate release, e. g. in 
hippocampus (Gifford & Ashby, 1996; Schlicker et al., 1997; Shen et al., 1996). CB 1 is 
also coupled to the activation of adenylate cyclase in striatal neurons upon simultaneous 
stimulation of the dopamine receptor D2 (Glass & Felder, 1997), possibly due to 
differential regulation of adenylate cyclase isozymes by CBI (Rhee et al., 1998). 
Endogenous ligands for CB 1 have been discovered (Devane et al., 1992; Stella et al., 
1997), sharing many of the properties of plant derived and synthetic cannabinoids. 
Therefore a cannabinoid system has been proposed to play an important 
neuromodulatory role in brain physiology (for review see Di Marzo et al., 1998). 
Several phannacological effects of cannabinoids (e. g. decrease of learning 
behaviour) are thought to be mediated by CB 1 expressed in forebrain structures. In situ 
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hybridization (ISH) and immunohistological studies described CB 1 expression in the rat 
forebrain in several cortical areas and in several non-cortical regions, such as striatum 
and some thalamic and hypothalamic nuclei (Mailleux & Vanderhaegen, 1992; Matsuda 
et al., 1993; Tsou et al., 1998a; Pettit et al., 1998). The pattern of CB 1 expression in the 
mouse forebrain, however, has not yet been described in detail. 
Determination of CB 1-positive neurons at a single cell resolution is a prerequisite 
for better understanding of the physiological role of the cannabinoid system in mouse. 
Based on morphological features, CB 1-expressing neurons in hippocampus and other 
cortical regions have been proposed to be GABAergic (Matsuda et al., 1993; Tsou et al., 
1998a), but conclusive evidence for this notion is still missing. GABAergic neurons 
express GABA and glutamic acid decarboxylase (GAD), and are classified according to 
criteria such as morphology, orientation of afferent and efferent fibres, type of 
innervating neurons and presence of distinct calcium binding proteins and neuropeptides 
(for review see Freund & Buszäki, 1996). Morphological criteria are difficult to be 
evaluated in ISH experiments, but detection of coexpression of CB1 with various 
markers can very well be accomplished using double ISH technique, as transcripts are 
generally localized in the soma of the cells. Thus, in this study, it was investigated which 
CB 1-expressing cells are GABAergic and whether CB 1 is coexpressed with other 
neuronal markers. 
Recent immunohistochemical studies in rats suggest that a fraction of CB 1- 
positive cells in the hippocampus has morphological features of basket cells, which are 
also called perisomatic inhibitory cells (Tsou et al., 1998a). Typically, basket cells are 
forming "basket" nets around principal cell bodies. From the neurochemical point of 
view, basket cells are GABAergic neurons that can further be divided into two distinct 
subpopulations: (1) basket cells containing the calcium binding protein parvalbumin 
(pV), and (2) basket cells containing the neuropeptide cholecystokinin (CCK) (Freund & 
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Buszdki, 1996; Soriano et al., 1990; Gulyas et al., 1991). In addition, Tsou et al. (1998a) 
described CB 1-positive neurons possessing fibers with orientations different from typical 
basket cells. Thus, CB 1-expressing cells might belong to an additional subpopulation of 
hippocampal GABAergic neurons. Two putative candidates for these CB 1-containing 
non-basket cells are calbindin D28k (C28)-positive mid-proximal dendritic inhibitory 
cells (Gulyas & Freund, 1996) and calretinin (CRT)-positive interneurons that are 
specialized in innervating other interneurons (Gulyas et al., 1996). Therefore, double ISH 
experiments were performed on hippocampus, but also on other cortical and some 
selected non-cortical areas of the mouse forebrain, using radioactive riboprobes for GAD 
65, CCK, C28, PV and CRT, respectively, together with a non-radioactive CB 1 
riboprobe. 
2.2 Materials and methods 
2.2.1 Tissue preparation 
Adult mice (3-5 months old; FVB/N and CD I strains) were killed by cervical 
dislocation. Brains were removed, snap-frozen on dry-ice and stored at -800C. After 
removing from -800C, brains were mounted on Tissue Tek (Polysciences, Warrington, PA, 
U. S. A. ), and 14-pun thick coronal sections were cut from forebrain on a cryostat Microtome 
HM560 (Microm, Germany). Sections were mounted onto frozen SuperFrost/Plus slides 
(Fisher Scientific, Ingolstadt, Germany), dried on a 42°C-warming plate and stored at -200C 
until used. 
2.2.2 Synthesis of probes 
Both radioactive (35S) and non-radioactive (fluorescein isothiocyanate, FITC) labeled 
riboprobes were used. Probes were generated by RT-PCR from cDNA derived from total 
mouse brain RNA. For each probe, GenBank accession number, length and sequence of the 
primers are listed below; nucleotide positions are identical to those used in deposited 
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sequences in GenBank: CB19 accession number U22948,1530 base pairs (bp) from 152 to 
1682 (forward primer 5'-GTT GAG CCT GGC CTA ATC AAA, reverse primer 5'-GTT 
GAC CGA ACC TCT GTT TTC); GAD 65, accession number D42051,1041 bp from 1055 
to 2096 (forward primer 5'-GGC GAT GGA ATC TTT TCT CCT, reverse primer 5'-CGA 
GGC GTT CGA TTT CTT CAA); PV, accession numbers X54613 and X67141,802 bp 
from 11 of accession number X54613 to 510 of accession number X67141 (forward primer 
5'-CAG CGC TGA GGA CAT CAA GAA, reverse primer 5'-GAT CTA GCT AGT CCT 
GAA GGA); CRT, accession number X73985,1023 bp from 35 to 1058 (forward primer 5'- 
CCG ACC GAA GAG AAT TTC CTT, reverse primer 5'-GGG AAG CCA AAG AGA 
AAA GGA); C28, accession number M21531,1016 bp from 166 to 1182 (forward primer 
5'-GAG ATC TGG CTT CAT TTC GAC, reverse primer 5'-GAT GAA CAC TTG GAT 
TTC CC); CCK, accession number X59520 and X59522,411 bp from 188 of accession 
number X59520 to 151 of accession number X59522 (forward primer 5'-ACT TAG CTG 
GAC TGC AGC TT, reverse primer 5'-GGA CTA CGA ATA CCC ATC GTA). PCR 
products were cloned into pBluescript KS- (Stratagene, CA, U. S. A. ) and used as templates 
for riboprobe synthesis. Identity of all fragments was checked by sequencing. Linearized 
template DNA was phenol-extracted, precipitated, resuspended in DEPC-treated H2O at a 
concentration of 1 µg/µ1, and stored at -200C. For 
35S-labeled riboprobes, in vitro 
transcription was carried out for 3 hours at 37°C in a total volume of 30 µl containing 1.5 µg 
of linearized DNA, 1x transcription buffer, 1 mM of rATP/rCTP/rGTP each, 16.7 mM DTT, 
40 units RNasin (Promega, U. S. A., WI), 10 pi of 35S-thio-rUTP (NEN, U. S. A., MA; 1250 
Ci/mmol) and 30 units of T7 or T3 RNA polymerase (Roche Molecular Diagnostics, 
Germany). For FITC-labeled nloprobes, in vitro transcription was carried out for 3 hours at 
37°C in a total volume of 50 µl containing 1.5 µg of linearized DNA, Ix transcription buffer, 
0.35 mM FITC-rUTP (Roche Molecular Diagnostics, Germany), 0.65 mM rUTP, 1 mM of 
rATP/rCTP/rGTP each, 80 units RNasin (Promega, WI, U. S. A. ) and 100 units of T3 or T7 
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RNA polymerase. Reactions were treated with 20 units of RNase-free DNasel (Roche 
Molecular Diagnostics, Germany) for 15 min at 37°C, and labeled probes were purified by 
a monium acetate precipitation. Restriction enzymes (New England Biolabs, MA, U. S. A. ) 
used for linearization and RNA polymerases used for each probe were as follows: CB 1 sense, 
PstI, T7; CB 1 antisense, BamHI, T3; GAD 65 sense, EcoRI, T7; GAD 65 antisense, BamHI, 
T3; PV sense, BamHI, T3; PV antisense, Hindill, T7; CRT sense, EcoRI, T7; CRT 
antisense, BamHI, T3; C28 sense, EcoRV, T7; C28 antisense, BamH, T3; CCK sense, 
BamHI, T3; CCK antisense, EcoRI, T7. Using these probes in ISH experiments, sense 
controls did not give any detectable signals, and antisense probes gave distribution patterns 
identical to those already published in rat or mouse (data not shown). 
2.2.3 In situ hybridization 
Slides were warmed-up for 30 min at RT, fixed in ice-cold 4% paraformaldehyde in 
PBS (PBS contains 136 mM NaCI, 2.7 mM KCI, 10 mM, Na2HPO4,1.8 mM KH2PO4, pH 
7.4), rinsed three times in PBS, incubated for 10 min in 0.1 M triethanolamine-HC1(pH 8.0) 
to which 0.63 ml of acetic anhydride were added dropwise, rinsed twice in 2x SSC (lx SSC 
contains 150 mM NaCI, 15 mM Na3 citrate, pH 7.4), dehydrated in graded series of ethanol, 
delipidized in chloroform for 5 min, rinsed in 100% and 95% ethanol and air-dried. 
Hybridization was carried out overnight at 64°C in 90 µl of hybridization buffer containing 
35S-labeled riboprobe (35,000 to 70,000 cpm/µl) and/or FITC-labeled nboprobe (1 µg/ml). 
Hybridization buffer consisted of 50% formamide, 20 mM Tris-HCl pH 8.0,0.3 M NaCI, 5 
mM EDTA pH 8.0,10% dextran sulphate (D8906, Sigma, Germany), 0.02% Ficoll 400 
(F2637, Sigma, Germany), 0.02% polyvinylpyrrolidone (MW 40,000, PVP40, Sigma, 
Germany), 0.02% bovine serum albumin (BSA; A6793, Sigma, Germany), 0.5 mg/ml tRNA 
(Roche Molecular Diagnostics, Germany), 0.2 mg/ml fragmented herring sperm DNA and 
200 mM DTT. 
After incubation in humid chamber, slides were rinsed four times for 5 min each in 4x 
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SSC at room temperature (RT), incubated 30 min at 37°C in 20 µg/ml of RNaseA in 0.5 M 
NaCI, 10 mM Tris-HC1 pH 8.0,5 mM EDTA, rinsed at RT in decreasing concentrations of 
SSC (lx, 0.5x and 0.1x SSC) containing 1 mM DTT, washed twice for 30 min each at high 
stringency in 0.1x SSC/1mM DTT at 64°C and washed twice for 10 min at RT in 0.1x SSC. 
At this point, 35S-labeled slides were dehydrated in graded ethanol series, air-dried and 
exposed to Biomax MR film (Kodak, Germany). On the next day, slides were dipped in 
photographic emulsion (NTB-2 from Kodak, diluted 1: 1 in distilled water). After exposure 
for 5 to 20 days at 4°C, slides were developed for 3 min (D-19, Kodak, Germany), fixed for 6 
min (Kodak fixer), rinsed for 30 min in tap water and air-dried. Slides were mounted in DPX 
(BDH, England). 
For non-radioactive (FITC) and double-labeled (35S/FITC) ISH experiments, slides 
were soaked after the last 0.1 x SSC wash at RT (see above) in buffer 1 (100 mM maleic acid 
pH 7.5,150 mM NaCl) for 1 min at RT, blocked in buffer 2 (1% Blocking Reagent in buffer 
1, Roche Molecular Diagnostics, Germany) for 30 min at RT, incubated with alkaline 
phosphatase-conjugated anti-FITC antibody (Roche Molecular Diagnostics, Germany) 
diluted 1/3000 in buffer 2 for 2 hours at RT, washed 2x in buffer 1 for 15 min at RT, washed 
2x in buffer 3 (100 mM Tris-HC1 pH 9.5,100 mM NaCI, 50 mM MgCb) for 2 min at RT. 
Chromogenic reaction was carried out with Vector Red kit (Vector Laboratories, U. S. A., 
CA) at RT for 24-36 hours with 2 changes of staining solution. Reaction was stopped by a 
10-min incubation in 0.1 M Tris-HC1 pH 8.2, followed by 10 min in 2.5% glutaraldehyde in 
PBS and four washes for 15 min in 0. lx SSC. In double ISH experiments, slides were treated 
at this point like slides from radioactive ISH, with dehydration, dipping and developing. At 
the end, slides were counterstained for 10 sec in 0.1% aqueous toluidin blue solution, rinsed 
2x for 10 sec in tap water, destained for 45 sec in 70% ethanol (containing 1 drop of 100% 
acetic acid per 100 ml), rinsed for 45 sec in 100% ethanol and air dried. Slides from double 
ISH were mounted in Kaiser's Gelatin (BDH, U. K. ). 
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2.2.4 Numerical evaluation of coexpression 
As CB 1 is expressed at various levels, cells stained with FITC-labeled riboprobe were 
classified according to the following criteria. Cells expressing CB 1 at high levels (termed: 
high CB 1-expressing cells) were considered those showing a round-shaped and intense red 
staining surrounding the nucleus or even covering the entire nucleus (e. g. see Fig. 2.2D, F). 
Cells expressing CB 1 at low levels (termed: low CB 1-expressing cells) were defined as cells 
clearly stained above background levels and in a discontinuous shape and/or at uniform and 
low intensity of staining (e. g. see Fig. 2.2D, F). Principal cells in CAl/CA3 regions of 
hippocampus displayed low and uniform levels of expression, with a slightly stronger intensity 
in CA3. Concerning numerical evaluation of the double ISH experiments, these principal cells 
were not included. Sections were analysed on a Leica DMRB microscope. All CB 1-positive 
cells were checked for coexpression with the following markers: GAD 65, CCK, PV, CRT or 
C28, respectively. Cells were evaluated and classified as high CB 1-expressing cells or as low 
CB 1-expressing cells with or without coexpression of above markers, respectively. In 
hippocampus, CCK- and GAD 65-positive cells were also evaluated for coexpression with 
CBI. 
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2.3 Results 
2.3.1 CB1 expression in the forebrain 
In hippocampus (Fig. 2.1 D; Fig. 2.2A, B), both low and high CB 1-expressing cells were 
detected. Pyramidal cells (Py) express low levels of CB 1, while cells with intensity of signal 
ranging from low to very high were observed in all layers of hippocampus, mostly in the 
subgranular layer of dentate gyros (SGr) (see also in Fig. 2.3C) and the lacunosum-molecular 
layer of CAI and CA3 regions (LMol) (Fig. 2.2A). Neocortex showed the presence of 
scattered low and high expressing cells, located primarily in layers 11-111 and V-VI (Fig. 2.1 D, 
2.2A). Few low CB 1-expressing cells are scattered in layers I and IV. CB 1-positive cells are 
more abundant in the primary and secondary motor (M 1 /M2) and sensory areas (S 1 FL/HL) 
(Fig. 2.1 C, D). CBI is also highly expressed in olfactory areas (Fig. 2.1 A). Low CB 1- 
expressing cells are distributed uniformly in the entire anterior olfactory nucleus (AO) with 
the presence of many scattered cells expressing high levels of mRNA (data not shown). 
Rather high numbers of CBI-positive cells (both low and high CBI-expressing cells) were 
observed also in piriform cortex (Pir) and olfactory tubercle (Tu) (Fig. 2.1 B, C). In 
amygdaloid region, not all nuclei showed equal intensities of expression. Both anterior (BLA) 
(Fig. 2.1 D; Fig. 2.2C, D) and posterior parts of basolateral amygdaloid nucleus (data not 
shown) contain a very high number of low CB 1-expressing cells uniformly distributed, and a 
rather high number of scattered high CB 1-expressing cells. Basomedial amygdaloid nucleus 
(BMA) showed a similar pattern of CBI expression (Fig. 2.1 D), while other amygdaloid 
nuclei contain lower levels of expression (data not shown). Entorhinal and perirhinal cortical 
areas (Ent) showed a very high number of both low and high CB 1-expressing cells (Fig. 
2.1 C, D; Fig. 2.2E, F). Non-cortical areas such as striatum (dorsolateral caudate putamen, 
Cpu, and globus pallidus, GP) and hypothalamus (ventromedial, VMH, and anterior 
hypothalamic nucleus) showed the presence of low CB 1-expressing cells that are uniformly 
distributed at high cell density (Fig. 2.1 D). Expression levels in other hypothalamic areas and 
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in thalamus are relatively low as compared to other forebrain regions. Rather strong 
hybridization signals were detected in the septal region (lateral, Ls, and medial septum, Ms, 
and vertical and horizontal nuclei of the diagonal band, VDB) (Fig. 2.1 B). 
Fig. 2.1. Dark-field micrographs of coronal sections from adult mouse forebrain showing the 
distribution of CBI mRNA, as detected by ISH with a 35S-radiolabeled riboprobe for CB 1. Note the 
high levels of CB I expression in anterior olfactory nucleus (A), neocortex (A-D), dorso-lateral caudate 
putamen (B, C), hippocampus (C, D), entorhinal/perirhinal cortex area (C, D), basolateral and 
basomedial amygdaloid nuclei (D). Scale bars: 1 mm. 
Rather high levels of expression were also observed in hypothalamic regions, such as 
medial and lateral preoptic nucleus, magnocellular preoptic nucleus and hypothalamic nucleus 
(not shown). More caudally, the premamnillaty nucleus showed low and uniform levels of 
expression (not shown). Scattered, low CB 1-expressing cells were observed in the lateral 
hypothalamus (Fig. 2.1 D). Weak signals were also observed in thalamic regions, such as the 
paraventricular thalamic nucleus (PVT), lateral habenula (Lhb), reticular thalamic nucleus 
(Rt) and zona incerta (ZI) (Fig. 2.1 C, D). In summary, the pattern of CB 1 expression in 
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mouse was found to be very similar, if not identical, to that observed in rats (Matsuda et al., 
1993). Distribution, number and intensities of ISH signals generated with radioactive and 
non-radioactive niboprobes specific for CB 1 were then compared. Representative examples 
are shown in Fig 2.2. No differences were detected between these two techniques, and, thus, 
non-radioactive riboprobes for CB 1 were further used for double ISH experiments. 
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Fig. 2.2. Bright-field micrographs of coronal sections showing CB1 distribution and levels of 
expression in cortical and limbic structures. Parallel coronal sections from three different brain regions 
were hybridized either with a 35S-radiolabeled (A, C, E) or with a FITC-labeled (B, D, F) riboprobe. 
(A, B) hippocainpus and dorsal neocortex; (C, D) basolateral amygdaloid nucleus; (E, F) entorhinal 
cortex. Note that number of labeled cells and intensity of signals are the same when comparing the two 
ISH techniques. Both high and low CBI-expressing neurons can clearly be classified. The light grey 
area between CAI and cortex in (B) is due to nonspecific staining of white matter. Filled arrowhead, 
high CB 1-expressing cell; open arrowhead, low CB 1-expressing cell; open arrow, CB 1-negative cell. 
Scale bars: A and B. 150 pm; C and D, 40 pm; E and F, 10 pm. 
For a detailed analysis of coexpression of CB 1 with five neuronal markers, five cortical 
(hippocampus, neocortex, anterior olfactory nucleus, entorhinal cortex area and amygdaloid 
area) and two non-cortical areas (dorsolateral caudate putamen and ventromedial 
hypothalamic nucleus) were chosen, because of their high expression levels and the proposed 
functional relevance of these regions in cannabinoid physiology and pharmacology (Breivogel 
& Childers, 1998). 
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Fig. 2.3. Bright-field micrograph of coronal sections showing examples of coexpression of CB l 
(red staining) with CCK and GAD 65 (silver grains), respectively, as detected by double ISH. All 
sections were counterstained with toluidine blue. (A) Overview of hippocampus double-stained for 
CBI and CCK. Note the expression of CCK in pyramidal cells of CA1/CA3 regions. (B) Higher 
magnification of dentate gyrus from (A) showing high degree of coexpression of CB l with CCK (filled 
arrow, filled arrowhead). (C) Dentate gyrus double-stained for CBI and GAD 65, showing complete 
coexpression for high CBI-expressing cells. (D) Double staining for CBI and CCK in basolateral 
amygdaloid nucleus. Note that CBI and CCK display almost complete coexpression. (E) Double 
staining for CB 1 and CCK in entorhinal cortex area, showing high degree of coexpression. (F) Double 
staining for CBI and GAD 65 in entorhinal cortex area, showing that low CBI-expressing cells do 
colocalize partly with GAD 65. This is in contrast to CCK as shown in (E). Filled arrow, high CB1- 
expressing cell coexpressing CCK or GAD 65; filled arrowhead, low CBI-expressing cell 
coexpressing CCK or GAD 65; open arrow, high CB 1-expressing cell not coexpressing CCK or GAD 
65; open arrowhead, low CBI-expressing cells not coexpressing GAD 65 or CCK; asterisks, cells 
expressing only CCK or GAD 65. Scale bars: A, 150 m; B and C, 40 µm; D, E and F, 20 fin. 
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Double-positive cells are located in granular and subgranular layers of dentate gyrus. 
GAD 65-negative, but CB 1-positive cells contain only low levels of CB 1 and are located in 
the polymorph layer of the dentate gyrus. These cells are often mistaken for interneurons, but 
are actually thought to be "misplaced" principal cells (Freund & Buszäky, 1996; Toth & 
Freund, 1992). Therefore, CB 1 expression in these scattered cells is consistent with the 
general observation that all principal cells of CAl /CA3 area express CBI at low levels, but 
lack GAD 65 expression. 
CB1/GAD CB1/CCK 
Low CBI 16.5 37.2 
CA1 Area* High CBI 26.9 47.8 
Total 43.4 (1154) 85.0 (460) 
Low CB1 20.7 37.6 
CA3 Area* High CBI 21.3 45.3 
Total 42.0 (1366) 82.9 (683) 
Low CBI 23.2 26.8 
Dentate Gyrus High CBI 14.6 26.1 
Total 37.8 (387) 52.9 (187) 
Table 2.2. Percentage of coexpression of CBI in GAD 65- and CCK-positive cells in adult mouse 
forebrain. Percentages indicate the total fraction of CBI-expressing cells among the GAD 65- and 
CCK-positive populations. Numbers of analysed cells are in parentheses. Low and high, respectively, 
indicate the percentages of cells expressing CB 1 at low or high levels among the total number of GAD- 
and CCK-expressing cells. Total means the percentage of all C131-expressing cells among the total 
number of GAD- and CCK-positive cells. 
* Principal cells in CA 1 /CA3 areas express low levels of CBI mRNA and are not included in 
coexpression data. GAD 65 is not expressed in these cells, but CCK is expressed. 
Table 2.2 shows the percentage of CB 1 expression among the GABAergic cell 
population. In CAl/CA3 area, 42-43% of GAD-65 expressing cells also contain mRNA 
coding for CB 1, while the value decreases to 3 7.8% in the dentate gyrus. 
In summary, these results show that, with exception of principal cells in CA 1 /CA3 and 
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of cells in polymorph layer, all CBI-expressing cells in the hippocampus are GABAergic 
intemeurons and that CB 1-positive cells represent about 40% of GABAergic neurons. In all 
pyramidal cells of the CA1 /CA3 region, CB 1 and CCK (Fig. 2.2A, B; Fig. 2.3A) show full 
coexpression. In hippocampal cells outside the pyramidal cell layer, CCK mRNA is also 
highly coexpressed with CB 1, as shown in Fig. 2.3A, B and Table 2.1. Low CB 1-expressing 
cells show about 70% colocalization in CAl /CA3 and 47% in dentate gyrus. In high CB 1- 
expressing cells, values increase to 91% and 94% in CAI and CA3, respectively, and to 73% 
in dentate gyrus. Table 2.2 shows that the fraction of CB 1 expressing cells among all CCK- 
containing neurons is also very high: 85% and 83% and more than 50% in CAI, CA3 and 
dentate gyrus, respectively. CCK containing intemeurons in the hippocampus and dentate 
gyrus have been described as a specific subset of basket cells (Gulyas et al., 1991). According 
to this study, a large fraction of CBI-expressing cells belongs to this particular type of 
hippocampal interneurons. In addition, considering that pyramidal cells in CAI /CA3 do 
express both CB 1 and CCK (Fig. 2.3A), a very high fraction of all CCK-positive cells in the 
hippocampus do also express CB I. 
Colocalization experiments with calcium binding proteins resulted in a rather different 
situation. In the hippocampus, PV and CRT are coexpressed with CB 1 only at a very low 
percentage (Table 2.3; Fig. 2.4C). Together with the results obtained with CCK, these 
observations showed that hippocampal CBI-positive cells can be classified as a subset of 
basket cells being CCK-positive and PV-negative (Gulyas et A, 1991). Since another subtype 
of hippocampal interneurons, the axo-axonic cells, were described to contain PV, it is clear 
from this study that CB 1-positive cells belong only to a negligible extent to this interneuronal 
subtype. 
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Law CBI High CBI 
expressing cells expressing cells 
C28 PV CRT C28 PV CRT 
CAI Area* 32.4 (294) 1.3 (307) 1.1 (251) 29.1 (204) 1.3 (198) 0.0 (242) 
CA3 Area* 29.1 (341) 1.8 (383) 5.2 (313) 22.3 (221) 1.3 (247) 2.5 (247) 
Dentate Gyrus 
Layers II-III Neocortex 
Layers V-VI Neocortex 
Anterior Olfactory Nucleus 
Entorhinal Cortex Area 
Amygdaloid Area 
Striatuffi** 
Hypothalamus'" 
31.5 (144) 0.0 (119) 2.0 (145) 
24.9 (983) 0.5 (637) 1.0 (577) 
13.7 (1011) 1.1 (575) 1.3 (525) 
ND 4.1 (236) 19.2 (241) 
16.8 (722) 3.5 (691) 2.8 (612) 
13.1 (787) 4.6 (681) '''"` 
-75 -15 0.0 
-100 0.0 -100 
31.5 (144) 2.6 (91) 2.3(96) 
32.8 (471) 1.0 (302) 0.0 (332) 
13.7 (354) 1.5 (384) 0.0 (414) 
ND 0.0 (91) 0.0 (103) 
39.7 (92) 1.2 (87) 1.3 (75) 
73.5 (89) 1.7 (119)"` 
Table 2.3. Percentage of coexpression of calcium binding proteins with CBI in adult mouse 
forebrain. Percentages indicate cells expressing low levels or high levels of CB 1 that were also 
labeled with riboprobes specific for calbindin 28k (C28), parvalbumin (PV), or calretinin (CRT). 
Numbers of analysed cells are in parentheses. Data were collected from 35 (CB 1 +PV, 
CBI+CRT) and 30 (CB1+C28) sections from two different brains. ND: not determined. 
* Principal cells in CA 1 /CA3 areas express low levels of CBI mRNA and are not included in 
coexpression data. C28 is expressed in CA 1 principal cells, PV and CRT are not expressed. 
** Due to the uniform distribution of low CBI-expressing cells in the dorsolateral part of striatum 
and in the ventromedial and anterior hypothalamic nuclei, numbers in these areas reflect an estimation 
only. 
*** CB 1 /CRT coexpression varies in different amygdaloid nuclei: Basolateral posterior part: 31.7 
(184) (low CBI), 14.3 (42) (high CBI); Basolateral anterior part: 8.8 (274) (low CBI), 2.5 (40) (high 
CBI); Basomedial anterior part: 4.5 (220) (low CBI), 0.0 (37) (high CBI). 
Instead, C28 showed a significant percentage of colocalization, in the range of 22% to 
32% (Table 2.3; Fig. 2.4A, B). C28-expressing cells in the hippocampus were described as 
interneurons innervating dendrites of pyramidal cells (Gulyäs & Freund, 1996), but they are 
not considered as basket cells, as these cells innervate mostly the soma of principal neurons 
(Soriano et a1., 1990). 
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Fig. 2.4. Bright-field micrograph of coronal forebrain sections showing examples of coexpression of 
CB I (red staining) with C28 and PV (silver grains), respectively. All sections were counterstained with 
toluidine blue. (A) Overview of hippocampus double-stained for CB1 and C28. Note the expression of 
C28 in pyramidal cells of CAI region and in granular cells of dentate gyrus. (B) Higher magnification 
of CA3 from (A) showing some coexpression of CBI and C28 in CA3 area (filled arrow, filled 
arrowhead). (C) Lack of coexpression of CBI with PV in CA3 area (open arrow, open arrowhead, 
asterisks). (D) In basolateral amygdaloid nucleus, C28 is present in many high CBI-expressing cells 
(filled arrow), but only in a few low CBI-expressing cells (filled arrowhead). (E) Double staining for 
CB 1 and PV in basolateral amygdaloid nucleus, showing only a small fraction of colocalization (filled 
arrowhead). (F) Double staining of CBI and C28 in entorhinal cortex area, showing some 
colocalization (filled arrow). Filled arrows, high CBI-expressing cells coexpressing C28; filled 
arrowhead, low CBI -expressing cells coexpressing C28 or PV; open arrows, high CBI-expressing 
cells not coexpressing C28 or PV; open arrowheads, low CB 1-expressing cells not coexpressing C28 
or PV; asterisks, cells expressing only C28 or PV. Scale bars: A, 150 µm; B and C, 40 fin; D, E and 
F, 20 µm. 
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2.3.3 CB1 expression in neuronal subpopulations in other cortical regions 
2.3.3.1 Neocortex 
In the entire neocortex, nearly all CB 1-positive cells also express GAD 65 (Table 2.1). 
Similarly to hippocampus, coexpression with CCK is more than 99% for high CB 1- 
expressing cells in layers V-VI, but is decreased to 77% for low CB 1-expressing cells in 
layers 11-111 (Table 2.1). No apparent differences in degree of coexpression were observed in 
various neocortical subregions. PV and CRT showed very low coexpression with CB 1 (Table 
2.3). Thus, neocortical CBI-positive cells are GABAergic neurons, expressing CCK, but 
neither PV nor CRT. However, C28 showed some extent of coexpression with CB 1, which is 
higher in layers 11-111 than in layers IV-V (Table 2.3). 
2.3.3.2 Entorhinal/perirhinal cortex area 
Entorhinal and perirhinal cortex are the major cortical site of efferents and afferents to 
and from the hippocampus (Suzuki, 1996; Lopes da Silva et al., 1990). Layers 11-111 and 
layers V-VI display very high numbers of low CB 1-expressing cells and many scattered high 
CB 1-expressing cells (Fig. 2.1 C, D; Fig. 2.2E, F), furthermore pointing out the modulatory 
functions of cannabinoids in memory processes. Fig. 2.3F and Table 2.1 show that GAD 65 is 
expressed in nearly all high CB 1-expressing cells. Much lower colocalization is observed in 
the population of cells expressing low levels of CB 1. The degree of coexpression with CB 1 is 
higher for CCK than for GAD 65 (Table 2.1, Fig. 2.3E). Taken together, these results 
indicate that nearly all high CB 1-expressing cells are GABAergic neurons containing CCK, 
while the cells containing low levels of CB 1 mRNA are only partly GABAergic, but do 
express CCK, This is a striking difference to neocortex, where all CBI-positive cells are 
GABAergic, regardless of the levels of CB I. As observed in hippocampus and neocortex, 
coexpression of CBI with CRT and PV is very low (Table 2.3), but coexpression with C28 is 
16.8% for low and 39.7% for high CBI-expressing cells (Table 2.3; Fig. 2.4F). 
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2.3.3.3 Olfactory system 
Cells expressing low levels of CB 1 were detected in piriform cortex and in dorsal 
regions of the olfactory tubercle, and few high CB 1-expressing cells were present in the 
nucleus of the lateral olfactory tract. The most prominent expression area is located in the 
anterior olfactory nucleus (Fig. 2.1 A), where a high number of low CB 1-expressing cells is 
present interspersed by a low number of strongly positive neurons. All CB 1-positive cells are 
equally distributed throughout all parts of the anterior olfactory nucleus, where the degree of 
coexpression with GAD 65 and CCK is comparable to that observed in the 
entorhinaiperirhinal cortex area (Table 2.1). High CB 1-expressing cells were found to be 
positive for both markers in almost 100% of the neurons evaluated, while the degree for low 
CBI-expressing cells decreases to 35.2% and 89.5% for GAD 65 and CCK, respectively. 
Thus, as in other cortical regions, high CB 1-expressing cells seem to belong to a population 
of GABAergic neurons containing CCK, while the cells containing low levels of CB 1 mRNA 
partly belong to a CCK/GAD 65-double positive population and partly to another population 
that is CCK-positive, but GAD 65-negative. For PV and CRT, there is nearly a lack of 
coexpression with CB 1 (Table 2.3). Only few CRT-positive cells (19.2%) were observed in 
the low CBI-expressing cell population. Together with some nuclei of amygdaloid region 
(see below), this is the only cortical area in which a significant coexpression of CB 1 with 
CRT was observed. 
2.3.3.4 Amygdaloid region 
CB 1 is expressed in several nuclei of the amygdala.. Only low levels were detected in 
the bed nucleus of stria tenninalis and in the central amygdaloid nucleus (data not shown). 
High numbers of both low and high CB 1-expressing cells were found, however, in the 
anterior and posterior parts of the basolateral amygdaloid nuclei and 
in the anterior part of the 
basomedial nucleus (Fig. 2.1 D; Fig. 2.2C, D). In these latter nuclei, high CB 1-expressing cells 
also contain GAD 65 (Table 2.1). Instead, 
low CB 1-expressing cells have different levels of 
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GAD 65 coexpression, depending on the nuclei A gradual decrease along the posterolateral 
to anteromedial direction was apparent (Table 2.1, see note). In the posterior part of the 
basolateral nucleus, the percentage of colocalization is 42.7%, while it decreases to 15.0% in 
the basomedial anterior part. Taken together, almost all high CBI-expressing cells are 
GABAergic, while a fraction ranging from 57% to 85% for low CB 1-expressing neurons is 
non-GABAergic. CCK highly colocalizes with CB 1 in an uniform manner in the amygdaloid 
nuclei examined (Fig. 2.3D; Table 2.1). Approximately 90% of low CB 1-expressing cells and 
nearly all high CB 1-expressing cells contain CCK mRNA. As other cortical areas, amygdala 
contains low CBI-expressing cells that are CCK-positive, but GAD 65-negative. A distinct 
population comprising all high CB 1-expressing cells and a fraction of low CB 1-expressing 
cells express both GAD 65 and CCK. As Table 2.3 and Fig. 2.4E show, PV is present in very 
few CB1-positive cells. Similarly to GAD 65, coexpression of CRT also decreases along the 
posterolateral to anteromedial direction (Table 2.3, see note). C28 displays uniform 
coexpression throughout the amygdaloid nuclei analyzed. A considerable percentage is 
observed for low CBI-expressing cells (13.1%), but is increased to 73.5% in high CBI- 
expressing cells. Thus, in amygdaloid region, about 70-75% of high CB 1-expressing cells 
belong to a population of GABAergic neurons that contains both CCK and C28. 
2.3.4 CB1 expression in neuronal subpopulations in non-cortical regions 
2.3.4.1 Striatum 
CB 1 hybridization signals were detected at low levels in many cells throughout the 
striatum. Nucleus accumbens, ventromedial caudate putamen, globus pallidus and 
entopeduncular nucleus contain cells expressing quite low levels of CB 1. In contrast, 
dorsolateral caudate putamen showed an intense staining due to a very compact and uniform, 
but low level expression (Fig. 2.1 B, C). Nearly all medium-sized cells in dorsolateral caudate 
putamen are CBI -positive. Number of labeled cells and 
intensity of signal decrease along the 
medioventral axis. Due to uniform distribution of 
low CB 1-expressing cells in this area, it was 
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not feasible to count coexpressing cells at a single cell resolution. Thus, the numbers reflect an 
estimation only. Table 2.1 shows the values of coexpression of CB 1 with GAD 65 and CCK. 
Basically all CB 1-positive cells in the dorsolateral caudate putamen contain GAD 65 mRNA, 
while none are CCK-positive. Spiny neurons in caudate putamen express GAD 65, and they 
constitute approximately 95% of the cells in this region (Ottersen & Storm-Mathisen, 1984). 
As shown in Table 2.3, many CB 1-positive cells (circa 75%) coexpress C28. Scattered cells 
(ca. 15%) coexpress PV, while there is a lack of colocalization of CB 1 with CRT. These 
results revealed that CBI-expressing cells in dorsolateral caudate putamen are GABAergic 
neurons that do not express CCK. They might belong to two distinct or partly overlapping 
populations, which express C28 and PV, respectively. 
2.3.4.2 Hypothalamus 
Several hypothalamic nuclei display low levels of CB 1 mRNA. Strongest hybridization 
signals were detected in ventromedial (Fig. 2.1 D) and anterior hypothalamic nuclei (not 
shown), where CB1-positive cells are uniformly distributed. There is a lack of coexpression of 
CB 1 and GAD 65 in these hypothalamic nuclei (Table 2.1), as GAD 65 is expressed mainly in 
hypothalamic areas surrounding the ventromedial and anterior hypothalamic nuclei. 
Remarkably, there is also a lack of coexpression with CCK (Table 2.1, see note). Among all 
areas analyzed, this is the only forebrain region in which neither GAD 65 nor CCK colocalize 
with CB I. C28 and CRT are highly enriched in cell bodies of ventromedial and anteromedial 
hypothalamus. Thus, they coexpress with CB1 to a high degree (Table 2.3). PV is not 
expressed in the hypothalamus (Celio, 1990). 
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2.4 Discussion 
The aim of this study was to define in detail the distribution pattern and the 
neurochemical characteristics of CB 1-expressing neurons in the adult mouse forebrain. 
Therefore, single ISH experiments using 35S-labeled or FITC-labeled CB 1 riboprobes, and 
double ISH experiments using a FITC-labeled CBI riboprobe in combination with 35S-labeled 
riboprobes to GAD 65, CCK, PV, C28 and CRT, were performed. CB 1-expressing cells can 
clearly be discriminated into two different populations: one expressing high levels and the 
other expressing low levels. High CB 1-expressing cells are in the great majority GABAergic, 
characterized mostly by the expression of CCK, the lack of PV and CRT, and, rarely, the 
presence of C28. Low CB 1-expressing cells belong only partly to the same subpopulations of 
GABAergic cells as high CB 1-expressing cells. Remarkably, for low CB 1-expressing cells, 
the presence of CCK characterizes also non-GABAergic neurons. In cortical areas, they can 
be considered as principal projecting cells. These results are in agreement with recent similar 
observations obtained by other groups which used single and double immunohistochemistry 
on rat hippocampus (Tsou et a1., 1999; Katona et at, 1999). 
The discrimination between high and low CB 1-expressing cells is also in agreement 
with immunohistochemical observations in rats (Tsou et al., 1998a), indicating that the 
different levels of expression of mRNA are probably connected to different levels of protein 
expression. The different neurochemical properties of CBI-expressing cells in various 
forebrain areas are likely to underlie different functional properties. 
2.4.1 CB1 and the GABAergic system 
Previous immunohistochemical and ISH studies performed in rats (Tsou et aL, 1998a; 
Matsuda et al., 1993) suggested that in cortical structures CB 1 receptor is present mainly in 
GABAergic neurons. Our results indicate that this is true in the mouse forebrain only for high 
CBI-expressing cells, where GAD 65 colocalizes with CBI at a degree close to 100%. 
However, low CB 1-expressing cells appear to be less correlated with the GABAergic system. 
61 
Pyramidal cells of CA 1 /CA3 areas in hippocampus express low levels of CB l, but do not 
express GAD 65. The same is true for many cells in the polymorph layer of dentate gyrus that 
probably represent misplaced pyramidal cells. From immunohistochemical studies in rats, it is 
not clear whether CB 1 protein is expressed in pyramidal cells of hippocampus. Some authors 
(Tsou et al., 1998a; Katona et al., 1999; Tsou et al., 1999) report negligible levels of 
expression of CB1 protein in pyramidal cells of CAI/CA3 region. In contrast, using a 
different antiserum and different fixation procedures, Pettit et aL (1998) observed a clear 
expression of CB 1 in these cells. This discrepancy might be explained by the fact that different 
fixation procedures might mask different epitopes or can destroy particular subcellular 
organelles in which the protein is localized. However, in agreement with results obtained in 
rats (Matsuda et al., 1993), the present ISH data in mouse clearly revealed that a low but 
significant amount of CB1 mRNA is expressed in pyramidal cells of CA1/CA3 hippocampal 
regions. Similarly to hippocampus, in the anterior olfactory nucleus, entorhinal/perirhinal 
cortex and amygdaloid nuclei, the majority of low CB 1-expressing cells is not GABAergic. 
Only in neocortex, CB 1 seems to be completely correlated with the GABAergic system, 
regardless of the levels of CB 1 expression. 
Hippocampus, amygdala, and entorhinal/perirhinal cortex comprise the so-called limbic 
system, which is considered to be a central circuit for important brain functions, such as 
learning and memory, as well as cognition (Miller et at, 1998; Suzuki, 1996). The effects of 
cannabinoids on memory processes are generally believed to be due to the interaction of CB 1 
with the GABAergic system (Terranova et al., 1995). Recently, Paton et aL (1998) analyzed 
the involvement of GABA transmission in the mechanism by which cannabinoids are able to 
inhibit long-term potentiation (LTP), an electrophysiological correlate of learning and 
memory in hippocampal slices. Unexpectedly, the authors observed a decrease of GABAergic 
transmission in the presence of CB 1 agonists. Therefore, they concluded that increased 
GABA activity is not directly involved in the inhibition of LTP by cannabinoids. Moreover, 
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they speculate that presynaptic CB 1 receptors located specifically on terminals of principal 
glutamatergic neurons, which synapse onto inhibitory interneurons, may mediate the 
reduction of the excitatory drive of these cells. This is in agreement with the present 
observation that pyramidal cells of CA1/CA3 express low levels of CB1, but lack expression 
of GAD 65. 
2.4.2 CB1 expression in distinct neuronal subpopulations 
In hippocampus, neurochemical characterization of GABAergic neurons defines at least 
four distinct subpopulations (Freund & Buszäki, 1996). (1) PV-positive GABAergic 
interneurons are considered as basket cells that innervate perisoma of pyramidal cells and as 
axo-axonic cells, innervating the proximal part of axons of pyramidal cells (Soriano et al., 
1990). (2) CCK-positive GABAergic interneurons represent a different population of basket 
cells that does not overlap with PV-positive GABAergic neurons, but also innervates the 
soma of pyramidal cells (Gulyas et al., 1991). (3) C28 is present in cells innervating mid- 
proximal dendrites of pyramidal cells (Gulyas & Freund, 1996). (4) CRT is characteristic for 
interneurons specialized in innervating other interneurons (Gulyäs et at, 1996). In this study, 
it was found a high degree of coexpression of CB 1 with CCK, some coexpression with C28 
and nearly a lack of coexpression with PV and CRT, indicating that CB 1-expressing cells are 
mostly basket cells of the CCK-positive and PV-negative type and, to a lower extent, C28- 
positive interneurons innervating mid-proximal dendrites of pyramidal cells. As almost no 
coexpression of CBI was observed with CRT and PV, CBI is not present neither in axo- 
axonic cells, innervating the proximal part of the axons of pyramidal cells nor in intemeurons 
specialized in innervating other interneurons. Interestingly, for low CB 1-expressing cells in 
CAI /CA3 regions of hippocampus, the percentages of coexpression with C28 and with CCK, 
respectively, appear to be complementary (30% versus 70%). Thus, low CB 1-expressing 
cells that are GABAergic might belong to two distinct intemeuronal subpopulations: basket 
cells (CCK coexpression) and, to a lower extent, cells 
innervating mid-proximal dendrites 
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(C28 coexpression). For high CB 1-expressing cells there must be an overlap of at least 10- 
20%, as CBI/C28 coexpression is approx. 20%, whereas CB 1 /CCK coexpression is more 
than 90%. 
In the limbic system (e. g. entorhinaYperirhinal cortex, amygdala and hippocampus), a 
significant percentage of low CB 1-expressing cells are not GABAergic, but express CCK. In 
neocortex, many CCK-positive pyramidal cells were described as corticostriatal and 
corticothalamic projecting neurons (Ingram et aL, 1989; Burgunder & Young, 1988; Morino 
et aL, 1994; Senatorov et at, 1997). Many CCK-positive cells also appear to be projecting 
neurons in entorhinal/perirhinal cortex and amygdala, as, for example, CCK was shown to be 
present in fibers connecting entorhinal cortex and hippocampus, and in fibres crossing the 
amygdalo-hippocampal border (Greenwood et a1., 1981; Roberts et at, 1984; Fredens et at, 
1984). Considering the high levels of coexpression between CB 1 and CCK in GAD-negative 
cells, these observations might indicate an involvement of CB 1 in the limbic system that is not 
only due to an influence on GABAergic inhibitory control, but also to a direct effect on CCK- 
positive projecting neurons (see below and Fig 2.5). It is interesting to note that neurons 
expressing CCK and low levels of CB1, but no GAD 65, were not observed in neocortex, 
where nearly all CB 1-expressing cells are GABAergic and, thus, are considered as 
intemeurons. 
In caudate putamen, CB 1 is coexpressed with GAD 65 and, partly, with C28 and PV, 
but not with CCK. CB 1 was shown to be important for the expression of GAD and 
neuropeptides such as substance P, dynorphin and enkephalin (Steiner et aL, 1999). This is an 
indication that the relation between neuropeptides and cannabinoids is very important in 
physiology and pharmacology of the cannabinoid system and that different neuropeptides are 
involved in different brain areas. 
64 
2.4.3 CB1 and CCK 
A striking finding of this study is the very high coexpression of CB 1 with CCK in 
cortical areas. Excluding the dentate gyrus, in which coexpression is slightly lower, in all 
cortical areas analyzed, mRNA encoding the neuropeptide is present in approx. 70-90% of 
the low CB 1-expressing cells and 90-100% of the high CB 1-expressing cells. CCK, originally 
characterized as a gastrointestinal hormone, is one of the most abundant neuropeptides in the 
brain. The active forms, derived from the precursor pre-procholecystokinin range from 4 to 
58 amino acids, but the most abundant peptide is the sulfated octapeptide CCK-8S (Fink et 
a1., 1998). They exert their actions through two receptors, CCK-A, present mostly in the 
gastrointestinal tract and CCK-B, expressed predominantly in the brain. CCK is involved in 
feeding, learning and memory, behavioural expression of anxiety, mediation of painful stimuli 
and is also involved in functions controlled by the dopaminergic, serotonergic and opioid 
systems (Crawley & Corwin, 1994). It is interesting to note that many functions, in which 
CCK is involved, are also modulated by cannabinoids. In some cases, the two systems seem 
to act in an antagonistic fashion. For example, CCK was shown to be hyperalgesic, and CCK 
receptor antagonists are used to increase the analgesic effects of opioids (Faris et al., 1983; 
Kernstein & Mayer, 1991; Duggan, 1992), while the antinociceptive effects of cannabinoids 
are very well known (for a review, see Martin & Lichturan, 1998). CCK is also considered to 
be a satiety factor (Reidelberger, 1994), while CB 1 agonism was proposed to induce feeding 
behaviour (Mattes et al., 1994). Also, many effects of cannabinoids seem to 
be mediated by 
interaction with the dopaminergic and opioid systems (e. g. Castellano et aL, 1997; Giuffrida 
et al., 1999; Tanda et A, 1997; Ledent et aL, 1999), both of which are interacting with CCK 
as well (Crawley, 1991; Duggan, 1992). Given these findings and given the high degree of 
coexpression of CBI with CCK, it is tempting to speculate about a possible functional cross- 
talk between the two systems; e. g., cannabinoids might have an effect on production, 
processing or release of CCK peptides. Depolarization of cell membrane was shown to 
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induce release of CCK both in vitro and in vivo (Raiteri et aL, 1993). Compounds that are 
able to increase intracellular concentration of cAMP enhance depolarization induced release 
of CCK, and a decrease of cAMP inhibits CCK release (Beinfeld, 1996). Considering that 
activation of CB1 can inhibit cAMP production, it appears likely that cannabinoids may 
modulate the release of CCK. Indeed, preliminary results obtained in our laboratory, indicate 
a significant dose-dependent inhibitory effect (ca. 50% of maximal reduction) of the potent 
CB 1 agonist WIN55,212-2 (1 µM and 0.1 µM) on the KCl-induced release of CCK from 
mouse cortical slices (Marsicano & Lutz, unpublished observations). 
Possible interactions between CB1 and CCK may also involve the regulation of CCK 
synthesis by cannabinoids. In this regard, it is interesting to note a possible involvement of 
both the receptor and the peptide in some pathophysiological conditions, such as 
schizophrenia. Based on similar scores in psychodiagnostic tests between schizophrenic 
patients and healthy volunteers to which cannabinoids were administered, and based on the 
interaction of cannabinoids with the dopaminergic and glutamatergic system, a "cannabinoid 
hypothesis" of schizophrenia has recently been proposed, suggesting an increased 
pathological cannabinoid tone in schizophrenic patients (Emrich et al., 1997; Schneider et at, 
1998; Leweke et al., 1999). On the other hand, abnormally decreased levels of CCK mRNA 
were observed in schizophrenic subjects, but not in Alzheimer patients in discrete cortical 
areas, such as entorhinal cortex (Gabriel et at, 1996; Bachus et a1., 1997). It would be 
tempting to relate these observations with our CBl/CCK coexpression study and to propose 
that an increased stimulation by cannabinoids might lead to decreased levels of CCK in 
distinct cortical brain areas. 
2.4.4 From anatomy to function: putative sites of action of cannabinoids in cortical 
areas 
CB 1 is distributed throughout the central nervous system of mammals in greater 
abundance than most of the other known G-protein-coupled receptors 
(Herkenham et al., 
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1990). Therefore, it would be an error to underestimate the physiological importance of 
cannabinoids in cells that express CB 1 at low levels, because such expression is in any case 
very high as compared to other identified receptors in the brain. For example, despite the 
rather low levels of CBI mRNA expressed by single cells in caudate putamen and in other 
subcortical areas (e. g. preoptic area in hypothalamus), the CB 1 receptor seems to exert 
essential functions in locomotor activity and in hypothermia, respectively (Steiner et al. 1999; 
Giuffrida et al., 1999; Zimmer et al., 1999; Breivogel & Childers, 1998). 
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Fig. 2.5. Schematic representation of the connectivity of hippocampus and cortical areas that are 
proposed to be modulated by the cannabinoid system. CB 1 is present at low but significant levels (L- 
CB 1) in principal neurons participating in the "trisynaptic loop" between entorhinal cortex and 
hippocampus. Due to the high number of low CBI-expressing cells (that are GAD-negative and CCK- 
positive) in perirhinal and amygdaloid areas, it appears likely that cannabinoid signaling might also 
modulate neuronal transmission between perirhinal, entorhinal and amygdaloid area. Note the high 
degree of CB I /CCK coexpression in projecting neurons, suggesting an involvement of the neuropeptide 
in cannabinoid action. 
CBI is present in many cells belonging to the so-called "trisynaptic loop" (Knowles, 
1992) between entorhinal cortex and hippocampus (Fig. 2.5). The present results show that a 
high percentage of low CB 1-expressing cells are GAD 65-negative and CCK-positive and, 
thus, are likely to be principal projecting neurons. Cannabinoid activity on these receptors, 
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therefore, might result in a direct modulation of the "trisynaptic loop". Other likely sites of 
action of cannabinoids in the hippocampus and probably also in other forebrain areas (e. g. 
neocortex) are the local GABAergic inhibitory circuits (Fig. 2.6). 
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Fig. 2.6. Schematic representation of local hippocampal circuits in CA3 area that are proposed to be 
modulated by the cannabinoid system. (1) and (2): CBI is expressed both at low and at high levels 
(L/H-CB 1) in GAD 65-positive interneurons. (1): The majority of neurons (70-80%) belongs to the 
CCK-positive, PV-negative subfamily of basket cells, innervating the soma of pyramidal cells. (2): 20- 
30% of CB 1-positive cells belong to the C2 8-positive subfamily of interneurons that innervate the mid- 
proximal tract of dendrites of pyramidal cells. For clarity, pyramidal cells are represented as three 
different cells, but a direct feed-back between one pyramidal cell and one interneuron is also possible. 
(+) and (-) indicate an excitatory and an inhibitory effect of synaptic transmission, respectively. In 
summary, the cannabinoid system might be involved in local inhibitory GABAergic circuits, by 
modulation of basket and mid-proximal dendritic inhibitory cells. 
In hippocampal slices, cannabinoids were indeed shown to cause a reduction of release 
of several neurotransmitters, including glutamate and GABA (Shen et al., 1996; Katona et al., 
1999), possibly suggesting differential modulatory effects on different cell types. 
In summary, these diverse sites of action could indicate a balanced modulatory effect of 
cannabinoids on principal projecting neurons and on interneurons. Endocannabinoids are 
believed to be locally produced, released and rapidly inactivated (for reviews, see Di Marzo & 
Deutsch, 1998; Di Marzo et a1., 1998; Piomel i et a1., 1998). Anandamide and 2- 
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arachidonylglycerol, the two major endocannabinoids described so far, were shown to be 
released upon chemical or electrical stimulation of neurons (Stella et at, 1997; Giuffrida et at, 
1999; Piomelli et a1.1998). This locally induced release and the rapid inactivation of 
endocannabinoids, together with the differential expression of CB 1, could suggest that the 
cannabinoid system has different modulatory functions depending on particular physiological 
or pathophysiological conditions. 
Glutamate transmission is one of the most important events that occurr in the brain.. 
The expression study described in this Chapter suggests that the cannabinoid system might be 
a potential modulator of glutamatergic transmission. It is therefore possible that other systems 
that interact with glutamatergic neurons have some functional cross-talks with the 
cannabinoid system. As an example, strong connections are known between the nitric oxide 
system and glutamate transmission (Bredt & Snyder, 1994; East et al., 1996; Contestabile, 
2000). In this view, a putative functional interaction between the cannabinoid system and the 
nitric oxide pathway was hypothesised and experiments in this direction will be described in 
the next Chapter, by the use of neuronal nitric oxide synthase-deficient mouse mutants. 
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Chapter 3 
Differential role of the nitric oxide pathway on A9-THC- 
induced central nervous system effects in mouse 
The work described in this Chapter is in press as Azad, Marsicano, Eberlein, Putzke, 
Zieglgänsberger, Spanagel and Lutz, European Journal of Neuroscience. Azad and 
Marsicano share the first authorship. My contributions were the in situ hybridization 
experiments and their quantitative evaluation, whereas Dr. Shahnaz Azad performed the 
behavioural experiments. Results are given without discriminating the various 
contributions in order not to disrupt the completeness of the experimental strategy. 
3.1 Introduction 
A9-tetrahydrocannabinol (A9-THC), the major psychoactive constituent of C. 
sativa, is known to exhibit a variety of central effects including hypothermia, 
antinociception and changes of locomotor activity (Felder & Glass, 1998; Ameri, 1999; 
Pertwee, 1997). These effects are mainly mediated by the "brain-type" cannabinoid 
receptor CB 1, a seven transmembrane G-protein-coupled receptor predominantly 
expressed in the central nervous system (Pertwee, 1997). The entity of cannabinoid 
receptors with binding, synthesis, release and degradation of their endogenous ligands is 
generally referred to as a novel neuromodulatory system called the cannabinoid system 
(Di Marzo et al., 1998). Results of recent studies imply that the cannabinoid system is 
likely to interact with several neurotransmitter systems such as the GABAergic, 
dopaminergic, opioid and glutamatergic systems (Herkenham et al., 1991; Bidaut-Russell 
& Howlett, 1991; Glass & Felder, 1997; Pertwee & Wickens, 1991; Manzanares et al., 
1999; Ameri, 1999; Piomelli et al., 2000; Hampson et al., 1998b). There is also a general 
consensus that the nitric oxide (NO) pathway 
is strongly linked to the glutamatergic 
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system (Bredt & Snyder, 1994; East et al., 1996; Contestabile, 2000), but also to the 
GABAergic, dopaminergic and opioid ones (e. g. Jayakumar et al., 1999; Liu, 1996; 
Herman et al., 1995). NO is an intra- and extracellular messenger, which is produced by 
the nitric oxide synthase (NOS). There are three NOS genes encoding the respective 
isoforms: endothelial (eNOS), inducible (INOS) and neuronal NOS (nNOS) (Garthwaite 
& Boulton, 1995; Huang & Lo, 1998; Contestabile, 2000) with the latter being the focus 
of the present investigation. nNOS is a calcium/calmodulin-dependent enzyme which was 
found first in neurons (Bredt & Snyder, 1994). It is considered to participate in a variety 
of physiological and pathological processes such as neuronal plasticity and neurotoxicity 
(Dawson et al., 1998). In addition, NO is known to be involved in the effects of many 
centrally acting anaesthetic and analgesic drugs (Johns et al., 1992; Tonner et al., 1997; 
Ferreira et al., 1991). 
In vitro studies have shown that there is a link between cannabinoid signalling 
through cannabinoid receptors and NO pathway in vertebrate brain. CP-55940, a potent 
agonist of CB 1, is able to decrease the release of NO from endotoxin/cytokine-activated 
rat microglial cells (Waksman et al., 1999). Similarly, several potent CB 1 agonists were 
shown to inhibit KCl-induced activation of NOS from primary cerebellar cultures, 
whereas the cannabinoids had no effect on basal NOS activity (Hillard et al., 1999). In 
vivo pharmacological studies have analysed the effects of NOS inhibitors on cannabinoid- 
induced behavioural and pharmacological responses (Thorat & Bhargava, 1994; Spina et 
al., 1998). Both groups did not observe any effect of NOS inhibitors on analgesic, 
hypothermic or cataleptic effects of acute cannabinoid administration in mice and rats, 
respectively. However, only Spina et al. (1998) described an inhibitory effect of the NOS 
inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) on tolerance to 
hypothermic and cataleptic effects induced in rats by chronic treatment with the potent 
cannabinoid agonist WIN 55,212-2. On the contrary. 
Thorat and Bhargava (1994), using 
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the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA), did not observe any similar 
effect on tolerance to analgesic and hypothermic effects induced by chronic treatment 
with O9-THC. Even though such studies seem to indicate that NOS and NO pathway are 
not involved in the acute effects of cannabinoid agonists, the discrepant results on 
tolerance induced by chronic treatment with cannabinoids, could indicate that in vivo 
administered NOS inhibitors may have different efficacies in blocking NOS activity, e. g. 
depending on the species used in the experiments or on time, route or dosage of 
administration. 
For this reason, a genetic approach was chosen to test the existence of a specific 
functional link between behavioural and pharmacological actions of cannabinoids and the 
nNOS/NO pathway. Therefore, body temperature, nociception and locomotion were 
measured both in neuronal nitric oxide synthase knock-out (nNOS-KO) (Huang et al., 
1993) and wild-type (WT) control mice after intraperitoneal application of A9-THC. In 
addition, the distribution of CBI and nNOS transcripts was determined in adult mouse 
brains using in situ hybridization to reveal possible changes in CBI gene expression in 
nNOS-KO as compared with WT mice, and to reveal the brain areas, where CB 1 and 
nNOS were coexpressed in the same neuron. 
3.2 Materials and methods 
3.2.1 Animals 
Homozygous males with a deficiency in the neuronal nitric oxide synthase gene 
(nNOS-KO) and wild-type male control mice (WT) were used for the study. Targeted 
disruption of the nNOS gene is described in Huang et al. (1993). The genetic 
background consisted of a combination of the strains 129/Sv and C57BL/6J, with a 
predominance of C57BL/6J, as mutants were backcrossed 
for three generations onto 
C57BL/6J and were then intercrossed to obtain experimental animals. As it is known that 
male nNOS-KO mice show a markedly 
increased aggressive behaviour (Nelson et al., 
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1995), all animals were housed individually in the same temperature- and humidity- 
controlled room with a 12 hour light-dark cycle (light from 07: 00 to 19: 00) and with 
access to food and water ad libitum. At the time of investigation, animals were 9 to 10 
weeks old and had a body weight of 21-26 g. All animals were drug naive and were 
injected only once with A9-THC or vehicle. All behavioural experiments were performed 
between 9: 00 a. m. and 1: 00 p. m. All behavioural and molecular investigations were 
evaluated in a blinded way. The experimental protocols were approved by the Ethical 
Committee on Animal Care and Use of the Government of Bavaria, Germany. 
3.2.2 Drugs and chemicals 
A9-THC was purchased (Sigma, Deisenhofen, Germany) as a 100 mg/ml (w/v) 
solution in 100% ethanol. Immediately before injection i9-THC was diluted 1: 100 in 
45% 0-hydroxy-cyclodextrin (RBI/Sigma, Deisenhofen, Germany) and stirred for 10 min 
at 37°C. As a vehicle control, 45% ß-hydroxy-cyclodextrin containing 1% ethanol was 
used. All drugs were administered i. p. with an injection volume of 10 ml/kg body weight. 
For behavioural tests, 10 mice of each genotype received A9-THC or vehicle, 
respectively. In a pilot study carried out in C57BL/6 mice using various doses of A9- 
THC, a dose of 10 mg/kg 09-THC was found to be the lowest dose leading to clear 
analgesic and hypothermic effects. 
3.2.3 Behavioural testing 
To reveal possible differences between the nNOS-KO and WT mice concerning 
behavioural and physiological reactions to A9-THC, common cannabinoid-induced 
effects such as changes in nociception, body temperature and 
locomotor activity were 
assessed in both genotypes. Antinociceptive effects were measured 
30,60 and 90 min 
after injection of A9-THC or vehicle using a 
hot-plate analgesia meter (Bachofer, 
Reutlingen, Germany). The latency until mice showed first signs of discomfort (licking or 
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flinching of the paws or jumping) on the plate, which was heated to 55 ± 0.5 °C, was 
recorded. A cut-off-time of 60 sec was set to prevent tissue damage. A9-THC-induced 
hypothermia. was determined using an infrared thermometer (C- 1600, Linear 
Laboratories, Fremont, California, USA) which was placed between the forepaws at a 
distance of exactly 3 cm. Body temperature was recorded immediately before as well as 
60 and 120 min after injection of drug or vehicle. Spontaneous locomotor activity was 
assessed by an automated open field system (box size 32 x 32 cm; illumination of 40-60 
lux, MOTION, TSE GmbH, Bad Homburg, Germany). 15 min after injection of A9-THC 
or vehicle, animals were tested individually for 30 min. The cumulative horizontal 
distance the animals moved within the box was recorded. 
3.2.4 In situ hybridization 
In situ hybridization on CB 1 mRNA was performed to reveal possible differences 
of CBI mRNA levels between the two genotypes. Six untreated mice of each genotype 
of the same age and weight as those tested in behavioural experiments were used. 
Animals were killed with C02, brains were rapidly removed, snap frozen on dry-ice and 
stored at -80°C. Coronal sections of 20 µm were cut on a cryostat microtome (HM 500, 
Microm, Walldorf, Germany). Sections were mounted onto frozen SuperFrost/Plus slides 
(Menzel, Braunschweig, Germany), dried and stored at -20°C. For hybridization, slides 
were warmed up for 45 min at room temperature. Labelling of the riboprobes and in situ 
hybridization with 35S-labelled riboprobes complementary to the mRNA of the mouse 
CB 1 were performed as described by Marsicano and Lutz (1999) and in Chapter 2. The 
slide-mounted sections were apposed to autoradiographic films (Kodak Biomax MR 
film, Integra Biosciences GmbH, Fernwald, Germany) for 11 hours. Developed films 
were illuminated with a light box and sections were scanned as grey scale images with 
256 grey values using a computer-assisted video camera. Mean densities of the regions 
of interest were measured using Object-Image1.62 
for Macintosh with a value of zero 
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reflecting white and 255 reflecting black. 
For the colocalization of CB 1 and nNOS, double in situ hybridization experiments 
were performed according to Marsicano and Lutz (1999) (see also Chapter 2). nNOS 
template was obtained by reverse transcriptase-polymerase chain reaction (RT-PCR) 
using the 5' primer 5'-CCT GGT GGA GAT TAA CAT TGC-3'and the 3' primer 5'- 
CTG GTA CTG CAA CTC CTG ATT-3'. Amplification product was 1197 bp and 
covered positions 1985-3182 of Genbank accession number NM008712. PCR product 
was cloned in pBluescript KS- (Stratagene, CA, USA), and the clone was confirmed by 
sequencing. Sense and antisense riboprobes were obtained as described in Marsicano and 
Lutz (1999), linearizing the plasmid with the restriction enzyme BamHI and EcoRI, 
respectively, and using T3 and T7 RNA polymerase to obtain 35S-labelled riboprobes. 
CB 1 and nNOS sense probes gave no detectable signals. Double in situ hybridization 
experiments were performed using CB 1 antisense riboprobe labelled non-radioactively 
with FITC, and using 35S-labelled nNOS probe. The FITC signal was revealed using the 
Vector Red kit (Vector Laboratories, CA, USA) for 24-36 hours. The radioactive signal 
was revealed by dipping the slides in photographic emulsion (NTB-2, Kodak) and 
developing after 10-20 days. 
3.2.5 Statistical analysis 
Hot plate analgesia and temperature were first analyzed using analysis of variance 
(ANOVA) with repeated measurement and the genotypes and therapy as between- 
subject-factors. In case of significant interactions, univariate F-tests were performed in 
order to evaluate significant differences at the respective time points. Univariate analysis 
of variance was used for statistical evaluation of the open field observations. Results of 
in situ hybridization of the different brain regions were evaluated using multivariate 
analysis of variance. In all cases, a p-value < 
0.05 was considered as statistically 
significant. All results are shown as mean and standard error of the mean 
(SEM) of the 
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absolute values. As the WT mice showed a lower basal activity in the open field system 
than the nNOS-KO mice, A9-THC-induced changes in locomotor activity were evaluated 
and expressed as a percentage of the mean activity of the vehicle-treated group for each 
genotype. 
3.3 Results 
3.3.1 Behavioural and pharmacological assessments 
Measurement of body temperature (Fig. 3.1 A) revealed no differences in basal 
values between the genotypes (Wilks multivariate test of significance; influence of 
genotype: F(2,34)=0.750; p=0.480). However, in contrast to the analgesic effects, there 
was a significant interaction between genotype and treatment (Wilks multivariate test of 
significance; effect of treatment: F(2,34)=5.87, p<0.01; effect of type x treatment: 
F(2,34)=3.407, p<0.05). 
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Fig. 3.1. Effects of intraperitoneal application of 10 mg/kg A9-THC in nNOS knock-out (KO) 
and wild-type control mice (WT). A. Body temperature B. Hot-plate 
latencies C. Spontaneous 
locomotion activity. Yellow bars, WT mice treated with vehicle; hatched yellow bars, WT mice 
treated with 09-THC; blue bars, KO mice treated with vehicle; 
hatched blue bars, KO mice 
treated with A9-THC. Data are shown as mean and SEM; asterisks, p<0.05 vs. vehicle. 
A hypothermic effect of 10 mg/kg A9-THC was observed only in the wild-type 
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mice reaching statistical significance at 120 min after injection (Univariate F-tests, p- 
value < 0.05). 
The effect of 09-THC on nociceptive responses to acute pain were assessed by 
using the hot plate test, which is considered to involve mainly supraspinal mechanisms of 
the nociceptive system. As shown in Fig. 3.1 B, hot plate latencies after injection of 
vehicle did not differ between the mutant mice and the wild-type controls. Acute 
intraperitoneal application of 10 mg/kg A9-THC exerted significant antinociceptive 
effects as measured by an increase of hot plate latencies in both the KO and the WT 
mice. Significant effects of A9-THC on latency was observed at all three time points 
analyzed (Univariate F-tests, p-value < 0.05), but there were no differences in the 
antinociceptive reactions to A9-THC between the genotypes. (Wilks multivariate test of 
significance; effect of treatment: F(3,34)=9.505, p<0.0001; influence of genotype: 
F(3,34)=0.151, p=0.928). 
Open-field observations revealed a significantly higher locomotor activity of the 
vehicle-treated nNOS-deficient mice as compared to the vehicle-treated wild-type 
controls (Univariate test of significance, p<0.01, data not shown). The 09-THC-induced 
changes in locomotion were therefore evaluated separately in each genotype and 
expressed as a percentage of the mean distance moved by the respective vehicle-treated 
group. The results in Fig. 3.1 C show that injection of 10 mg/kg A9-THC led to a 
decrease of movement in both genotypes, but this reduction reached significance only in 
the wild-type animals (Univariate test of significance, p<0.05). 
3.3.2 Cannabinoid receptor CB1 mRNA expression 
As a result of the different effects of A9-THC in the two genotypes regarding body 
temperature and locomotor activity, the levels of CB 1 mRNA were determined using in 
situ hybridization to reveal possible changes of CB 1 gene expression in the nNOS-KO as 
compared to the WT mice. Evaluation was performed by measuring the mean density 
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values on the autoradiographic films and included those brain areas which are proposed 
to be involved in mediating the respective cannabinoid-induced effects (Breivogel & 
Childers, 1998; Ameri, 1999; Martin & Lichturan, 1998). Periaqueductal grey, dorsal 
raphe, ventroposterolateral thalamus and amygdala were investigated regarding 
antinociceptive effects. Median preoptic area and ventromedial hypothalamus were 
evaluated in respect to hypothermia.. Caudate putamen, globus pallidus and substantia 
nigra were analysed regarding locomotor activity. 
Area Wild-type mice Knock-out mice 
Periaqueductal grey 63.2+5.5 
Dorsal raphe 38.9+6.5 
Ventroposterolateral thalamus 10.2+3.2 
Amygdala 144.1+6.7 
Median preoptic area 107+10.7 
Ventromedial hypothalamus 151.2+10.3 
Caudate putamen 201+8.9 
63.2+ 7.4 
38.3+ 4.7 
8.4+2.4 
128+6 
101+17.8 
114.8+ 23.9 
182 + 8.7 * 
Globus pallidus 21.3+3.6 18.0+1.4 
Table 3.1. Density values of the regions of interest reflecting CB 1 mRNA levels in nNOS knock- 
out (KO) and wild-type (WT) control mice. Hybridization was made using the same probe and in 
the same experiment. Slides from KO and WT were exposed to the same autoradiographic film. 
Data are shown as mean and SEM of averaged values from four sections from each mouse. N=6 
mice for each genotype; *p<0.05 between the two genotypes. 
Statistical analysis revealed a significant interaction between the genotype and the 
mean density values reflecting CB 1 mRNA levels (Wilks multivariate test of significance; 
effect of genotype: F(8,1)=12371.84, p<0.01). A subsequent detailed analysis of the 
particular areas (Table 3.1) showed that there were significantly lower levels of CB 1 
mRNA in the ventromedial hypothalamus and the caudate putamen of the KO in 
comparison to the WT mice (p<0.05). No significant 
differences between the two 
genotypes were observed in either of the other regions. 
Representative examples of the 
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in situ hybridization analysis are depicted in Fig. 3.2, showing decreased CB 1 expression 
in the ventromedial hypothalamus and caudate putamen, as compared with areas where 
no significant differences were observed (i. e. periaqueductal grey and median preoptic 
area). 
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Fig 3.2. Reversed dark-field micrograph of coronal sections showing examples of CB 1 mRNA 
expression levels in different brain areas, as compared between WT and nNOS-KO animals. (A, 
A') Periaqueductal grey and dorsal raphe. (B, B') Medial preoptic area. (C, C') Ventromedial 
hypothalamus. (D, D) Dorsolateral caudate putamen. Note the lower expression of CB 1 mRNA 
in VMH and Cpu in the nNOS-KO. Abbreviations: 3V, third ventricle; Aq, aqueductus; Cpu, 
caudate putamen; DR, dorsal raphe; MPA, medial preoptic area; PAG, periaqueductal grey (DM, 
dorsomedial; VL, ventrolateral); VMH, ventromedial hypothalamus. Scale bars: 100 fin. 
3.3.3 Analysis of CB1/nNOS coexpression 
Since mice lacking nNOS responded to A9-THC treatment at a reduced extent in 
particular behavioural paradigms and, moreover, showed a decreased expression of CB I 
in the brain areas that are considered to be involved in the behavioural effects of 09- 
THC, the question arose whether these results are based on a cell autonomous event, i. e. 
on changes in the physiology of neurons expressing both nNOS and CB 1, or whether the 
differential responses of nNOS-KO mice to A9-THC are the consequence of an altered 
cross-talk between different neurons. 
To answer this question, a double in situ hybridization study was carried out on 
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forebrain tissue of wild-type animals to describe the expression of nNOS and CB I at a 
single cell level. The mouse forebrain contains cells that express both high and low levels 
of CB 1 mRNA and protein (Matsuda et al., 1993; Tsou et al., 1998a; Pettit et al., 1998; 
Marsicano & Lutz, 1999, Chapter 2). While cortical areas possess both high and low 
CB 1-expressing cells, subcortical regions contain mostly low CB 1-expressing cells that 
are usually densely packed. Cortical areas, such as the hippocampus (Fig 3.3A), 
neocortex (Fig. 3.3B), entorhinal cortex or basolateral amygdala (data not shown) 
display a very low extent of coexpression of CB l with nNOS. 
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Fig. 3.3. Bright-field micrographs of coronal sections showing examples of coexpression of CB 1 
(red staining) with nNOS (silver grains), respectively, as detected by double ISH in WT mice. All 
sections were counterstained with toluidine blue. (A) CA3 area of hippocampus, showing 
coexpression only in the principal cell layer. (B) Double staining for CB1 and nNOS in 
neocortex. Almost no coexpression is observed. (C) Dorsal caudate putamen. Note the scattered 
distribution of nNOS-positive cells and the diffuse staining of CB 1. A certain fraction of nNOS- 
expressing cells contain also CBI mRNA. Filled arrows: CBI-expressing cell. Open arrows: 
nNOS-expressing cell. Arrowheads: cells coexpressing CBI and nNOS transcripts. Scale bars: 
20 µm. 
Only principal cells in CAI and CA3 regions of the hippocampus (Fig. 3.3A) and a 
few cells in the basolateral amygdala (data not shown) express low levels of CBI 
together with low levels of nNOS mRNA. Due to the low levels of CB I expression and, 
thus, to the diffuse appearance of the signals in subcortical areas, it was not always 
possible to determine single CB I -expressing cells with the same high precision as in 
cortical regions. However, in dorsolateral caudate putamen, one of the two regions 
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where an altered CB 1 expression was observed in the nNOS-KO as compared to the WT 
controls, an indicative evaluation of coexpression was possible. In the striatum, nNOS is 
present in scattered cells containing generally high levels of mRNA. In comparison, CB 1 
is expressed at low and uniform levels in the majority of medium-spiny neurons of the 
dorsolateral caudate putamen (Marsicano & Lutz, 1999; Chapter 2). An approximate 
numerical evaluation of nNOS/CB 1 coexpressing cells revealed that about 50% of 
nNOS-positive cells also express low levels of CBI mRNA (Fig. 3.3C). Due to the low 
levels of both CBI and nNOS mRNA in the ventromedial hypothalamus, it was not 
possible to evaluate numerically the coexpression in this area using the double in situ 
technique. 
Fig. 3.4. Dark-field micrographs of parallel coronal sections from a WT mouse showing the 
expression of nNOS (A) and CB 1 (B) in ventromedial hypothalamus. Note the similar 
distribution pattern of the two transcripts. Abbreviations: 3V, third ventricle; VMH, ventromedial 
hypothalamus. Scale bars: 100 gm. 
However, parallel sections hybridized either with radioactive riboprobes for CB 1 
or nNOS revealed a similar pattern of expression in this brain area (Fig 3.4). This 
observation allowed to conclude that in the mouse ventromedial hypothalamus, nNOS- 
expressing cells contain also CB 1 mRNA at a rather high levels. 
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3.4 Discussion 
This study aimed to investigate whether the nitric oxide pathway is involved in 
mediating 09-THC-induced central nervous system effects. Thus, the effects of 09-THC 
were examined in mice with targeted disruption of the neuronal nitric oxide synthase 
(nNOS) gene and in wild-type controls. Intraperitoneal injection of 10 mg/kg i\9-THC 
resulted in the same increase of the hot plate latencies in both genotypes, indicating that 
A9-THC-mediated antinociceptive effects do not require nNOS. In contrast, a significant 
09-THC-induced decrease of body temperature and locomotor activity was observed 
only in the wild-type mice, while the nNOS-KO mice showed a markedly reduced 
response. Determination of the expression of CB 1 by in situ hybridization revealed 
significantly lower levels of CB 1 transcripts in the ventromedial hypothalamus and the 
caudate putamen of the nNOS knock-out animals than in WT controls. These two areas 
are known to be among the regions involved in thermoregulation and cannabinoid- 
induced decrease of locomotion, respectively. Moreover, in these areas, CB 1 and nNOS 
mRNAs are expressed to a rather high levels in the same neurons. 
3.4.1 Antinociceptive effects 
The lack of differences in nociceptive response between the two genotypes 
observed in this study is surprising as it would be expected that 09-THC, which has been 
shown to reduce NMDA-receptor-mediated Ca 
2+ influx (Hampson et al., 1998b), also 
inhibits the production of NO and, thus, the NO-mediated increase of presynaptic release 
of glutamate, which in turn plays a major role in pain transmission (Zieglgänsberger & 
Tölle, 1993; Tölle et al., 1996). Other studies indicate that A9-THC-induced 
antinociception also involves systems such as the spinal noradrenergic and the kappa 
opioid systems, both of which do not play a role in other central effects of A9-THC. For 
example, intrathecal administration of the a2-noradrenergic antagonist yohimbine was 
shown to block the antinociceptive effects of 
intravenously applied A9-THC, but failed to 
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antagonize its cataleptic or hypothermic effects, indicating that involvement of the 
adrenergic system is relatively specific to antinociception (Lichtman & Martin, 1991). In 
addition, intrathecal or intracerebroventricular administration of the kappa antagonist 
nor-BNI (nor-binaltorphimine) was able to block the antinociceptive effects of 
intrathecally applied A9-THC, but again without affecting i\9-THC-induced catalepsy or 
hypothermia (Martin & Lichturan, 1998). These results together with the present findings 
suggest that 09-THC-induced supraspinal antinociception involves transmitter systems 
different from the NO pathway. 
3.4.2 Effects on thermoregulation and locomotion 
The results of pharmacological studies investigating the central role of the NO 
pathway in thermoregulation and locomotion are still contradictory (Scammell et al., 
1996; Gourine, 1995; Simon, 1998; Calignano et al., 1997; Sandi et al., 1995; Johansson 
et al., 1997). However, the behavioural results described here clearly show that nNOS is 
required for A9-THC-induced decrease of body temperature and locomotor activity. 
Several hypotheses can be put forward to explain the lack of effect of A9-THC in 
thermoregulation and locomotion in nNOS-KO mice. A very recent report (Nava et al., 
2000b) showed that in rats the hypothermic effect of A9-THC is mediated by a 
coactivation of CB 1 and dopamine D2-like receptors. Blockade of either CB 1 or D2 
completely abolished the hypothermic effects of 09-THC. The authors discuss that this 
effect could be attributed to the ability of A9-THC in vivo to induce the release of 
dopamine (Chen et al., 1990a, b) and to activate dopamine neurons (Diana et al., 1998; 
Gessa et al., 1998), which would consequently lead to a simultaneous activation of CB 1 
and D2-like receptors. Recently, Glass and Felder (1997) showed that in striatal neurons 
costimulation of CB 1 and D2-like receptors 
leads to an accumulation of cAMP, in 
contrast to the decrease normally observed upon activation of either receptor alone. In 
neuroblastoma cells (Inada et al., 
1998), cAMP accumulation was shown to stimulate 
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NO production. Dopamine D2 receptors are expressed in the striatum and in the 
ventromedial hypothalamus (Weiner et al., 1991) and are also colocalized with CB 1 to a 
considerable extent at least in the dorsolateral caudate putamen (Hermann, Marsicano & 
Lutz, unpublished results). CB1 is expressed in aproximately 50% of nNOS-positive cells 
in dorsolateral caudate putamen and in ventromedial hypothalamus a considerable 
number of neurons express both transcripts. Although triple colocalization studies would 
be required, it seems possible that CBI and D2 receptors are coexpressed with nNOS in 
the same cell. 
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Fig. 3.5. Schematic representation of a putative mechanism through which A9-THC might exert 
its effects on thermoregulation and locomotor activity, involving the nNOS pathway. A9-THC 
administration would induce the release of dopamine (DA). A9-THC and DA would 
simultaneously or sequentially stimulate CB1 and D2 receptors, respectively, provoking an 
accumulation of cyclic adenosin monophosphate (cAMP). cAMP accumulation would lead to an 
activation of nNOS with a release of NO, which would exert the decreases in temperature and/or 
locomotion, through a still unknown mechanisms (X). 
Taken together, as depicted in Fig. 3.5, these observations speak in favour of the 
following cascade of events: coactivation of CB 1 and D2-like receptors on the same cell 
may result in an accumulation of cAMP with a subsequent 
increase of nNOS activity and 
A9-THC 
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an enhanced release of NO, which would finally exert the hypothermic and, possibly, also 
the locomotor effects of A9-THC. This interpretation of the results, however, appears to 
be inconsistent with the report of Thorat and Bhargava (1994). These authors found that 
pretreatment of mice with the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA) 
did not change analgesic or hypothermic effects of A9-THC. Such an apparent 
discrepancy could be explained by intrinsic differences between pharmacological and 
genetic approaches. It is possible that the treatment of animals with L-NMMA is not 
sufficient to completely block the stimulation by 09-THC. Alternatively, the disruption of 
the nNOS gene could lead to profound alterations, such as defective brain development, 
or/and to the disruption of downstream pathways that cannot be achieved by a 
pharmacological treatment with nNOS inhibitors. One example of a long-term effect 
caused by the disruption of the nNOS gene is our observation of decreased levels of CB 1 
mRNA in the striatum and the ventromedial hypothalamus in the knock-out mice. 
Alternatively or complementary to the explanation depicted in Fig. 3.5, this change in 
CB 1 expression could also serve as a molecular mechanism to explain the decreased 
effects of A9-THC in locomotion and thermoregulation in nNOS-KO mice (Fig. 3.6). 
Investigations using human neuroblastoma, lymphoma and endothelial cells have revealed 
that anandamide is rapidly taken up by a high affinity transporter which can be activated 
by NO (Maccarrone et al., 1998,2000). Within the cell, anandamide is then hydrolyzed 
to arachidonate and ethanolamine by the fatty acid amide hydrolase (FAAH) 
(Mechoulam et al., 1998; Di Marzo & Deutsch, 1998). In this context, it could be 
hypothesized that the lack of NO in the nNOS-KO mice may lead to a decreased re- 
uptake of endogenous anandamide and, thus, to an increased extracellular concentration. 
High levels of extracellular anandamide may in turn downregulate CB 1 expression in 
selected areas such as the caudate putamen, as it 
is also described for long-term 
treatment of rats with A9-THC (Corchero et al., 1999; Zhuang et al., 1998). Finally, 
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decreased levels of CB 1 would lead to a reduced responsiveness to A9-THC as observed 
in this study (Fig. 3.6). 
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Fig. 3.6. Schematic representation of a putative mechanism through which the lacking of nNOS 
might lead to a decrease in CBI mRNA expression and, thus, a decreased responsiveness to A9- 
THC in selected areas. A, Wild type situation: NO is able to activate the anandamide transporter 
(AT), thus contributing to the equilibrium between extracellular anandamide (AEA) and 
intracellular uptake and degradation through the enzyme fatty acid amide hydrolase (FAAH). 
Extracellular AEA binds to CB 1 receptors in an equlibrate fashion and thus the turnover of CB 1 
mRNA is maintained physiologically constant. B, nNOS knock out situation: the lack of a 
functioning nNOS decreases the levels of NO and thus also the positive drive onto AT. Therefore 
extracellular levels of AEA are free to overstimulate CB1 receptors, with the consequent 
alteration of the receptor mRNA turnover and a decrease of CB I mRNA synthesis. Decreased 
levels of CB 1 would, in turn, account for the decreased activity of A9-THC in selected brain areas 
related to locomotion and thermoregulation. For clarity, the processeses are depicted in different 
cells, but it is possible that they happen in the same cell. 
Another mechanism explaining the observed down-regulation of CB 1 can also be 
put forward. NO-responsive elements were characterized in the promoter of the tumor 
necrosis factor alpha gene and were found to be Spl binding sites (Wang et al., 1999). 
As the mouse CB 1 gene also contains several Sp I binding sites (Marsicano & Lutz, 
unpublished results), the down-regulation of CB 1 mRNA levels could also be mediated 
by the reduced transcriptional activation of the CB 1 gene due to reduced stimulation by 
NO. In other terms, the changed A9-THC responsiveness observed in the nNOS-KO 
86 
mice could then mainly or partly be due to the reduced levels of CB 1 transcripts in the 
respective brain regions, i. e. in the ventromedial hypothalamus and in the dorsolateral 
caudate putamen. 
In conclusion, the behavioural and molecular findings described in this Chapter 
clearly suggest that the nitric oxide pathway is involved in some of the central effects of 
A9-THC including hypothermia and decrease of locomotor activity. In addition, it 
appears that this transmitter system plays only a minor role in A9-THC-induced 
supraspinal antinociception. 
In Chapter 2 and in the present Chapter, CB 1 was analysed in some of its 
neuroanatomical and functional aspects. However, the cannabinoid system represent a 
potentially very important and complex neuromodulatory apparatus that is likely to 
interact with many neuronal systems in the brain. CB 1-deficient mice could represent 
very powerful tools to gain deeper insights into the specific functions of the cannabinoid 
system in different brain activities. For this reason, a genetic approach was carried out to 
understand the functions of CB 1 during the preparation of this Thesis. Next Chapter will 
describe an innovative gene targeting approach to enable us obtain a spatio-temporal 
specific disruption of CB 1. 
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Chapter 4 
Generation of mouse CB1 mutants 
4.1 Introduction 
During the last decade, targeted mutagenesis in mice has become one of the most 
powerful tools to study gene function. The potential to disrupt or modify in principle any gene 
of interest in the mouse genome has led to fundamental discoveries in all fields of mammalian 
biology, ranging from embryonic development to the generation of animal models for human 
diseases. A milestone in the development of the gene targeting technology was the 
establishment of totipotent cell lines (embryonic stem cells, ESCs) derived from mouse 
blastocysts (Bradley et al., 1984). If kept in appropriate conditions, these cells can contribute 
to all cell types of the body including germ cells. The second hallmark was the observation by 
Capecchi and colleagues (Folger et a1., 1982) that mammalian somatic cells possess the 
enzymatic machinery for efficiently mediating homologous recombination between newly 
introduced, non-replicating DNA molecules. Both, homologous recombination and the 
availability of embryonic stem cells led to the first gene disruption experiments (Thomas & 
Capecchi, 1987; Doetschman et al., 1987), now currently referred to as gene "knock-out". 
When this approach became available for the scientific community, hope arose to study 
and understand protein functions in the entire animal, thus avoiding many of the limitations of 
in vitro models. Also for behavioural studies, this technology appeared to be suitable to 
understand the basic mechanisms underlying highly complex brain functions, such as learning 
and memory, cognition and pain perception. Indeed, in the last 10 years, enormous progress 
has been made in the study of higher brain functions by using this technology. As an example, 
the study of learning and memory in gene targeted mutant animals has led to the discovery of 
important key mechanisms by which the brain is able to select, to store and to recall 
information (Silva et al., 1992; Grant et al., 1992). 
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Despite the progress enabled by this new technology, some intrinsic caveats and 
limitations became soon evident. 
1. Lack of temporal restriction. In a "conventional" gene targeting experiment, the gene of 
interest is disrupted in every cell of the animal; thus, it is inactivated both during development 
and adult life in all tissues. However, many proteins have different functions in various stages 
and tissues, e. g. early functions, essential for the normal embryonic growth and development 
and later functions in the adult, participating in molecular mechanisms to control the 
physiological status of the organism, including specific behaviours. Thus, in a "conventional" 
knock-out, we might provoke general developmental defects that mask the function(s) of a 
gene in the adult. 
2. Lack of spatial selectivity. The central nervous system is highly complex. Different 
anatomical regions and different cell types in the same regions differentially contribute to 
various physiological functions. On the other hand, particular brain functions, such as 
behaviour, are the result of coordinate interactions between different anatomical regions and 
cell types. In most cases, proteins are expressed in many anatomical regions and cell types, 
very often exerting different tasks. Therefore, in the attempt to understand the contribution of 
a given gene product to particular CNS functions, it is essential to "dissociate" this 
contribution into its anatomical and cellular aspects. When a gene function is disrupted by 
"conventional" gene targeting, all body cells will carry this modification. Therefore, it is 
difficult, if not impossible, to relate the protein function to particular anatomical brain regions 
and cell types. 
3. Compensatory mechanisms. Mammalian cells in general, and neuronal systems in 
particular, are equipped with finely regulated control systems which help to overcome 
naturally occurring imbalancies. Thus, the disruption of a gene at early stages of development 
could induce compensatory mechanisms which could mask important functions of the gene in 
the adult physiology. Such mechanisms could range from the simple compensatory 
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overexpression of other related proteins with similar functions, to the misexpression of non- 
related genes, finally leading to a possible phenotype masking the function of the targeted 
gene and resulting in an interpretation of gene function that is only partially correct (for a 
review, see Gerla. i, 2000). 
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Fig. 4.1. Schematic representation of the Cre/loxP system. A. Graphical representation of loxP site 
(red triangle), Cre recombinase (blue circle) and nucleotide sequence of the loxP site. LoxP consists of 
two sequences forming a palindrome, which is separated by a non-palindromic nucleotide stretch. 
Orientation of the loxP site is given by the orientation of this core sequence. Two molecules of Cre bind 
to one loxP site (Mack et al., 1992). B. When loxP sites are oriented "head-to-head", Cre recombinase 
catalyzes an inversion of the sequence between the two IoxP sites. C. When loxP sites are oriented 
"head-to-tail", Cre recombinase catalyzes an excision of the interposed sequence. 
Therefore, during the last years, great efforts have been made to improve the gene 
targeting methodology in order to reduce the intrinsic problems of the "conventional" knock- 
out, and to obtain disruption or modification of targeted genes in a more selective way. This 
+tft 
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new technology is commonly referred to as "conditional" gene targeting, using the Cre/loxP 
system (Sauer & Henderson, 1989). 
A 
XX 
B 
Fig. 4.2. Schematic representation of different gene targeting strategies. A. "Conventional" gene 
targeting. The sequence to be deleted (X, top) is displaced by the selection cassette (usually an 
antibiotic resistance gene, bottom). B. "Conditional" gene targeting. The wild type gene (top) is 
conserved, but two loxP sites and a selection cassette from the targeting construct (bottom) are 
introduced. In order to guarantee the completely wild type expression of the floxed gene, the selection 
cassette is flanked by two different recombination sites (FRT), that will be excised by another 
recombinase, called flipase (see below, same paragraph). X, sequence of interest; selection, selection 
cassette; red triangles, loxP sites; blue triangles, FRT sites; black bars, homology arms. 
Cre recombinase is aP1 bacteriophage-derived enzyme that is able to mediate site- 
specific recombination between a 34 bp-long sequences referred to as loxP (locus of 
crossover x in P 1) (Sternberg & Hamilton, 1981). The loxP site consists of two 13 bp-long 
repeats oriented head-to-head and forming a palindrome, which is interrupted by an 8 bp-long 
non-palindromic sequence. This sequence gives an intrinsic orientation to the loxP site (Fig. 
4.1). 
To generate a "conditional" knock-out with the Cre/loxP system, two components are 
required. First, by homologous recombination in ES cells, two loxP sites are introduced 5' 
and 3' to the gene of interest (Fig. 4.2). Second, cells containing the correctly recombined 
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locus are then used to generate a mouse line expressing the "floxed" (i. e. flanked by two loxP 
sites) sequences of interest. Given the shortness of the loxP sequences, and provided the 
excision of the selection cassette (see below, same paragraph) this mouse line is still 
expressing the gene of interest in a wild type manner. This line is then crossed with a 
transgenic mouse line expressing Cre-recombinase in a defined tissue and/or at a distinct time 
point. In the progeny mice, Cre will recognize the two loxP sites and will excise the 
sequences between these sites. Depending on the regulatory sequences that drive the 
expression of Cre, the excision of the sequence of interest will be "conditioned" in a temporal 
and/or spatial way (Fig. 4.3). 
wild type 
1 
º IoxP " Cre recombinase 
- gene of interest 
i- 
_L 
modified = "wild type" Tissue-specific 
or floxed allele expression of 
re recombinase 
Tissue-specific mutant 
Fig. 4.3. Schematic representation of a "conditional" gene targeting using the Cre/loxP system. Red 
triangles are loxP sites; blue circle is Cre recombinase; black box is the gene of interest. 
CB 1 is expressed in several different regions of the CNS and, as shown in Chapter 2 
and 3, in different cell populations. It is also expressed, even though at lower levels, in 
peripheral tissues (e. g. Shire et al., 1995) and at high levels during the entire embryonic 
development (Buckley et al., 1998; Paria et al., 1995; Berrendero et al., 1998). Therefore, a 
"conventional" gene knock-out might not give conclusive insights into the roles of CB 1 in the 
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adult brain physiology. Indeed, despite the valuable information gained, the published CB 1 
mutants obtained by "conventional" gene targeting approaches reveal phenotypic aspects 
whose origin might be partially due to the lack of temporal and/or spatial restriction of the 
gene deletion. As an example, it cannot be excluded that the lack of CB 1 expression during 
embryonic development of the mutants is among the causes leading to the defects described 
by Zimmer et al. (1999) in adult animals. These mice showed hypomotility, hypoalgesia and 
premature death. Both hypomotility and hypoalgesia are surprising, considering the similar 
effects caused by pharmacological treatment with CB 1 agonists (Chaperon & Thiebot, 1999). 
Locomotion defects are likely due to alterations in gene expression in striatal cells, where the 
transcripts encoding for the opioid peptides dynorphin and enkephalin are present at higher 
levels in mutant animals as compared to wild type controls (Steiner et a1., 1999). As it was 
shown that cannabinoid treatment during pregnancy can increase the adult expression of 
opioid peptides, decrease opioid receptors and increase the morphine self-administration in 
adult offspring (Vela et at, 1998; Corchero et at, 1998; Manzanares et at, 1999), it cannot 
be excluded that the defects observed in adult CB 1 mutant animals are due to alterations 
occurring during in utero development. In other words, it is possible that the disruption of a 
functional cross-talk between cannabinoid and opioid system in utero is one of the principal 
causes of the adult phenotype observed in the mutants, thus, the function of CB 1 in the adult 
brain physiology might be masked by alterations during development (Gerlai, 2000). 
Embryonic deficits could also account for the early mortality described in this mutant line 
(Zimmer et al., 1999). At birth, the expected Mendelian distribution is not completely 
reached, likely indicating a certain rate of embryonic lethality of CB 1 null mutants. 
Furthermore, homozygous mice died without any obvious sign of disease in a higher 
incidence than heterozygous or wild type littermates, starting as early as 6-8 weeks after birth. 
Obviously, this might represent a major obstacle in the phenotypic analysis of the adult. In 
addition, the hypomotility of the mice described by Zimmer et al (1999) might mask other 
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important phenotypic aspects of the mutants. As an example, the majority of learning and 
memory paradigms require the animal to accomplish tasks in which a correct locomotion 
system is necessary. It appears obvious that it is very difficult to test hypomotile mice in such 
paradigms. A spatially restricted deletion of CB1 in brain regions not directly involved in 
locomotor functions would presumably avoid this obstacle (see 4.4 "Discussion"). Also 
Ledent and colleagues (1999) described another mutant CB 1 mouse line obtained by 
"conventional" gene targeting. In contrast to the results of Zimmer et a1. (1999), these mutant 
mice did not present any evident phenotypes without pharmacological treatment. They were 
unresponsive to cannabinoid treatment and, interestingly, showed reduced sensitivity to 
addictive effects of opiates (Ledent et aL 1999). The apparent discrepancies between the 
phenotypes of these two mouse lines are likely to be caused by the different genetic 
background used during analysis. CB 1-KOs from Ledent at A (1999) were bred in the 
outbred CD 1 strain, while the line of Zimmer et al. (1999) was back-crossed into the inbred 
C57BL/6J strain. It is possible that CB1 has different functions in adult brain physiology in 
these two mouse strains, but it appears also likely that the lack of CB 1 causes different 
developmental alterations in different strains, thus, leading to different adult phenotypes. 
Generally, outbred strains possess a higher vigor than inbred strains, probably due to the 
lower homozygosity rate. Therefore, it could be suggested that inbred strains such as 
C57BL/6J have compensatory mechanisms during prenatal development insufficient to 
completely compensate the lack of CB 1. On the other hand, the outbred CD 1 strain may have 
a better compensatory machinery. Moreover, it is interesting to note that the alterations in 
gene expression described by Zimmer and colleagues (Steiner et a1., 1999) also involve 
components of the endogenous opioid system, such as dynorphin and enkephalin. This 
observation, together with the above mentioned experiments showing that prenatal 
cannabinoid treatment causes profound alterations in the adult endogenous opioid signalling 
(Manzanares et a1., 1999), might indicate a similar interaction between CBI and opioid 
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system at prenatal stages also in the CB 1-mutant mice described by Ledent et al. (1999). 
Therefore, it cannot be excluded that also the cause of the reduced sensitivity to the addictive 
effects of opiates as observed in the mice generated by Ledent et at (1999) resides in the 
disruption of the functional cross-talk between CB 1 and opioid system in utero, similarly to 
as hypothesized above for CBI mutants in C57BL/6J background. These potential 
developmental effects of the disruption of CBI were not analysed by the two groups. 
However, it appears possible that the phenotypes described by Zimmer et al. (1999) and 
Ledent et al. (1999) in adult mutant animals are only partially due to the lack of the gene at 
the moment of the analysis. Moreover, it is possible that the discrepant results obtained in the 
two different strains are due to a different compensatory potential to similar alterations 
occurring during in utero development. In other words, the hypoalgesia and hypolocomotion 
observed in the mutant mice from Zimmer et a1. (1999) and the lack of morphine self- 
administration described in the mice of Ledent et al. (1999) cannot necessarly be attributed to 
specific functions of CB 1 in the adult brain physiology. 
As mentioned above, one of the aims of "conditional" gene targeting is to avoid any 
possible misinterpretation caused by "conventional" approaches, where compensatory 
mechanisms might mask the real function of a deleted gene. Moreover, while "conventional" 
gene targeting experiments do not have spatial resolution, the "conditional" approach can 
provide information about the specific region or cell type where CB 1 function resides. Taken 
together, in order to analyze the physiological roles of CBI in the adult mouse brain, a 
"conditional" gene targeting approach was chosen, with the hope to obtain information as 
precise as possible and not to mask the phenotypes by "compensatory" mechanisms. 
The generation of a "floxed" mouse line is a time-consuming experiment. It is therefore 
important to be able to show the actual functioning of the system as soon as possible. The 
quickest way to demonstrate the Cre-mediated excision of the gene in the living animal is the 
generation of a "null mutant", by crossing the "floxed" mouse line with a so-called "Cre- 
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deleter" mouse line, in which Cre expression is driven by a constitutive promoter (Schwenk et 
al., 1995). By this way, the excision of the gene of interest is achieved in all body cells, 
including germ cells. Moreover, despite the fact that a "conventional" null mutation approach 
has the main limitations described above, e. g. for behavioural analyses, such mutants can 
constitute an useful tool for phenotypic analyses at cellular levels, such as investigations on 
primary neuronal cultures. CB 1 null mutant mice (designated here as CBN) were generated in 
order to study the neuroprotective effects of cannabinoid compounds in vitro (Chapter 5). 
Another important prerequisite of the Cre/loxP approach is the perfect wild type expression 
of the "foxed" gene before the Cre-mediated excision. The targeting approach needs the 
presence of a selection gene to select for the recombined locus. Usually, the enzyme 
neomycin phosphotransferase "Neo") is used to confer to the cells the ability to survive in 
presence of the neomycin derivative geneticin (G418). Generally, the presence of such a 
"cassette" in the gene locus is not a problem in the "conventional" gene targeting approach, as 
the gene of interest is simply substituted by the selection cassette (Fig. 4.2A). In a 
"conditional" gene targeting approach, however, the presence of the "Neo" cassette might 
influence the expression of the targeted gene. Therefore, in the gene targeting construct 
described in this Chapter, the "Neo" cassette is flanked by two other recombination sites, 
named "FRT" (Flipase Recombination Target). These sites are recognized by another 
recombinase called "flipase" (Flp) (Landy, 1992). As Flp/FRT system is originally derived 
I, -- yeast, which grow at 30°C, it is less efficient than Cre/loxP at 370 C. However, Flp/FRT 
still maintains a sufficient activity to allow a Flp-mediated excision in mammalian cells 
(Dymecki, 1996). In this thesis, it was decided to excise the "Neo" cassette by crossing the 
"floxed-Neo" CBI mice with a "Flp-deleter" mouse line, which express Flp recombinase 
ubiquitously (Dymecki, 1996). 
In this Chapter of my thesis I will describe the generation of the "floxed CB 1', mouse 
line. Moreover, the in vivo functioning of the Cre-mediated excision of the "floxed" CB 1 gene 
96 
will be shown by the generation of the CB 1 null mutant (CBN). Further potential applications 
of the technology to the study of the cannabinoid system in the mouse physiology are also 
discussed. 
4.2 Materials and methods 
4.2.1 Molecular biology 
Where not differently stated in the results section, these are the basic methods used 
during the work. Solutions are described as final concentration. Stock solutions were 
prepared according to Sambrook et al. (1989). DNA sequencing was performed by MWG 
Biotech (Germany). The plasmid pFTM-loxP, containing the 34 bp-long loxP site, was 
obtained from Dr. Theo Mantamadiotis, Heidelberg, Germany. The plasmid pSVpaZl1- 
PGK-Neo, containing the selection Neo cassette (neomycin phosphotransferase gene) under 
the control of the human PGK (phosphoglycerate kinase I) promoter and flanked by two FRT 
sites was a kind gift of Dr. Bernhard Löscher, Zurich, Switzerland. This plasmid constitutes a 
derivative of pSVpaZll, generated by Dr. Francis Stewart, Heidelberg, Germany. "Cre- 
deleter" mouse line is described in Schwenk et al. (1995) and was kindly provided by Prof. 
Rajewsky, Köln, Germany. "Flp-deleter" mouse line is described in Dymecki (1996) and was 
kindly provided by Dr. Susan Dymecki, Baltimore, U. S. A. Both these mouse lines were bred 
in a C57BL/6 genetic background. 
4.2.1.1 Restriction digestions and ligations 
Restriction enzymes and modification enzymes were purchased from New England 
BioLabs (NEB, USA). Digestions of plasmid DNA were carried out in the appropriate buffer 
at the recommended temperature for 1-5 hours. Enzyme units used were adjusted to the 
amount of DNA to be digested. When necessary, DNA fragments were blunted after 
digestion. Briefly, DNA digest (2-5 µg) was mixed in a total volume of 100 µl containing 1x 
T4 DNA polymerase buffer, 0.5 mg/mi BSA, 0.1 mM each of dATP, dCTP, dTTP, dGTP, 
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4.5 units of T4 DNA polymerase. The mixture was incubated 20 minutes at 11 IT, and the 
enzyme was inactivated by adding 20 of 0.5 M EDTA. For ligation, DNA fragments and 
vectors were separated by gel electrophoresis (0.8-1.5% agarose in Ix TAE: 40 mM Tris- 
acetate, 1 mM EDTA, pH 8.0, containing 0.1 µg/ml ethidium bromide) and purified using the 
Gel Extraction kit (Qiagen, Germany). Ligations were performed with T4 DNA ligase, in 10 
µl of provided ligation buffer and with molar ratios of vector: insert ranging from 1: 2 to 1: 10. 
All plasmids generated in this thesis are derived from pBlueScript KS(-) (pKS, Stratagene, 
U. S. A. ). Digestions of genomic DNA were performed after precipitation of 10-20 µg DNA 
from mouse tail or of the entire DNA content of a single well of a 96-well plate of DNA from 
ESC clones (see below). DNA pellets were resuspended in 30 µl of final digestion solution, 
containing 1x buffer, 100 µg/ml RNase A (NEB, USA) and 100 units of restriction enzyme. 
After 6-12 hours of incubation at the recommended temperature, spermidine at final 
concentration of 4 mM and 60 units of enzyme were added, and the reaction was further 
incubated at the same temperature overnight. 
4.2.1.2 Polymerase Chain Reaction (PCR) 
PCR reactions were performed in a final volume of 50 0 containing 10 mM Tris-HC1 
pH 8.3,50 mM KCI, 1.5 mM MgCI2,0.2 mM dNTPs, 0.5 pmoVgl of both forward and 
reverse primers, 1 µl of DNA template (50-500 ng), 10 of DNA polymerase. Taq 
polymerase was used for most of the reactions. When particularly precise amplification was 
needed, recombinant Pfu polymerase (Stratagene, USA) was used. All primers were designed 
to have a T. of approximately 58°C. Thus, all PCR reactions were carried out in a 
Robocycler (Stratagene) with the following parameters: 1 cycle at 95°C for 5 minutes; 37 
cycles at 95°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute; 1 cycle at 72°C for 5 
minutes. Table 4.1 shows name, sequence, orientation and relative position of the primers 
designed and used in this chapter. 
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Name Sequence Orientation Position 
GI 5' - GTT GAG CCT GGC CTA ATC AAA - 3' forward - 30 bp from CBI ATG 
G2 5' - CCG ATG AGA CAA CAG ACT TCT - 3' reverse + 1500 bp from CB1 ATG 
G3 5' - GTT GAC CGA ACC TCT GTT TTC - 3' forward - 182 bp from CB1 ATG 
G7 5' - GGA CTT GGC AGA CGA ATT GTA - 3' forward - 199 from putative intron donor site 
G8 5'- CTA CCC CTG AAG GAA GTT AGA - 3' reverse + 167 from CB1 ATG 
G50 5'- GCT GTC TCT GGT CCT CTT AAA - 3' forward - 563 bp from CB 1 ATG 
G51 5' - GGT GTC ACC TCT GAA AAC AGA - 3' reverse - 150 bp from CB 1 ATG 
G52 5' - GAC TGT CAC CGT GCT TAC TTA - 3' forward + 1539 bp from CB1 ATG 
G53 5'- CTC CTG TAT GCC ATA GCT CTT - 3' reverse + 1957 bp from CBI ATG 
G54 5' - CCT ACC CGG TAG AAT TAG CTT - 3' reverse + 22 bp from 5' FRT site in FRT-PGK-Neo cassette 
Table 4.1. PCR primers. 
"Cre-deleter" mice were genotyped by PCR as described in Schwenk et al. (1995), 
using the primers B42 (5'- GAT CGC TGC CAG GAT ATA CG - 3') and B43 (5'- CAT 
CGC CAT CTT CCA GCA G- 3'), in the same conditions as described above. "Flipase- 
deleter" mice were genotyped as described in Dymecki (1996), using the primers B34 (5'- 
GTG GAT CGA TCC TAC CCC TTG CG - 3') and B35 (5'-GGT CCA ACT GCA 
GCC CAA GCT TCC - 3'), in the following conditions: 1 cycle at 95°C for 5 minutes, 
70°C for 3 minutes and 72°C for 5 minutes; 34 cycles at 90°C for 1 minute, 70°C for 1 
minute, 72°C for 1 minute; 1 cycle at 72°C for 10 minutes. 
4.2.1.3 Transformation and growth of bacteria, bacterial colony lift and plasmid 
purification 
Bacteria were transformed with a few ng of plasmid DNA, or with 5µl of ligation 
reaction. Competent DH5a cells were thawed on ice. Plasmid DNA or ligation reaction was 
added to 200 µl of bacterial suspension and incubated for 30 minutes on ice. After 1 minute 
and 30 seconds at 42°C, 800 µl of SOC buffer (20 g/1 bactotryptone, 5 g/1 yeast extract, 
0.5 g/l NaCl, 20 mM glucose) were added and cells were shaken for 30 minutes at 37°C. 
Finally, bacteria were plated onto Luria Broth (LB)-agar plates containing 100 µg/ml 
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ampicillin. In some cases, colony lifts were necessary to find positive clones. The procedure 
for bacterial colony lifts was identical as for the phage plaque lifts (see below, 4.2.1.4 
"Growth of genomic DNA phage library and phage plaques lift"), with the only differences 
that one single Hybond NX membrane (Amersham, USA) was used for each plate and that, 
after transfer, bacterial plates were reincubated at 37°C for 2-4 hours in order to rescue the 
colonies. Mini plasmid purifications were carried out by growing single bacterial colonies in 2 
ml of LB overnight. 1 ml of the culture was then centrifuged and the cell pellet was lysed in 
300 µl of TENS buffer (10 mM Tris/HC1 pH 7.5,1 mM EDTA, 0.1 M NaOH, 0.5% SDS). 
After 5 minutes of lysis, 150 µl of 3M Sodium acetate pH 5.2 were added and, after 
vortexing, the lysate was incubated on ice for 5 minutes. Then, the preparation was 
centrifuged at 16,000 xg for 10 minutes at 4°C. 400 µl of the supernatant was collected in a 
fresh tube containing 900 µl of 100% ethanol. DNA was precipitated for 5 minutes at 4°C, 
and centrifuged at 16,000 xg for 5 minutes. The DNA pellet was washed with 70% ethanol, 
air-dried and resuspended in 30 0 of TE buffer (10 mM Tris/HC1 pH 7.5,1 mM EDTA), 
containing 100 µg/ml RNase A. 
4.2.1.4 Growth of genomic DNA phage library and phage plaques lift 
A lambda DASHII genomic library constructed from E14 embryonic stem cells partial 
Sau3A genomic digestion (Kühn et al., 1991) was screened to isolate DNA fragments 
containing the CB1 locus. A single colony of the host e. coli LE392 was inoculated in 50 ml 
of LB, supplemented with 0.2% maltose and 10 mM MgSO4. Cells were incubated overnight 
at 300C and were then centrifuged at 2000 rpm. Bacterial pellet was gently resuspended in 30 
ml of 10 mM MgSO4. From this point on, bacteria were kept on ice. The optical density at 
600 nm (OD6oo) of bacterial suspension was measured and the cells were diluted in 10 mM 
MgSO4 to OD6oo = 0.5. NZY agar plates (22x22 cm for primary screening or 9 cm diameter 
for further screenings) were prewarmed at 43°C. NZY agar plates contain 5 g/l NaCl, 2 g/l 
MgSO4-7FbO, 5 g/l yeast extract (LIFE Technology, U. S. A. ), 10 g/l NZ Amine (casein 
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hydrolysate, Sigma, U. S. A. ), and 1.5% Difco bacto agar. Absorption of phages onto bacteria 
was obtained by incubating (15 minutes at 37°C) 1.2 ml of host bacteria (Moo = 0.5) with 
900 µl of phages diluted in SM buffer (primary screenings), or 200 µl of host bacteria with 
100 0 of phages (further screenings). SM buffer consists of 5.8 g/1 NaCI, 2 g/1 MgSO4-7H20, 
50 mM Tris-HCI, and 0.01% gelatin, pH 7.5. As determined by preliminary titration 
experiments, 100,000 plaque forming units (pfus) were used for primary screening, 10,000 
pfus for secondary, 1,000 pfus for tertiary and 100 pfus for quarterly. Top agar (as NZY agar 
plates, but containing 0.7% agarose instead of Difco bacto agar) was melted in microwave 
and cooled down in water bath to 48°C. 25 ml (primary screenings) or 2.5 ml (other 
screenings) of top agar were added to the phage/bacteria mixture, quickly mixed and 
immediately poured onto NZY agar plates that were prewarmed at 43°C. After solidification 
of top agar/phage/bacteria mixture, plates were incubated overnight at 37°C. After growth of 
phages, appearing as plaques in the layer of bacteria, plates were chilled at 4°C. Hybond NX 
membranes (Amersham, USA) of the appropriate size were carefully placed onto the surface 
of the plates and were let soak for 2 minutes. Asymmetrical holes were made onto the 
membrane with a syringe needle, in order to know the relative position of plaques. After 
peeling the first membrane, a second membrane was put onto the plate surface for a second 
transfer of 5 minutes. Membranes with phage plaques uppermost were placed onto a series of 
sheets of 3MM filter paper soaked with denaturing and neutralizing solution, for 5 minutes 
and twice for 3 minutes, respectively. Denaturing solution contains 1.5 M NaCl, and 0.5 M 
NaOH. Neutralizing solution contains 1.5 M NaCl, and 0.5 M Tris-HCl pH 7.4. After the 
second neutralizing step, membranes were vigorously washed in 2x SSC (20x SSC is 3M 
NaCI, 0,3 M Na3 citrate, pH 7.0) to remove protein debris and were then air-dried. DNA was 
fixed to the membrane by UV crosslinking in a Stratalinker (Stratagene, USA). 
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4.2.1.5 Isolation of genomic DNA 
4.2.1.5.1 DNA preparation from mouse tails 
About 0.5-1 cm of a mouse tail was cut and put into 700 µl of tail lysis buffer (50 mM 
Tris-HC1 pH 8.0,100 mM EDTA, 100 mM NaCI, 1% SDS). 40 µl of 10 mg/ml Proteinase 
K stock were freshly added and tails were incubated overnight at 56°C. Then, 300 µl of 
saturated NaCl (7 M) were added, and the mixture was shaken for 5 minutes. After 
centrifugation at room temperature at 16,000 xg for 5 minutes, 750 µl of the supernatant 
were transferred to a fresh tube, containing 500 pi isopropanol. After mixing by inversion and 
centrifugation as above, the supernatant was removed, and the DNA pellet was washed once 
in 70% ethanol and air-dried for 10-20 minutes at room temperature. Finally, the DNA pellet 
was resuspended in 150-300 µl of TE and stored at -20°C. 
4.2.1.5.2 DNA preparation from embryonic stem cells 
G418 resistant embryonic stem cells clones (see 4.2.2.3 "Electroporation of ESCs, 
antibiotic selection, picking and expansion of resistant clones") were grown on gelatin-coated 
96-wells plates until they reached complete confluence. Then, cells were rinsed twice with 
PBS (139.9 mM NaCI, 2.7 mM KCI, 10.1 mM Na2HPO4-H20,1.8 mM KH2PO4, pH 7.4) 
and 50 µl of ESC lysis buffer (10 mM Tris HCI, 10 mM EDTA, 10 mM NaCI, 0.5% Sarcosyl 
and 1 mg/ml Proteinase K freshly supplemented) was added. Plates were incubated overnight 
at 500C in a sealed humid chamber. Then, plates were spun 1 minute at 2500 rpm, and 100 µl 
of a freshly prepared mixture containing 150 µl of 5M NaCl dissolved in 10 ml of 100% 
ethanol were added to precipitate nucleic acids. Plates were shaken at room temperature for 
30 minutes and were then spun again at 2500 rpm. Supernatant was discarded, and 
precipitated nucleic acids were rinsed three times with 150 µl of 70% ethanol. After the final 
wash, precipitated nucleic acids were either left in 70% ethanol and stored at -200C, or air- 
dried for 10 minutes and resuspended in digestion solution (see above, 4.2.1.1 "Restriction 
digestion and ligation") for Southern blot analysis or in TE buffer for PCR analysis. 
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4.2.1.6 Southern blotting 
4.2.1.6.1 Electrophoresis and transfer 
Digested genomic, phage or plasmid DNA was electrophoresed in 0.8-1.2% agarose 
gels. The gels were then photographed on a UV transilluminator and then shaken 10 minutes 
in a solution of 0.25% HCI. After rinsing with distilled water, the gels were shaken 30 
minutes in denaturation buffer and then, 30 minutes in neutralizing buffer (see above, 4.2.1.4 
"Growth of genomic DNA phage library and phage plaques lift", for composition of the 
buffers). Capillary blot was performed in lOx SSC, as described in Sambrook et al. (1989), to 
transfer DNA onto Hybond NX filters (Amersham, USA). Gels with genomic and phage 
DNA were blotted overnight, whereas gels containing plasmid DNA were blotted with three 
different filters for 10 minutes, 5 minutes, and overnight, respectively. This procedure allows 
to hybridize the same plasmid digestions with three different probes at the same time. 
4.2.1.6.2 Hybridization 
Membranes containing either digested genomic, phage or plasmid digested DNA after 
blotting, or bacterial colonies or phage plaques after membrane lifts, were pre-incubated for 2 
hours at 65°C in 20 ml of pre-warmed hybridization buffer (0.5 M Na-phosphate buffer pH 
7.2,7% SDS, 10 mM EDTA). Probe labeling was performed using the Random Primers 
DNA Labeling System kit (LIFE, USA) following the manufacturer's recommendations. 
Briefly, 100 ng of DNA fragment was denatured 5 minutes at 95 °C in 10 µl of H2O. Then, 15 
µl of Random Primer Mix, 6 µl of a mixture containing 0.5 mM of each dATP, dCTP, dGTP, 
1 µl of Klenow enzyme (3 units) and 5µl 
32P-dCTP (3000 Ci/mmol; 50 mCi, Amersham, 
U. S. A. ) were mixed with the denatured fragment in a final volume of 50 µl. Labeling reaction 
was carried out at 37°C for 30-60 minutes. Radioactive probe was purified using MicroSpin 
Column S-300HR (Pharmacia, Germany), following manufacturer's recommendations. 
Indicative evaluation of incorporation rate was performed with a hand radioactivity counter, 
comparing the amount of radioactivity in the MicroSpin Column (unincorporated) to the 
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amount in the eluted fraction (incorporated). Eluted probes were denatured for 5 minutes at 
95°C and chilled on ice. After preincubation of the membrane, hybridization buffer was 
substituted with 10 ml of fresh prewarmed buffer and the radioactive probe was added. 
Hybridization was carried out at 65°C overnight. After hybridization, the hybridization 
mixture was frozen at -200C (re-used up to three times, but not for genomic DNA), and 
membranes were subjected to stringent washes according to the following protocol: brief 
rinse in 50 ml of 2x SSC/0.1% SDS at room temperature, 10 minutes in 50 ml of 2x 
SSC/0.1% SDS at 650C, twice for 10 minutes in 0. lx SSC/0.1% SDS at 65°C. Wet 
membranes were sealed in plastic bags and exposed for 3 hours to 3 days to autoradiographic 
films (DuPont, U. S. A. ), using markers for orientation of the film to the membrane 
(Stratagene, U. S. A. ). 
4.2.1.7 Screening of genomic DNA phage library and large-scale preparation of lambda 
phages 
After hybridization with the probe CB 1 HII, corresponding to the CB 1 ORF (Fig. 4.4), 
only signals present on both membranes from the same plate were considered as 
corresponding to positive plaques. After orienting of the autoradiographic film with 
membranes and with plates, positive plaques were picked from the agar plate. In primary 
screenings, the wider end of a sterile Pasteur pipette was used to pick the surrounding area of 
positive plaques, and the piece of agar containing the phages was blown into an Eppendorf 
tube containing 1 ml of SM buffer. Phages were eluted by cutting the agar piece in small 
fragments and incubating at 4°C overnight with gentle shaking. For storage of phages, 2 
drops of chloroform were added to the eluted SM buffer. For secondary and tertiary 
screenings, the eluted phages were treated as described above (see "4.2.1.4 Growth of 
genomic DNA phage library and phage plaques lift"), with the only differences that higher 
phage dilutions were plated out onto smaller plates and that smaller positive areas were 
picked from the plates. Finally, after 3 or 4 rounds of screening, positive phages were 
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considered as homogeneous when all plaques on a plate gave a hybridization signal. For large 
scale preparation of lambda phage DNA, 3x 10' pfus of the positive phages in 0.5 ml of SM 
buffer were mixed with 0.5 ml MgCbICaCb (10 mM each) and 0.5 ml of the bacteria (OD6oo 
1, e. coli strain LE392). After incubation at 37°C for 10 minutes, the mixture was 
inoculated into 400 ml NZY broth and incubated at 37°C overnight with shaking. NZY broth 
contains 5 g/l NaCl, 2 g/l MgSO4-7H20,5 g/1 yeast extract (LIFE Technology), 10 g/l NZ 
Amine (casein hydrolysate, Sigma). When cell lysis was apparent (12-18 hours), 0.8 ml of 
chloroform was added, and the incubation was continued at 37°C for another 15 minutes. 
The lysate was then centrifuged in chloroform resistant 500-ml buckets at 7000 rpm for 10 
minutes at 4°C. Supernatant was transferred to a1 liter glass beaker and 23.4 g NaCl and 40 
g polyethyleneglycol (PEG) 8000 were added. After shaking at 37°C until complete 
dissolving of PEG, the beaker was incubated 30 minutes on ice. Phages were then collected 
by spinning at 7000 rpm for 30 minutes at 4°C. Phage pellet was carefully resuspended in 6.5 
ml of 1x Buffer A and transferred to a 50 ml Falcon tube. Buffer A was prepared as al Ox 
concentrated stock, stirred overnight at 4°C and stored at 4°C. It contains 5% (v/v) NP40,36 
mM CaCI2,300 mM Tris-HC1(pH 7.5), 50 mM MgCI2,1.25 M KC, 5 mM EDTA (pH 8.0), 
2.5% (w/v) Na-deoxycholate. lx Buffer A was freshly prepared by mixing 5 ml of IOx stock 
buffer A, 45 ml H2O and 20.5 ul of 14.63 M ß-mercaptoethanol solution. 160 µg of DNase I 
(Sigma, U. S. A. ) and 400 µg of RNase A were added to the phage suspension, and the 
mixture was incubated 30 minutes at 300C. PEG was then removed by addition of an equal 
volume of chloroform, shaking and centrifugation for 10 minutes at 3000 rpm at room 
temperature. Phages were carefully collected from the upper layer. Conical polyallomer 1 O-m1 
tubes (Beckmann) were used to prepare a one-step gradient with a bottom layer of 750 µl of 
a 40% glycerol solution and an upper layer of 2.5 ml of a 5% glycerol solution. 40% glycerol 
solution contains 40% glycerol, lx buffer B, 0.4 µJ/ml of 14.63 M ß-mercaptoethanol. 5% 
glycerol solution is the same, but with a decreased amount of glycerol. IOx buffer B stock 
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solution contains 5% NP40,300 mM Tris-HC1(pH 7.5), 1.25 M KCl and 5 mM EDTA. The 
8 ml phage solution was finally placed on top of the two step gradient and centrifuged at 
35,000 rpm for 1 hour at 4°C. Supernatant was carefully discarded and the phage pellet was 
resuspended in 1.6 ml of 2x ET buffer (0.04 M Tris-HCI, pH 7.5; 0.1 M EDTA) and 
transferred to a5 ml cryotube (Nunc, U. S. A. ). After adding 0.4 ml of a 10% SDS solution, 
the phage suspension was incubated overnight at 55°C. Phage DNA was then extracted with 
an equal volume of phenol, by gentle shaking, centrifugation at 2000 rpm for 5 minutes at 
room temperature, and removal of the lower organic phase. Liquid phase was further 
extracted with an equal volume of phenol/chloroform (1: 1) in the same way. Finally, the 
liquid phase was extracted with an equal volume of chloroform and the upper liquid phase 
was saved in a 15-ml Falcon tube. DNA was precipitated with 2 volumes of 100% ethanol 
and the visible DNA clump was pulled out with a bent glass micropipette. After a brief 
washing in 70% ethanol, the DNA was dissolved in 500 µl of TE buffer. The concentration of 
DNA was determined by spectrophotometric absorption at 260 nm and, then, phage DNA 
was stored at 4°C. 
4.2.2 Embryonic stem cells 
E14 mouse embryonic stem cells (129o1a strain; Kühn et al., 1991), were kindly 
provided by Dr. Klaus Pfeffer, Munich, Germany. Tissue culture plates were purchased from 
NUNC (Germany). Sterile plastic tubes (50 ml and 15 ml) were purchased from Falcon 
(Germany). 
4.2.2.1 Preparation of embryonic mouse fibroblast feeder cells 
In order to maintain their undifferentiated and totipotent status, embryonic stem cells 
(ESCs) need the presence of factors that inhibit differentiation. Early experiments showed that 
primary embryonic mouse fibroblast constitute a very good source of these factors (Bradley 
et at., 1984). 
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Primary embryonic fibroblast cells were obtained from mice embryos at 14-16 days 
post coitus (dpc). The pregnant mouse was killed and embryos were isolated from the uterus 
free of membranes. Embryos were transferred to a petri dish containing sterile PBS (Ca 
2+ and 
Mg 2+ free, LIFE Technologies GIBCO, Germany) and heads, internal organs and limbs were 
removed. Carcasses were washed three times in 35 ml of sterile PBS. After the PBS washes, 
carcasses were quickly minced on ice with a sterile scalpel Minced carcasses were incubated 
in 10 ml 0.5% trypsin/1 mM EDTA (LIFE Technologies GIBCO, Germany), supplemented 
with 200 µg/m1 of DNase I (Boehringer Mannheim, Germany) at 37° C for 15 minutes. A 
teflon mesh was sterilized for 30 minutes in boiling Ampuwa water (Fresenius, Germany). 
After cooling to room temperature and sequential washing in PBS and trypsin/EDTA 
solution, the mesh was placed into a 250 ml Erlenmeyer flask. After the trypsin incubation, 
the minced embryos were pressed with a sterile 5 ml syringe plunger through the mesh. A 
total of 50 ml trypsin/EDTA solution was used to rinse the mesh. The solution was further 
incubated for 30 minutes at 37° C with shaking, and then it was decanted in two 50 ml Falcon 
tubes. After filling the tubes with complete feeder cells medium, cells were centrifuged at 
1500 rotations per minute (rpm, about 300x g) and the cell pellet was resuspended in 10 ml of 
complete medium. Complete feeder cell medium consists of Dulbecco's Modified Eagles 
Medium (OMEN, high glucose, with Na-pyruvate, LIFE Technologies GIBCO, Germany, 
cat. 41966052), supplemented with 10% foetal calf serum (FCS, PAA Laboratories, 
Germany, cat. A15-041), 2 mM glutamine (LIFE Technologies GIBCO, Germany), 100 
U/ml Penicillin and 100 U/ml Streptomycin (100x Penicillin/Streptomycin solution, LIFE 
Technologies GIBCO, Germany). Cells were again centrifuged and the cell pellet was again 
resuspended in 10 ml of complete feeder cells medium Viable cells were counted using the 
Trypan blue exclusion method (Sigma, Germany). Cells were plated at the density of 5x106 
cells/dish onto 15-cm cell culture dishes containing 25 ml of complete feeder cell medium. 
After overnight culture at 37°C, 5% C02 (cell culture incubator, Haereus, Germany), the 
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medium was replaced with fresh medium. After 2-3 days, cells formed a confluent monolayer 
and were washed twice in PBS and trypsinized in 0.5% trypsin/1 mM EDTA for 5 minutes at 
37° C. Cells were then centrifuged at 200 xg (about 270x g) and replated at a dilution of 1: 5 
and further incubated. After another 2-3 days, the cells were confluent. They were again 
trypsinized as above and resuspended at the concentration of about 10-20x 106 cells/ml. Cell 
suspensions were pipetted into 0.5 ml aliquots into 2 ml-freezing vials (Nalgene, Germany). 
The content of each vial was mixed with 0.5 ml of ice-chilled 2x concentrated freezing 
medium. 2x freezing medium consists of 6 ml of complete feeder cells medium, supplemented 
with 2 ml of FCS and 2 ml of Dimethylsulfoxide (DMSO, Sigma, Germany). Cells were 
frozen at -80° C, and then stored in liquid nitrogen until used for the preparation of feeder cell 
plates. 
One vial of frozen primary embryonic fibroblast cells was quickly thawed and 10 ml of 
complete feeder cells medium were added. After centrifugation at 200 xg (about 270x g) for 
5 minutes and resuspension of the cell pellet in 10 ml of complete DMEM, cells were plated 
onto 5 cell culture dishes (15 cm diameter) and incubated for 4 days in cell culture incubator, 
or until they formed a confluent monolayer. After washing twice in PBS, cells were 
trypsinized at 37°C for 5 minutes. After centrifugation as above and resuspension in complete 
DMEM, the cells were plated at a 1: 4 dilution onto 20 cell culture dishes (15 cm diameter). 
After 3 days, cells were treated with mitomycin C (Sigma, Germany), in order to block cell 
proliferation. The medium was removed and substituted with fresh medium containing 10 
µg/ml of mytomicin C and the cells were put into the incubator for 3 hours. Cells were 
washed twice in PBS, trypsinized as above, counted and then plated at the concentration of 
onto convenient plates (ranging from 96 well-plates to 10 cm cell culture 4x 104 cells/cm 2 
dishes). 
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4.2.2.2 Thawing and expanding of ESCs 
An aliquot of E14 embryonic stem cells (ESCs, 129Sv strain; Kühn et at, 1991) was 
quickly thawed and transferred to a 50 ml Falcon tube containing 10 ml of complete ESC 
medium. Complete ESC medium consists DMEM, supplemented with 10% foetal calf serum 
(FCS, Boehringer Mannheim, Germany, cat. 210471, lot 14870302), 10-4 M (3- 
mercaptoethanol (LIFE Technologies GIBCO, Germany), 2 mM glutamine, 1000 U/ml 
leukemia inhibitory factor (LIF, LIFE Technologies GIBCO, Germany), 100 U/ml Penicillin 
and 100 U/ml Streptomycin. The cells were centrifuged 5 minutes at 200 xg, the cell pellet 
was resuspended in ESC medium and then the cell suspension was plated onto a 6-cm cell 
culture dish, containing mytomicin-treated primary mouse embryonic fibroblasts (feeder 
plate). On the second day, the cells were washed in PBS and trypsinized in order to obtain a 
single cell suspension. After centrifugation, cells were resuspended in ESC medium and 
plated at a 1: 4 dilution. After 2 days, the cells were split in the same way onto 10 cm-feeder 
plates at a 1: 4 dilution. After another two days, cells were trypsinized and plated onto 4 
gelatin pre-treated 10 cm plates. Gelatin pre-treatment of the plates consists of an incubation 
with 0.1 % gelatin (BDH, Germany) in Ampuwa water for few minutes, followed by two 
washes in PBS. After 36 hours of incubation, the cells were ready for electroporation. 
4.2.2.3 Electroporation of ESCs, antibiotic selection, picking and expansion of resistant 
clones 
60 µg of the targeting construct were digested overnight with Notl to obtain complete 
linearization (clone G134.1, see below 4.3.2 "Generation of the targeting construct"). The 
restriction enzyme was then inactivated at 70° C for 20 minutes. The ESCs were carefully 
trypsinized in order to obtain a single cell suspension. After centrifugation (3 minutes at 
200 xg) and resuspension in 10 ml PBS, the cells were kept in ice and counted. 7x106 cells 
were again centrifuged for 5 minutes at 200 xg. Cell pellet was resuspended in 800 pJ of cold 
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PBS and 20 0 of linearized DNA (1 mg/ml) were added. The cell suspension was transferred 
into one electroporation cuvette (BioRad, Germany). Electroporation was obtained in a Gene 
Pulser electroporation apparatus (BioRad, Germany) at the following conditions: 0.24 kV, 
500 gF for 5.6 milliseconds. After electroporation, the cells were let in ice for 15 minutes and 
then diluted into 20 ml of complete ESC medium. The cells were then plated onto 2 gelatin- 
pretreated 10 cm-plates and put into the incubator. After 1 day, the medium was changed 
with fresh medium and after another day, the medium was substituted with selection medium, 
consisting of complete ESC medium supplemented with 200 µg/ml of geneticin (G418, LIFE 
Technologies GIBCO, Germany). G418 is prepared as a 100x concentrated stock solution in 
PBS and stored at -20° C. Fresh complete ESC/G418 medium was changed every two days. 
After 8 days of selection, resistant clonal colonies had appeared. Single colonies were picked 
with the aid of plastic sterile pipette tips and plated onto single 96 well-feeder plates in 
complete ESC medium without G418. After one day, the clones were trypsinized with 50 µl 
of Trypsin/EDTA, resuspended to single cells and, after adding 50 µl of complete ESC 
medium, were replated in the same well "tryplation"). When clones had grown enough 
(ranging from 1 to 4 days later), they were split onto two 96 well-feeder plates and one 
gelatin-pretreated 96 well-plate. The expansion continued until three 96 well-feeder plates 
and 3 gelatin-pretreated 96 well-plates were obtained for each clone. At this point, gelatin- 
treated plates were used for genomic DNA extraction (see above 4.2.1.4.2 "DNA preparation 
from embryonic stem cells"), while cells grown on feeder plates were frozen in the following 
way: cells were washed once with PBS, and 50 µl of trypsin/EDTA solution were added. 
Cells were incubated at 37°C for 20 minutes to obtain a single cell suspension. 50 µl of cold 
complete ESC medium and 100 µl of cold 2x concentrated freezing medium were added. 2x 
freezing medium consists of 6 ml of complete ESC medium with 2 ml FCS and 2 ml DMSO. 
After mixing the cells with the freezing medium, the plates were sealed with Parafilm 
(American National Can, U. S. A. ) and immediately frozen at -80°C. In this way, 96 well- 
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plates with viable cells were stored for up to 3 months. 
After Southern analysis of the DNA derived from the cells grown on gelatin-treated 
plates revealed the presence of positive clones, the corresponding frozen clones were thawed 
and expanded. Thawing of 96 well-plates was similar as described above (4.2.2.2 "Thawing 
and expanding of ESCs"). Cells were split progressively onto larger feeder plates (24 well- 
plates, 6 well-plates, 6 cm-plates, 10 cm plates). When sufficient numbers of cells were 
obtained from positive clones, aliquots of cells were frozen. Briefly, the cells of one 10 cm- 
feeder plate were trypsinized to single cell suspension, centrifuged and resuspended in 1 ml of 
cold complete ESC medium. 1 ml of cold 2x freezing medium was added, and cells were 
frozen at -80°C in 2 ml-freezing vials (Nalgene). After a few days, frozen vials were 
transferred to liquid N2, where they were stored until used for blastocyst injections. Blastocyst 
injection were performed according to Hogan et a1. (1986). 
4.2.3 In situ hybridization 
Non-radioactive in situ hybridization on brain sections derived from wild type and 
CB 1-mutant mice was performed as described in Chapter 2. The only differences were that 
the Tyramide Signal Amplification kit (NEN, USA) was used following the manufacturer's 
instructions and that diaminobenzidine was used as chromogenic substrate for visualization of 
the riboprobes. The riboprobe for CB 1 was the same as used in Chapters 2 and 3. 
4.3 Results 
4.3.1 Genomic organization of the mouse CB1 
4.3.1.1 Cloning ofphage insert 
To characterize the genomic organization of the mouse CB 1 gene, a mouse genomic 
phage hibrary (Kühn et al., 1991) was screened with a1 kb EcoRV-HindHII fragment from 
CB 1 ORF (CB I HIII, Fig. 4.4). From this screening, four phage genomic clones were 
obtained (CB 1.1, CB 1.2, CB 1.4 and CB 1.5). After phage DNA purification, restriction 
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mapping and Southern blot hybridization using the CB 1 HIII probe (Fig. 4.4), phage clones 
CB 1.2, CB 1.4 and CB 1.5 appeared to have an identical 21 kb insertion; CB 1.1 was about 2 
kb shorter than the others, included about 1 kb more at the 5' end of the gene, and 
overlapped with them by abouth 18 kb. After Not I digestion, the insert from clone CB 1.2 
was subcloned into pBlueScript KS(-) (pKS). Given the length of the insert, this cloning step 
was quite difficult. After some fruitless attempts using standard ligation procedures, the phage 
insert was cloned by coprecipitation of the fragment and the plasmid in sodium acetate and 
70% ethanol and resuspension in a small volume (5 µl) of complete ligation mixture. After 
colony screening, using CB 1 HIII (Fig. 4.4) as probe, six clones were identified as positive, 
and after restriction mapping, three clones were shown to contain the entire phage fragment. 
Among these, clone G23.10 was chosen for further experiments. 
4.3.1.2 Mapping of CBI locus 
Gross mapping and fragment subcloning. Several restriction digestions were carried 
out on clone G23.10, to reveal the gross restriction map of the CB 1 genomic locus. Smaller 
fragments of G23.10 were subcloned to obtain more detailed information about the restriction 
map and to facilitate sequencing. Thus, a 4.1 kb EcoRV-BamHI fragment, covering about 1.5 
kb of the CB 1 ORF and about 2.6 kb of the 3' flanking region, was subcloned into pKS 
(clone G34.10; Fig. 4.4) and completely sequenced. A 3.0 kb Pstl-EcoRV fragment, covering 
about 2.8 kb of the 5' flanking region of CB 1 ORF and about 100 bp of the CB 1 ORF, was 
also subcloned into pKS (clone G35.2; Fig. 4.4) and entirely sequenced. These two clones 
together contained the entire CB 1 ORF, which was confirmed to be identical to the mouse 
CB 1 sequence present in GenBank database (accession number U22948). 
Defining limits of the targeting construct. In order to further restriction map the 5' and 
3' regions of the genomic locus of CB 1, two other probes were chosen, Spe6 and EIX (Fig. 
4.4), and Southern blots were hybridized with these probes. This revealed the presence of two 
convenient restriction sites for designing the termini of the two homology arms for the 
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targeting construct. At a distance of about 2 kb from the 5' end of the phage insert (about 7 
kb 5' to the CB 1 ORF) a EcoRV site is present, while at a distance of about 2 kb from the 3' 
end of the phage insert (about 5 kb 3' to the CB 1 ORF) a HindIIl site was found (Fig. 4.4). 
These sites were chosen as the margins of the targeting construct. 
Finding probes for screening of targeted ESCs. The fragments outside the homology 
margins (corresponding to the 5' and 3' end regions of clone G23.10) were subcloned (clones 
G88.2 and G95.1, respectively; Fig. 4.4), to find suitable restriction sites for diagnostic 
digestions of genomic DNA of embryonic stem cells after homologous recombination and to 
characterize external probes for screening these diagnostic digestions (see below, 4.3.3 
"Electroporation and selection of targeted embryonic stem cell clones"). A Xbal and a Spel 
site were found in clone G88.2 (5' region) and in clone G95.1 (3' region), respectively. Xbal 
is absent in the entire 5' region of CB 1 locus covering the chosen homology arm and is 
present only at the 3' end of CBI ORF, at a distance of about 10 kb. Spel is absent in the 3' 
region of CB1 locus chosen as the 3' homology arm, and it is present only in the 5' region, at 
a distance of about 12 kb from the other Spel site outside the 3' homology arm (Fig. 4.4). 
The regions between the Xbal site and the 3' end of clone G88.2, and between the Spei site 
and the 5' end of clone G95.1, were checked for the presence of repetitive sequences by 
reverse Southern blot hybridization using 129Sv genomic DNA as probe. By this approach, 
positive hybridization signals would reveal the presence of genomic repetitive sequences. This 
could represent a problem for the use of a fragment as probe for genomic DNA screening. 
The 0.6 kb XbaI-HindJIl fragment (XH6) in clone G88.2 and the 0.4 kb Spei Xbal fragment 
(SpeX4) in clone G95.1 were found to be free of repetitive sequences, as shown by lack of 
hybridization signal (data not shown). Therefore, these fragments were chosen as probes for 
the screening of targeted ESC clones (Fig. 4.4, XH6 and SpeX4). 
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Fig. 4.4 Schematic representation of the mouse CB I genomic locus with restriction mapping (clone 
G23.10). Underlined restriction sites were fully mapped. Grey box represents the intron sequence. 
White box represents the open reading frame (ORF) of CB1. Black boxes are the 5' and 3' flanking 
regions of the CB I ORF. Red bars are fragments used as probes in Southern blot experiments. Black 
bars represent subclones as described in the text. 
Characterization of 5' intronic sequence. Another important feature of a conditional 
gene targeting construct is the position where to place the loxP sites, in order to minimize the 
disturbance that they might cause to the normal expression of the "floxed" gene. Rat and 
human CB 1 loci have an approximately 2 kb intron sequence at about 60 bp 5' of the CB 1 
ORF (Shire et a1., 1995). To detect whether there was a similar intron sequence in the mouse 
locus, PCR was performed on mouse genomic DNA and on whole brain mouse cDNA, using 
the primer pairs GI-G2 and G3-G2 (Table 4.1). Primer pair GI-G2, as expected, amplified a 
1.6 kb fragment both on genomic and on cDNA, whereas G3-G2 amplified a 1.7 kb fragment 
only on genomic DNA, indicating the putative presence of an intron sequence in the area of 
primer G3 (data not shown). A further analysis of the sequence of clone G35.2 (2.8 kb 5' of 
CB 1 ORF), revealed the presence of a splice donor site (5'- GAGCAG/GTAAAT -3') at 
position -2102 (considering the ATG of CB1 ORF as position +1), and of a splice acceptor 
site (5' -GTTAG/GGTT- 3') at position -62, thus suggesting the presence of the intron 
sequence 5' to the CB 1 ORF also in the mouse genomic locus (Fig. 4.5). 
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Clone G3ä. 4---------- TTTTAAGCTT CTTCCAGTGT GCCATACATT GTGGTGAGAA TTGAATACTA 
Genomicseq---------- TTTTAAGCTT CTTCCAGTGT GCCATACATT GTGGTGAGAA TTGAATACTA 
AGATAGATTA AGTCTCCAGG GAGGTCCTCG TGGAACTTTC TGTGGAGCTT GGGAGCAAGA 
AGATAGATTA AGTCTCCAGG GAGGTCCTCG TGGAACTTTC TGTGGAGCTT GGGAGCAAGA 
SPLICE 
-2102 -62 
GGCAGAGCAG GGTTCCCTCC 
GGC-AL&GCA2_GTAAAjjG ------2040 bp intron------ CTCC TTAG GGT CCTCC 
+1 
1 
r TGGCACCTCT TTCTCAGTCA CGTTGAGCCT GGCCTAATCA AAGACTGAGG TT ýZAAGTC 
TGGCACCTCT TTCTCAGTCA CGTTGAGCCT GGCCTAATCA AAGACTGAGG TTATGAAGTC 
GATCTTAGAC ------------- 
GATCTTAGAC ------------- 
Fig. 4.5. Sequence alignment of clone G3 8.4 (derived from cDNA) and genomic CBI locus (derived 
from clone G35.2, see Fig. 4.4), showing the presence of a 2040 bp intron from position -2102 to -62 
upstream to the mouse CB 1. Box, donor and acceptor splice sequences. 
Primers G7 and G8 (Table 4.1) were designed to be located upstream of the putative 
splice donor site and downstream of the putative splice acceptor site, respectively. PCR 
reaction using mouse whole brain cDNA as template was performed with this primer pair and 
the product (about 1 kb) was cloned and sequenced (clone G38.4). By comparing the 
genomic sequence from clone G35.2 (Fig. 4.4) with the cDNA sequence from clone G38.4, it 
was possible to confirm the existence of a 2040 bp intron sequence from position -2102 to - 
62 upstream of the ATG of mouse CB 1 (Fig. 4.5). 
Determination of appropriate locations for loxP sites. At position -372, inside the 
intron sequence, there is an AvrII restriction site that is unique in the 5' region of the genomic 
locus. As loxP sites are rather unlikely to perturb the normal expression of a gene when they 
are introduced into introns (Torres & Kühn, 1997), the AvrII site was chosen to introduce the 
5' loxP site. On the 3' side of CBI ORF, no intron was revealed to be present, but at least 
two "non-canonical" polyadenylation signals are present. A unique Ach site, at about 2 kb 
downstream of the AvrII site, is present between the first and the second polyadenylation 
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signal. This was considered to be a good position to place the 3' loxP site. 
In conclusion, restriction mapping, Southern hybridization and sequencing of the CB 1 
genomic locus revealed the presence of a single ORF encoding for CB 1, confirmed the 
presence of a2 kb intron sequence at about 60 bp 5' to CB1 ORF and allowed me to design a 
conditional gene targeting construct. 
4.3.2 Generation of the targeting construct 
Given the sequence information and the restriction mapping data, the construction of 
the gene targeting construct was carried out. Fig. 4.6 shows the cloning steps that were 
necessary to achieve this construct. Restriction sites were introduced, during the cloning 
steps, in order to facilitate the Southern blotting screening of targeted ESC clones. Major 
difficulties were encountered at the last steps, because of the dimensions of the inserts and 
vectors. In some cases, i. e. steps 8-10, bacterial colony lifts were necessary to find positive 
clones, and, given the low yields of large plasmids, high amounts of bacterial cultures (up to 3 
liters) were used for plasmid preparations. No blunt ligation was used in the steps where big 
fragments (> 5 kb) were to be cloned. An Xbal site was left in the neighboring 3' region of 
the 5' loxP site (Fig. 4.6, step 2), while a Spei site was carried on from the subcloning of the 
FRT-PGK-Neo cassette in position 3' to the second FRT site (Fig. 4.6, steps 5,6 and 8). At 
step 2, a Notl site carried from the loxP original plasmid (pFTM-loxP), was destroyed by 
digestion, blunting and self-ligation (clone G 105.16 to clone G 109.2), in order to maintain a 
unique Nod site in the 5' polylinker region of the final construct, since a single restriction site, 
external to the targeting construct, is necessary for linearization of the plasmid prior to 
electroporation of ESCs. 
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Fig. 4.6 (continued) 
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4. Insertion of the "left arm" (LA) 5' of IoxP. 
Note the presence of the Xba I sites 5' of CB1 that will be used for 
targeting screening of cell clones. 
117 
1Xh1C1$p1H3R5 1 c" gh6p1Xb1'1 S28X1SI 
[pSVpaz11- 
PGK-Neo 241 pKS 
BstB1 Sm1 
Blunted Sm 1 
K1Xh1C1 Se1H3 R5 1 P1 BHSp1Xb1N1 S2BX1S1 
OK 
pBS-FRT-Neo 
G111.1. 
5. Subcloning of FRT-PGKNeo-FRT 
cassette into pKS. 
1BX1S2 
xblS 18H1P1 R1 R5H3S8 C1Xhl 
N1 R5 d N1 
pKS-CBI ýocu. 
UZ3.1U k 
ACH H3 
Blunted Blunted 
1Xh1CI SSIH3 RS 1 P1 BHIS 1Xb1N1 S2BX1S1 
]Smi 
pKS - 
Xh1C7 SeIH3 R5 Rl P7 
pKS-RA 
G117.7 
%. Subcloning of "Right Arm" (RA) into pKS. 
n'C'ISa'ý3 R' Pi B-'SOlXb1N1 528x151 
pKS-MT-Ieo 
1.1 W 
C1 P1 R1 R5 H3 Cl Sol 1N/ S28XIS1 
K1 R5 
K1 op- 
pFTM-loxP 34 bp SP Blunted 
K7 Cl P1 R1 R5 H3 Cl Ssl BHIS 1Xb1N1 S2BX1S1 
R1 Pt 
w W, [PKS-IOXP-FRT-NeO 
.4 
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8. Insertion of RA 3' of the "IoxP-Neo" cassette. 
Note the presence of the Spe I site 3' of "Neo" that will be 
used for the screening of targeted cell clones (see step 10). 
Fig 4.6 (continued) 
118 
Kt C1 P7 RI R5 HMO B{1 SpIXb1 R1 Pl SHISplXb S2 BX1S1 
ýP, 
pKS-IoxP-FRT-Neo-RA 
G128.2 
Sal N1 
e 
K1 Xh1CI H3 R5 RI P1 Sm1BMISplXb S2 BX1 S1 
lSa1 
KS JNI 
K1Xh1C1Ss1 BHlS IXb1RIP1 BM1B IXb1NIS2BXISI 
RI P7 
i 
[pKXPRTNl. 
d 
G131.1 
9. Subcloning of the "IoxP-Neo-RA" 
cassette into pKS. 
This step was necessary to obtain a Xho I site 5' and a 
Not I site 3' to the entire insert that will be used in the 
step 10. 
S1 BX1 2 N/Xb1S H7 S1 
S1 Xb1Xb 
pK3-LAaoxP-CB1 
G121.8 jkb jub 1kb 
Xh1 KI 
Blunted 
K1 ciS. 1 BH1S 1Xb1R1P1 BHlS 1Xb1 S2BX1S1 
R1 P1 
tý-Wl 
Xh1 
pKS-IoxP-FRT-Neo-RA (inverted) 
G131 1 1fß N' - . Blunted 
1 
1B 121 1S 1B 1B 18 111 P1 B8, 
S/b, X 
, P1 
[pK.. 
MoxPB1-IoxP-FRT-Neo-FRT-RA 
G134.1 FINAL m 
0. Final insertion of the "IoxP-Neo-RA" 
cassette 3' of "LAaoxP-CBI". 
Important restriction sites: Not I for linearization of the 
plasmid; Xba 15' of CB1 for cell clone screening ("left arm"); 
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Fig. 4.6 (see also previous two pages). Schematic representation of the cloning steps performed to 
obtain the gene targeting construct. Steps 1 to 4 were performed to assemble the left arm of homology 
(LA, black box), the 5' loxP site (loxP, red triangle) and the CBI ORF (CBI, white box) (clone 
G 121.8). Steps 5 to 8 were necessary to assemble the 3' loxP site (loxP, red triangle), the FRT-PGK- 
Neo cassette (FRT, black triangle; PGK-Neo, yellow box) and the right arm of homology (RA, black 
box) (clone G 128.2). Steps 9 and 10 were used to assemble the two arms of the construct, in order to 
obtain the final gene targeting construct G134. I. Grey box represents the intron sequence. Scale bars 
are 1 kb, but the backbone plasmid sequence, the loxP site, the FRT site and the polylinker regions are 
not represented in correct proportion. At each step, used restriction enzymes are bold and circled. 
Abbreviations: pKS, pBlueScript KS(-); restriction enzymes: Acll, Ac1I; Avr2, AvrII; BH I, BamHI; 
BXI, BstXI; C 1, C1aI; H3, Hindill; K1, Kpnl; N1, Not!; P 1, Pstl; R1, EcoRI; R5, EcoRV; S 1, 
SacI; S2, Sac11; Sa 1, Sall; Sm 1, SmaI; Sp 1, Spel; Xb 1, Xbal; Xh 1, Xhol. 
Before proceeding to embryonic stem cells electroporation, the final clone G 134.1, was 
sent for sequencing of the complete CBI ORF and of the most important regions of the 
construct (lox P sites, FRT sites, junctions between different fragments). Sequencing data 
confirmed the identity of the construct and the lack of mutations. 
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4.3.3 Electroporation and selection of targeted embryonic stem cell clones 
60 µg of clone G134.1 were linearized by Nod digestion and 20 µg were used for 
electroporation of E 14 mouse embryonic stem cells (129Sv strain; Kühn et al., 1991). After 
8 days of selection in geneticin (G418) at 200 µg/ml, approximately 400 resistant clones were 
picked, grown in 96-well plates and subsequently expanded for screening and freezing. In a 
loxP gene targeting construct, there are three regions of homology where homologous 
recombination can occur: the region 5' to the first loxP site (left arm of homology, LA), the 
sequence of interest (in this case: the CB1 ORF) and the region 3' to the second loxP site 
(right arm of homology, RA). To obtain the desired gene targeting, recombination events 
should occur exclusively in the first (LA) and the third (RA) of these homology regions. If 
one of the homologous recombinations between gene targeting construct and genomic DNA 
involves the second of these homology regions (CB 1 ORF), one of the two loxP would be 
inevitably lost, thus blocking the Cre/loxP approach. In the 3' region (RA) of clone G134.1, 
the selection cassette PGK-Neo is present, conferring the resistance to the drug G418 in the 
ESCs. It is therefore very likely that G418-resistant ESC clones contain the RA of homology. 
Thus, the primary screening was addressed to the LA, using XbaI genomic DNA digestions 
of picked and expanded clones. Southern blot hybridization, using the probe XH6 (Fig. 4.4) 
revealed the presence of two bands at about 10 kb (wild type allele) and at 8.5 kb (targeted 
allele) in 11 clones (about 3% recombination efficiency) (Fig. 4.7A, B). As expected, a further 
digestion with Spel and subsequent Southern blot hybridization using the probe SpeX4, 
revealed that the wild type (WT) band at about 12 kb and the correctly recombined band at 
about 6.5 kb were also present in all the 11 clones (Fig. 4.7A, Q. Additional random 
integrations of the Neo cassette were checked by restriction digestion of genomic DNA of 
positive ESC clones with three different enzymes (Xhol, Sall and Spel) and Southern 
hybridization using a 600 bp-long Xbal-Pstl fragment of the Neo gene as a probe. Only 
clones that showed a single positive band with all three digestions (not shown), indicating a 
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single correct targeted site of integration, were used for further experiments. Two clones out 
of the eleven targeted ones showed additional random integration sites (data not shown). 
4.3.4 Blastocyst injection, generation of chimeras and germ line transmission 
Three ESC clones (clones SD7, SSB12 and MBH2) were chosen for injection of 
C57BL/6-derived blastocysts. Table 4.2 summarizes the results of blastocyst injection 
experiments. A total of 538 blastocysts were injected with either of the three ESC clones. Of 
the 77 pups born from these experiments, 29 were chimeric (37,7%), with various values of 
chimerism. 
Number of Number of Number of Clone injected chimeras 
Germ line 
born pups transmission 
embryos (% of chimerism) 
SD7 152 17 7 (20-80%) YES 
SSB12 197 42 14 (3-100%) YES 
MBH2 189 18 8 (2-80%) YES 
Table 4.2. Sununaiy of blastocyst in ion experiments. The percentage of chimerism was 
empirically evaluated based on the coat colour of chimeras. 
Chimeras derived from all the three ESC clones were mated with wild type C57BL/6 
mice to check the germ line transmission of the targeted allele. Germ line transmission was 
revealed by the coat colour of offspring (black, not germ line; agouti, germ line transmission 
of agouti ESCs), and was confirmed by PCR (Fig. 4.7D) and by Southern blot experiments 
(data not shown) of tail-derived genomic DNA. Two primers, G50 and G5 1, were used for 
PCR analysis (Tab. 4.2). Both primers correspond to wild type sequences, one located 5' 
(G50) and the other located 3' (G5 1) of the AvrII restriction site, where the 5' loxP site was 
inserted. 
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Fig. 4.7. Analysis of targeted ESC clones and germ line transmission of the gene targeting construct. 
A. Schematic representation of the wild type (WT) and "flox-Neo" alleles. B. Southern blot analysis of 
G418-resistant ESC clones. Clone SD7 (and also SSB12 and MBH2, not shown) contains the correct 
recombination of the 5' region of the targeting construct (primary screening, left arm of homology, 
LA). C. Southern blot analysis of G418-resistant ESC clones. Clones SD7, SSB 12 and MBH2 contain 
the correct recombination of the 3' region of the targeting construct (secondary screening, right arm of 
homology, RA). D. PCR analysis of germ line transmission. Agouti offsprings derived from crossing 
of wild type C57BL/6 mice with clone SD7-derived chimeras. Double PCR bands correspond to germ 
line transmitted animals. Black bars, homology arms (LA and RA); grey bar, intron sequence; white 
bar, CBI open reading frame; yellow bar, PGK-Neo cassette; red triangle, loxP site; black triangle, 
FRT site; G50 and G5 1, primers used for PCR analysis; XH6 and SpeX4, probes used for Southern 
blot analysis. 
Using these primers, wild type alleles give an amplicon of 413 bp, whereas targeted 
alleles give a 493 bp amplicon (Fig. 4.7A, D). These two bands are clearly distinguishable in a 
1.5 % agarose gel, and easily allow to distinguish between wild type homozygosity (only the 
X=6 Sp eX4 
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lower band), mutant homozygosity (only the higher band) and heterozygosity (both bands) in 
the genomic DNA. 
Southern blot analysis was performed on mouse tail DNA with the same conditions as 
for ESC genomic DNA and gave identical results (not shown). All three lines gave rise to 
germ line transmission, with efficiencies (evaluated as percentage of agouti pups per litter), 
ranging from 10% to 100%. These germ line-transmitted animals were defined as the "flox- 
Neo" line, as they contain the complete sequence of the targeting construct, with the "floxed" 
CBI and the PGK-Neo cassette flanked by FRT sequences. The following experiments were 
carried out using only mice derived from SD7 and SSB12 cell clones, keeping the MBH2 
derived mice as a "back-up" line. 
4.3.5 Generation of CB1 "Null mutant" ("CBN"mouse line) 
To check the efficiency of the Cre-mediated excision of the "floxed" CB 1 gene and to 
generate a CB 1-null mutant (CBN) mouse line to be used for further experiments, 
heterozygous animals of the "flox-Neo" line were crossed with "Cre-deleter" mice. The "Cre- 
deleter" mice are a transgenic line that express Cre recombinase under the control of a human 
cytomegalovirus minimal promoter (PBi-2, Baron et al., 1995). Given the relatively low 
specificity of the promoter, these mice express rather high levels of Cre recombinase in 
virtually all the cells of the body, including germ cells (Schwenk et at, 1995). The excision of 
CB 1 (CBN allele) was checked by PCR and Southern blotting of tail-derived DNA from mice 
of the Fl generation (offspring of heterozygous "flox-Neo" mice and heterozygous "Cre- 
deleter" mice). PCR was performed using three primers in the same reaction: G50, G51 and 
G54. G50 and G51 are described in the previous paragraph (Fig. 4.7A, D), while G54 is a 
reverse primer located in the 5' end region of the "PGK-Neo" cassette (Table 4.2 and Fig. 
4.8A). Best results were obtained when the final concentrations of the primers were as 
follows: G50 I nmoVml, G51 0.5 nmoUml, G54 0.7 nmol/ml. On wild type alleles, which lack 
the "PGK-Neo" cassette, the G50/G51 primer pair gave an amplification product of 413 bp 
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(Fig. 4.8C). On CB 1-deleted alleles (CBN), G51 does not have the template to anneal with, 
while the PGK-Neo cassette is moved closer to the G50 primer (Fig. 4.8A). In this case, the 
G50/G54 primer pair gave a 342 bp amplification product, clearly distinguishable from the 
wild type G50/G51 product on a 1.5% agarose gel (Fig. 4.8C). Also in this case, it was easy 
to discriminate between homozygosity or heterozygosity. 
Southern blot analysis was performed by digesting tail-derived genomic DNA with the 
restriction enzyme Spei. A 0.6 kb BamHI fragment in the LA of homology, located 3' to the 
Spel site in the same area, was used as a probe (Fig. 4.4 and Fig. 4.8A, B). Wild type alleles 
gave an approximately 12 kb band that was the same as described in the previous paragraph 
for the SpeX4 probe (Fig. 4.7C). An Spel site in the 3' flanking area of the first loxP site (i. e. 
inside the region excised by Cre recombinase) was kept during the cloning steps of the 
targeting construct (Fig. 4.6, step 2). Moreover, another Spel site is present in the 5' region 
inside the PGK-Neo cassette (Fig. 4.8A). Therefore, in case of Cre-mediated deletion of CB 1 
("CBN allele"), Southern blot hybridization gives a 3.3 kb band, whereas a "flox-Neo" allele 
(i. e., where no recombination had occurred), gives a 2.7 kb band (Fig. 4.8B). Southern 
blotting analysis gave the same conclusions as the PCR experiments described above. 
Mice carrying a CBN allele were then crossed with wild type C57BL/6 mice to check 
the germ-line transmission of the mutation. The efficiency of Cre-mediated deletion of CB 1 
ORF was very high. In the Fl generation (offspring of heterozygous "flox-Neo" mice and 
heterozygous "Cre-deleter" mice), 50% of the mice containing the Cre transgene carried the 
CBN locus, thus showing the high activity of Cre-mediated CB 1 excision in vivo (Fig. 4.8B, 
C). Nevertheless, in the F1 generation, the Cre-mediated deletion might have a "mosaic" 
character, with only a limited number of cells in which the recombination has actually 
occurred. However, also in F2 generation (Fl crossed with wild type C57BL/6 mice), about 
50% of the offspring carried the deletion of the CBI ORF band (Fig. 4.8D). This gives a 
strong indication of the high efficiency of the Cre-mediated excision of "floxed" CB 1 in vivo. 
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Fig. 4.8. Cre recombinase-mediated deletion of CB 1 ORF and generation of the "CBN" (CB 1-null) 
mouse line. A. Schematic representation of the wild type (WT) allele, of the "flox-Neo" allele and of the 
"CBN" allele after the Cre-mediated deletion of the CB 1 ORF. Symbols are as in Fig. 4.7. B. Southern 
blot analysis of individuals of the F1 generation obtained by mating "flox-Neo" with "Cre-deleter" 
mice. About 50% of the offspring mice containing the Cre transgene carried the deleted allele. C. PCR 
analysis of FI generation as in B, but not in the same order. D. PCR analysis of mice of the F2 
generation obtained by mating "F 1" deleted mice (as in A and B) with C57B1/6 wild type mice. 50% of 
the offspring carry the germ line-transmitted deletion, indicating a very efficient Cre-mediated deletion 
of the CB I locus already at FI generation. 
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In further F3 breedings, heterozygous CBN mice (CBN/+) were successively 
intercrossed, in order to generate homozygous null mutants (CBN/CBN). Such breedings 
gave rise to 53% (63/119) heterozygous (CBN/+), 24% (29/119) homozygous mutant 
(CBN/CBN) and 23% (27/119) wild type (+/+) mice, as counted in the first days of life. Such 
proportions corresponds to the expected Mendelian transmission, thus revealing no 
embryonic lethality of the mutation. The majority of mice were sacrificed during the first days 
of life for in vitro experiments using primary neuronal cultures (see Chapter 5 of this Thesis). 
However, animals that were allowed to age (up to four months, at the time of writing) did not 
show any gross phenotypical defect, and body weight and growth rate were normal. The 
expression of CBI was checked in wild type (+/+) and homozygous mutant (CBN/CBN) 
littermates by in situ hybridization on coronal brain sections. Fig. 4.9 shows the lack of CB 1 
expression in CBN/CBN mice in the hippocampus, in contrast to wild type control 
littermates. 
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Fig. 4.9. Non-radioactive in situ hybridization on coronal sections of hippocampi derived from wild 
type (A) and CBN/CBN (B) mice. The CBI riboprobe was the same as described in Chapter 2. 
Diaminobenzidin (DAB) was used as chromogenic substrate. Both sections were counterstained with 
toluidine blue. 
In conclusion, the Cre-mediated excision of CB 1 was shown to occur in a reliable and 
efficient way. This is an important observation, because the efficiency of the Cre/loxP system 
in the mouse can be influenced by many events that are very often unpredictable (Torres & 
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Kühn, 1997). Therefore, these results constitute a strong indication that the "conditional" 
deletion of CB 1 will be possible by using "floxed CB 1" mice as described in the next 
paragraph and suitable Cre-expressing mouse lines. Moreover, the lack of expression of CB 1 
in CBN/CBN mice will constitute a valuable tool for in vitro investigations (e. g. see Chapter 
5). 
4.3.6 Generation of "floxed mutant" "floxed CB1" line) 
As mentioned in the Introduction of this Chapter, one of the key points of a conditional 
gene targeting approach is the completely wild type expression of the gene of interest before 
the Cre-mediated excision (i. e. before the crossing with a Cre-expressing mouse line). To 
achieve this result, the length of sequences artificially introduced into the genomic locus must 
be as short as possible. Any long sequence introduced might cause alterations in the wild type 
expression of the gene of interest. For this reason, given the presence of the 1.8 kb "PGK- 
Neo" cassette in the 3' region of CBI locus, the "flox-Neo" mouse line obtained from the 
gene targeting and the blastocyst injection of the ESCs, cannot yet be considered as optimal 
for a further conditional gene mutation. The "PGK-Neo" cassette used for the gene targeting 
construct is flanked by two recombination sites, different from loxP (Fig. 4.2B and Fig. 
4.7A). These are FRT sites, and they are recognized by a yeast derived recombinase, called 
flipase (flp) (Dymecki, 1996). The flp/FRT system is less efficient than the Cre/loxP one at 
37°C, but still maintains a certain activity (Buchholz et al., 1996). Since efficient transfection 
conditions of a flipase-expressing vector into ESCs are still to be established, it was decided 
to induce the excision of the FRT-flanked PGK-Neo cassette by crossing the "flox-Neo" 
mouse line with a "flipase-deleter" mouse line. In this transgenic mouse line, the recombinase 
is under the control of the constitutively active promoter of the human (3-actin gene and is, 
therefore, rather ubiquitously expressed (Dymecki, 1996). The deletion of the "PGK-Neo" 
cassette in the progeny of this cross was checked by PCR and by Southern blot analysis on 
tail-derived genomic DNA. PCR was performed using the primers G52 and G53 (Tab. 4.1 
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and Fig. 4.10A). These primers anneal to wild type sequences on either side of the AcII 
restriction site where the loxP-PGK-Neo cassette was inserted (Fig. 4.6). On wild type alleles, 
G52/G53 gave an amplification product of 418 bp, whereas in the "PGK-Neo"-deleted 
alleles, the product is 520 bp, clearly distinguishable from wild type in a 1.5% agarose gel. 
Alleles where no deletion has occurred should give a >2 kb band. However, in a 
heterozygous state, the presence of the much shorter wild type and "Neo-deleted" products, 
which are more efficiently amplified in the PCR reactions than the >2 kb band, made it 
impossible to distinguish between animals where the recombination was complete and animals 
where a "mosaic" situation was present. In fact, given the relatively low efficiency of the 
flp/FRT system at 37°C (Buchholz et al., 1996), it was expected that in the F1 generation 
("flox-Neo" heterozygous mice crossed with heterozygous "Flp-deleters"), single animals 
would be mosaic, with the deletion of the "PGK-Neo" cassette only in limited number of 
cells. However, in the Fl generation, about 50% of the animals carrying the Flp transgene 
showed to have at least a mosaic deletion of the "PGK-Neo" cassette (Fig. 4.10B). The 
"mosaic" situation of the F1 generation was confirmed by checking the germ line transmission 
of the deletion of the "PGK-Neo" cassette. Only mice where the deletion had occurred in 
germ line cells were expected to be able to transmit the mutation to the next generation, after 
mating with wild type C57BL/6 mice (F2 generation). Indeed, by using PCR analysis (using 
primers G52 and G53) on tail-derived DNA from offspring of the F2 generation, only about 
10% of the mice were shown to contain the deletion of the "PGK-Neo" cassette (Fig. 4.1 OC). 
These mice were further used for breeding a new mouse line, called "Floxed CB I" line. To 
confirm the reliability of the PCR-based genotyping, Southern blot analysis was also 
conducted in F3 generation mice (F2 generation "Floxed CB 1" crossed with wild type 
C57BL/6 mice) (Fig. 4.10D). BamHI digests of genomic DNA from mouse tails were 
electrophoresed, blotted and hybridized with the CB 1 Hill probe (Fig. 4.4). 
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Fig. 4.10. Flipase-mediated deletion of the "Neo" cassette and generation of the "floxed CB 1" mouse 
line. A. Schematic representation of the wild type allele (WT), the "flox-Neo" allele and the "flox" allele 
after the flipase-mediated deletion of the ' Neo" cassette. Symbols are as in Fig. 4.7. B. PCR analysis of 
individuals of the FI generation obtained by mating heterozygous "flox-Neo" with heterozygous "Flp- 
deleter" mice. About 50% of the offspring mice containing the Fip transgene carried the deleted allele. 
C. PCR analysis of F2 mice obtained by mating Fl deleted mice (as in A) with C57BL/6 wild type 
mice. Only 10% of these mice carried the germ line-transmitted deletion, indicating a "mosaic" status of 
most mice that carried this deletion in the F1 generation. D. Southern blot analysis of 4 individuals of 
the F3 generation (F2 x wild type). 
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As expected, about 50% of the F3 offspring carried both the wild type band of 4.7 kb 
and the "flox" band of 2.5 kb. No animal contained the 4.0 kb band, thus, excluding the 
possibility of residual presence of the "PGK-Neo" cassette. 
The "floxed CB 1" mouse line was then ready for further experiments, in which crossing 
it with specific Cre-expressing mouse lines should generate progeny carrying a spatially 
and/or temporally conditioned deletion of the CB 1 ORF. This progeny should allow the 
analysis of region-specific functions of CBI and the cannabinoid system in mouse brain 
physiology. 
4.4 Discussion 
In this Chapter, the generation of CB 1 mutant mouse lines is described. The steps 
involved in this task were: screening of a genomic DNA phage library, characterization of the 
CB 1 genomic locus, generation of a "conditional" gene targeting construct, transfection and 
selection of embryonic stem cells, injection of positive clones into mouse blastocysts, 
generation of mouse chimeras and germ line transmission of the mutation, and, finally, 
breeding of mutant animals to obtain two different mouse lines. These are the CB 1-null 
"CBN" line) and the "floxed CB V" line. The first one was obtained by crossing mice 
containing the original gene targeted sequences "flox-Neo" line) with "Cre-deleter" mice, 
which express Cre recombinase in an ubiquitous manner (Schwenk et al, 1995), thus, 
deleting the CBI ORF in the progeny. FI mice were crossed with wild type C57BL/6 mice, 
obtaining F2 progeny to check the germ line transmission of the deletion of the CB 1 ORF. In 
this way, two aims were accomplished: first, the Cre recombinase was actually able to delete 
the "floxed" CBI, in vivo, thus, providing the direct demonstration that the "conditional" gene 
targeting approach indeed works in the CBI locus; second, CBI null mutant mice ("CBN" 
line) were generated in order to analyze the CB 1 functions in experimental conditions where 
no spatio-temporal resolution is required, such as in in vitro cell biology assays (see Chapter 
5). The second mouse line generated during the work was obtained by crossing the gene- 
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targeted allele with "flipase-deleter" mice, expressing the enzyme flipase in an ubiquitous 
manner (Dymecky, 1996). Fl mice were then used for further crossing with wild type 
C57BL/6 mice to check for the germ line transmission of the flipase-mediated deletion of the 
"PGK-Neo" cassette. Flipase is able to recognize and recombine short sequences, called FRT, 
in an analogous fashion as Cre recombinase with loxP sites (Buchholz et al., 1996). In the 
gene targeting construct, FRT sites, flanked the selection cassette "PGK-Neo", necessary for 
the selection of positive targeted clones in ESCs. As the presence of this cassette might be 
deleterious for a perfect wild type expression of the "floxed" gene of interest, the deletion of 
the selection cassette is a necessary step for the generation of an optimal "conditional" 
inactivation of any gene. The mouse line obtained in this way, the "floxed CB I" line, is the 
starting mouse line for any "conditional" knock-out approach to analyze the behavioural 
functions of CB 1, in the living mouse. 
In "conditional" gene inactivation using the Cre/loxP system, the expression of the Cre 
recombinase is of fundamental importance. The regulatory sequences driving the expression 
of Cre recombinase in the transgenic mice are currently the main limiting points of this 
technique. Expression of the recombinase in specific areas or cell types and, possibly, at 
specific time points is often required. Such characteristics are present in some genes 
expressed in the brain. As an example, 8.5 kb from the promoter of the CaMK IIa gene, 
encoding the calcium/calmodulin-dependent kinase, can direct Cre expression and, thus, Cre- 
mediated recombination into specific forebrain areas at postnatal stages in transgenic mice 
(Tsien et a1., 1996; Minichiello et al., 1999). CB 1 is widely expressed in the mouse brain 
(Matsuda et al., 1993; Tsou et al., 1998a; see Chapter 2 and 3), and, in single brain areas, 
specific cell types appear to coexpress CB 1 with various neuronal cell markers. In the mouse 
forebrain, CB 1 is expressed partly in GABAergic and non-GABAergic (glutamatergic) cells 
(Marsicano & Lutz, 1999; Katona et a1., 1999; Chapter 2). Glutamic acid decarboxylase 65K 
(GAD 65), a specific marker for GABAergic cells, is coexpressed with CB 1 in a subset of 
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cells of hippocampus, neocortex, entorhinal cortex, amygdala and striatum, while the 
neuropeptide cholecystokinin (CCK), a marker for a subset of both GABAergic and 
glutamatergic cells, is highly coexpressed with CB 1 in hippocampus, neocortex, entorhinal 
cortex, amygdala, but not in striatum. Thus, transgenic mice carrying Cre recombinase under 
the control of GAD 65 and CCK, respectively, after crossing with the "floxed CBI " line, 
could lead to the excision of the gene in specific neuronal subpopulations. "GAD 65-Cre" 
should lead to the disruption of CB 1 in all GABAergic cells, while "CCK-Cre" should lead to 
the lack of CBI in both GABAergic and glutamatergic cells, but leave CBI expression still 
intact in basal ganglia, thus possibly avoiding locomotor defects that were observed in the 
CB 1 knock out mice of Zimmer et a1. (1999). 
The major limitation of the Cre/loxP system is the temporal control. Cases like the 
CaMK IIa gene with a perinatal start of expression, are very rare. GAD 65 and CCK are 
expressed at very early embryonic stages (Pinal & Tobin, 1998; Lay et al., 1999). As a 
consequence, in GAD 65-Cre or CCK-Cre mice with "floxed CBI", recombination would 
occur already during development. Therefore, there is the risk of inactivating the gene in 
neuronal precursors, with the final result of a mouse lacking CB 1 in the great majority of 
neurons, including many cells not expressing GAD 65 or CCK in the adult. Therefore, 
inducibility of Cre activity is needed to use such such promoters for Cre expression to best 
effect. Recent reports (Indra et al., 1999; Li et al., 2000) have suggested that a fusion protein 
of a mutated estrogen receptor ligand binding domain (ET2) and Cre recombinase is an useful 
tool to regulate the activity of Cre recombinase. This fusion protein is normally inactive, but 
can be activated by administration of the synthetic steroid hormone tamoxifen. Using this 
method, a broad range of regulatory sequences is now suitable to drive the expression of Cre 
recombinase, regardless of its "intrinsic" start of expression. Such "inducible" Cre-expressing 
transgenic mouse lines under the control of GAD 65 and CCK are in progress to be generated 
in the laboratory of Dr. Lutz. 
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As mentioned above in this paragraph, the generation of a "conventional" CB 1- 
deficient mouse line, named CBN, can constitute an useful source of primary tissues where 
CB 1 expression is totally abolished. These tissues can be used in experiments where no 
spatio-temporal specific disruption of the gene is necessary. One example is the use of 
primary neuronal cultures, in which the functions of CB 1 can be studied by comparing the 
characteristics of wild type cells and of the CB 1-deficient cells in different experimental 
conditions. Such an approach will be adopted in the next Chapter, where the role of CB 1 in 
neuroprotective properties of cannabinoids will be analysed in oxidative stress experiments. 
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Chapter 5 
Neuroprotective properties of cannabinoids in vitro: role 
of CB1 
The work described in this Chapter is in preparation as Marsicano, Moosmann, Behl & 
Lutz. My contributions were the generation of CB 1-expressing cell lines and their 
characterization, the preparation of primary cerebellar granule cells and the in vitro 
neurotoxicity assays. Bernd Moosmann contributed the biochemical antioxidant assay. 
Results are given without discriminating the various contributions in order not to disrupt 
the completeness of the experimental strategy. 
5.1 Introduction 
Natural and synthetic cannabinoids, as well as endocannabinoids, appear to exert 
most of their actions in the central nervous system through the "brain type" cannabinoid 
receptor 1, CB 1 (Matsuda et al., 1990; Zimmer et al., 1999; Ledent et al., 1999). 
However, non CB 1-mediated actions of many cannabinoids have been proposed. In 
particular, the highly lipophilic character of many cannabinoids (see Chapter 1.3.3 "CB 1 
ligands") could be the basis for a direct interference with cell membranes (Hillard et al., 
1985). 
Neuroprotective effects have been proposed for natural, synthetic and endogenous 
cannabinoids in several in vitro and in vivo neurotoxicity models (Hampson et al., 
1998a; Nagayama et al., 1999; Sinor et al., 2000). However, the exact mechanism(s) 
mediating neuroprotection have not been clearly understood yet. "Classical" and "non 
classical" cannabinoids, such as 09-THC and CP 55,940 contain a phenolic ring (Fig 
5.1). This chemical structure could confer the antioxidant activity to the lipophilic 
cannabinoids able to enter the cell membrane (Moosmann & Behl, 1999). Indeed, 
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"classical" cannabinoids, such as the CBI agonist A9-THC and the non CBI-binding 
component of Cannabis sativa cannabidiol, were shown to protect cells from oxidative 
stress (Hampson et al., 1998a). These observations would indicate a completely 
receptor-independent action of cannabinoids in this regard. Indeed, for many phenolic 
natural and synthetic compounds, a protective activity against oxidative stress, 
independent of any specific receptor-mediated action, has been recently proposed 
(Moosmann & Behl, 1999). However, CB 1 has been implicated in some neuroprotective 
mechanisms. WIN 55,212-2, a potent CBI agonist belonging to the family of 
aminoalkylindoles (see 1.3.3 "CB 1 ligands"), exerted a potent neuroprotecting effects in 
a rat model of of global and focal ischaemia (Nagayama et al., 1999). Such an effect 
appeared to be blocked by the previous administration to the rats of the specific CB 1 
antagonist SRI 41716A, pointing to the involvement of CB 1 in this effect. Interestingly, 
in the same report, WIN 55,212-2 was also able to protect cultured rat primary cortical 
neurons from in vitro hypoxia and glucose deprivation, but this effect did not appear to 
be blocked by CB 1 or CB2 antagonists, thus, indicating different mechanisms of action 
in in vivo versus in vitro neuroprotection of WIN 55,212-2. 
In the present study, some aspects of neuroprotective effects of cannabinoid 
compounds, and the involvement of CB 1 in these effects, were analyzed. Biochemical 
assays were performed to test the chemical antioxidant potential of several 
cannabinoids, and their antioxidant neuroprotective effects were tested in cell lines and 
rat primary cerebellar granule cell models of oxidative stress. Nine compounds were 
tested in these experiments: four "classical cannabinoids" (A9-THC, cannabinol and 
cannabidiol as Cannabis sativa derivatives, and the synthetic HU 210); one synthetic 
"nonclassical cannabinoid" (CP 55,940); one aminoalkylindole (WIN 55,212-2); one 
metabolically stable synthetic analogue of anandamide (methanandamide); one CB 1 
antagonist (SR 141716A); one inhibitor of "anandamide transporter" (AM 404, see 
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Chapter 1,1.4.2 "Inactivation of endocannabinoids"). Subsequently, in order to analyze 
the involvement of CB 1 in the neuroprotective effects of various cannabinoid 
compounds, two genetic approaches were adopted. First, cannabinoids belonging to 
different subgroups (classed on their ability to activate CB 1 and their chemical 
antioxidant properties) were tested in oxidative stress assays, using cell lines stably 
transfected with CB 1 cDNA and expressing the functional receptor in comparison with 
parental wild type cells. Second, two cannabinoids, CP 55,940 (antioxidant and CB 1 
agonist) and WIN 55,212-2 (CB 1 agonist, but not antioxidant) were tested as 
neuroprotective agents in primary granule cell cultures derived either from CB 1-knock 
out mice (CBN mouse line, as described in Chapter 4) or from wild type controls. By 
these experiments, CB 1 was shown not to be directly involved in the mechanism(s) by 
which antioxidant cannabinoids protect cells from oxidative stress in vitro. Moreover, 
the ability of WIN 55,2121-2 to protect primary neurons (but not neuronal cell lines) in 
in vitro oxidative stress assays was also shown not to depend either by intrinsic 
antioxidant properties of the compound nor by a CB 1-mediated mechanism. 
5.2 Materials and methods 
5.2.1 Chemicals 
Cannabinoids were purchased from Sigma, Germany (A9-THC, cannabinol and 
cannabidiol), from Tocris, U. S. A. (CP 55,940, WIN 55,212-2, methanandamide, HU 
210 and AM 404) and from Sigma/RBI, Germany (SR 141716A). These compounds 
were prepared as 10 mM stock solutions in 100% ethanol (A9-THC, cannabinol, 
cannabidiol and methanadamide) or in 100% DMSO (CP 55,940, WIN 55,212-2, HU 
210 and AM 404). Forskolin was purchased from Sigma and was prepared as 10 mM 
stock solution in DMSO. 
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5.2.2 Brain lipid oxidation assays 
Dissected cerebral cortex of adult Sprague-Dawley rats was homogenized in 
3 volumes of degassed lipid buffer (20 mM Tris/HCI, 1 mM MgCl2,5 mM KCI, pH 7.4) 
with a Kontes glass homogenizer (all steps were performed at 4°C). After centrifugation 
(3000x g, 5 minutes), the pellet was solubilized by sonication in 3 volumes of lipid 
buffer supplemented with 0.5 M NaCl, incubated for 10 minutes, and centrifuged 
(100,000x g, 20 minutes). This step was repeated and followed by three washings using 
3 volumes of degassed water instead of lipid buffer. Finally, the pellet was resuspended 
in water at a concentration of 5 mg/ml protein, snap-frozen on dry ice and stored at - 
80°C. 
For the oxidation assay, the rat brain membrane preparation was diluted with PBS 
to a concentration of 0.6 mg/ml protein and sonicated. Cannabinoids to be tested were 
added to the 1-ml aliquots at various concentrations (final concentration of ethanol or 
DMSO was 0.4%) and the oxidative chain reaction was started by adding 50 µM 
ascorbate and incubated at 37°C. Six hours later, single photon counting was done for 1 
minute in a Beckman scintillation counter set in the visible light range. Data were 
corrected for the baseline photocurrent and normalized to control values. 
5.2.3 Cell cultures 
Tissue culture plates were purchased from NUNC (Germany). Sterile plastic tubes 
(50 ml and 15 ml) were purchased from Falcon (Germany). 
5.2.3.1 Cell lines 
The two neuroblastoma cell lines PC 12 and HT22 were used for oxidative stress 
experiments. Cells were cultured in complete DMEM at 37°C, 5% CO2 in humidified 
atmosphere. Complete DMEM consists of Dulbecco's Modified Eagles Medium 
(DMEM, LIFE Technologies GIBCO, Germany), supplemented with 15% (PC12 cell 
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line) or 10% (HT22 cell line) foetal calf serum (FCS, LIFE Technologies GIBCO, 
Germany) and 100 U/ml penicillin and 100 U/ml streptomycin (100x 
Penicillin/Streptomycin solution, LIFE Technologies G1BCO, Germany). Cells were kept 
on 10 cm-cell culture dishes and trypsinized prior to experiments. Briefly, after washing 
twice with sterile phosphate buffer saline (PBS, containing 139.9 mM NaCl, 2.7 mM KCI, 
10.1 mM Na2HPO4-H20,1.8 mM KH2PO4, pH 7.4), 3 ml of 0.5% Trypsin/1 mM EDTA 
(LIFE Technologies GIBCO, Germany) were added to the culture plate, and cells were 
incubated at 37°C for 10-15 minutes. Cells were pipetted to obtain a single cell 
suspension, reaction was stopped with complete DMEM, and cells were counted in a 
haemocytometer. 104 cells/well (PC 12 cell line) and 103 cells/well (HT22 cell line) were 
plated onto 96-well plates. Each well contained 100 µl of complete DMEM. Cells were 
incubated overnight and then used for the oxidative stress experiments (see below, 5.2.5 
"Oxidative stress assays"). In some experiments, differentiation of PC 12 cells was induced 
by treatment with 1 µM forskolin overnight. 
5.2.3.2 Primary cerebellar granule cells 
Primary cerebellar granule cells were obtained from Sprague-Dawley newborn rats 
(3 days old) and from newborn mice (3 to 6 days old). For genotyping of the CBN allele 
(Chapter 4), PCR was performed on DNA derived from tails of 1-2 day old pups. 
Homozygous wild type (WT) and homozygous CBN/CBN mice (CB 1 KO) were used 
for the experiments. The methods for isolation and culture of primary cerebellar granule 
cells were identical between rats and mice. Newborn animals were sacrified by 
decapitation and cerebella were isolated and put in ice-cold, sterile DMEM containing 
100 U/ml penicillin/streptomycin. Using a stereomicroscope which was placed into a 
cell culture hood, cerebella were dissected free of meninges and put into a 50-ml Falcon 
tube containing 10 ml of cold DMEM. 10 ml of 0.1% Trypsin/1 mM EDTA were then 
added to the tube and cerebella were incubated with gentle shaking for 10-20 minutes at 
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37°C. The tissue was then throughly pipetted first with 5-ml plastic pipettes and then 
with Pasteur glass pipettes. Tissues were centrifuged at 500x g for 4 minutes and then 
resuspended in 10 ml complete DMEM medium (see previous paragraph). After a 
further step of disruption by throughly pipetting in Pasteur glass pipettes, the tubes were 
let stand for 5 minutes at room temperature, in order to allow the heaviest debris to 
sediment. Supernatant, containing cells and small debris, was transferred to a fresh tube 
and centrifuged. Cell pellet was resuspended in 1 ml of complete DMEM. A drop of the 
cell suspension was checked under an inverse microscope for the presence of debris and 
cell clumps. Centrifugation and resuspension were repeated until the quantity of single 
cells was higher than tissue debris and cell clumps. At this point, cell suspension was 
counted with a haemocytometer and cells were plated onto poly-L-lysine-treated 96- 
wells plates, at a density of about 106 cells/well. Poly-L-lysine pre-tretament of plates 
consisted of an incubation for 1-2 hours at room temperature with 50 µl/well of a 
10 µg/ml sterile solution of poly-L-lysine (Sigma, Germany), followed by two washes 
with sterile PBS. After plating, cells were incubated at 37° C in a cell culture incubator. 
After two days, the cytostatic drug cytosin arabinofuranoside (Sigma, Germany) was 
added to each well at 10 µM (final concentration), in order to block the overgrowth of 
fibroblasts and glial cells. After 10-15 days of incubation, the cultures appeared to 
contain >90% neurons and were ready to be used in oxidative stress experiments (Fig. 
5.3C). 
5.2.4 CB1 expressing cell lines 
5.2.4.1 Cloning of CBI into an eukaryotic expression vector 
Molecular biology methods were as described in Chapter 4. Mouse CB 1 cDNA 
was obtained by PCR using as template clone G23.10 (Chapter 4,4.3.1.1 "Phage insert 
cloning"), and the high fidelity Pfu polymerase (Stratagene, Germany) was used to 
minimize the errors caused by PCR. The primer pair was G1-G2 (see Chapter 4, Table 
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4.1). PCR product was eluted from a gel and subcloned into the Smal site of pBlueScript 
KS (-) (pKS, Stratagene, U. S. A. ), to produce the clone G73.3. The insert was entirely 
sequenced to check for PCR-induced mistakes. A 1.6 kb BamHI Xhol fragment, 
containing the whole open reading frame of CB 1, was then subcloned into the 
corresponding sites of the eukaryotic expression vector pcDNA3 (Invitrogen, Germany) to 
generate clone G160.1, which was then used for the stable transfection of CBI in PC 12 
and HT22 cells. 
5.2.4.2 Electroporation of cells and selection of resistant clones 
Electroporation protocols were identical for PC 12 or HT22 cell lines. A confluent 
10-cm cell culture plate was trypsinized as described above (5.2.3 "Cell cultures"). 
Single cells were transferred into a 50-ml Falcon tube and centrifuged for 4 minutes at 
200x g. Cell pellet was resuspended in 390 pl of electroporation buffer (50 mM 
K2HPO4,63.9 mM K2HPO4,16.17 mM potassium acetate, pH 7.35). 10 µl of 1M 
MgSO4 were freshly added to the cell suspension. Cell suspension was carefully mixed 
with 10 µl of a solution containing 1 pg/gl of Notl-linearized plasmid G160.1. The 
mixture was then transferred to an electroporation cuvette (BioRad, Germany). 
Electroporation was performed in a Gene Pulser electroporation apparatus (BioRad, 
Germany) at the following settings: 0.3 kV, 500 µk'. After electroporation, cells were kept 
on ice for 5 minutes and then plated onto a 10-cm cell culture plate with complete DMEM. 
Cells were incubated for two days and medium was changed every 24 hours to remove 
dead cells. Cells were then split at dilutions 1: 3 (PC 12) and 1: 4 (HT22), and selection with 
geneticin (G418, LIFE Technologies GIBCO, Germany) was started. Preliminary dose- 
response experiments on parental cells showed that 3.5 mg/ml and 2.5 mg/ml were the 
optimal concentration of G418 to induce cell death in HT22 and PC 12 cells, respectively 
(data not shown). After 8-10 days selection, resistant cell clones became readily visible 
and were picked with the aid of sterile 200 pl pipette tips. Clones were transferred to 24- 
140 
well plates containing 0.5 ml of complete DMEM. Cells were pipetted up and down to 
disrupt the colony and obtain a single cell suspension. Clones were grown until they 
formed confluent monolayers (medium was changed every two days). Confluent clones 
were trypsinized and transferred to 6-cm cell culture plates. After reaching confluence, 
cells were split to a 10-cm cell culture plate. At confluency, cells were split at dilution 1: 3. 
After 2-3 days, cells from two plates were frozen (see Chapter 4,4.2.2.3 "Electroporation 
of ESCs, antibiotic selection, picking and expansion of resistant clones"), whereas one 
plate was used for RNA extraction. After Northern blot screening, positive cell clones 
were thawed and expanded to generate several aliquots of frozen cells. 
5.2.4.3 Northern blot analysis of resistant clones 
RNA extraction from confluent 10-cm cell culture plates was performed using the 
PeqGold RNApure kit (PeqLab, Germany), following the manufacturer's instructions. 
All plasticware used for Northern blot analysis was treated with 1M NaOH and 
subsequent rinses with RNase-free water to get rid of RNAase; all solutions were 
prepared RNase-free by DEPC treatment and autoclaving. RNA extracts were 
electrophoresed in a gel containing Ix running buffer, 1% agarose and 6% 
formaldehyde. Running buffer was prepared as al Ox solution containing 200 mM 3-(N- 
morpholino) propane sulfonic acid (MOPS), 50 mM sodium acetate, 10 mM EDTA, pH 
7.0. Samples were prepared by mixing on ice 4 µl of RNA (5 µg/µ1) and 16 pl 
denaturing mix. After incubation at 55°C for 15 minutes, samples were chilled on ice 
and 2. l of loading buffer were added. Denaturing mix consists of 200 µl formamide, 70 
µl of 37% formaldehyde, 40 µl of lOx running buffer and 10 µl H2O. Loading buffer 
was prepared as al Ox stock solution containing 50% glycerol, 1 mM EDTA, 0.2% 
bromophenol blue. After electrophoresis, capillary blot was performed in 1Ox SSC, as 
described in Sambrook et al. (1989) to transfer RNA onto Hybond NX filters (Amersham, 
USA). Hybridization was performed using the fragment CB I HIII as probe (see Chapter 4, 
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Fig. 4.4). Probe labeling was performed using the Random Primers DNA Labeling System 
kit (LIFE Technologies GIBCO, Germany) following the manufacturer's 
recommendations. Hybridization was performed as Southern hybridization (see Chapter 4, 
4.2.1.5.2 "Hybridization") with the only differences that pre-hybridization, hybridization 
and washing were at 68°C. Washed membranes were exposed 1-3 days onto 
autoradiography films (DuPont, U. S. A. ). 
5.2.5 Oxidative stress assays 
The day before the experiment, cell lines were plated onto 96-well plates as 
described above (5.2.3 "Cell cultures"). Cannabinoids were prepared as pre-dilutions in 
ethanol or DMSO, and 1 pl of each pre-dilution was added to each well containing the 
cells and 100 µl of medium. Controls were obtained by adding 1 µl of 100% ethanol or 
DMSO to each control well. Experiments were performed in triplicate or quadruplicate 
and were repeated at least twice for each cell clone or primary cell culture. After adding 
the drug, cells were incubated overnight, and then, different concentrations of H202 
(prepared in sterile water) were added, ranging from 60 pM to 250 µM. The volume of 
the H202 pre-dilution added to each well was 1 to 3 pl. After overnight incubation, 10 
pl of a5 mg/ml solution in water of dimethylthiazollyl-diphenyl-tetrazolium bromide 
(MTT, Sigma, Germany) were added to each well. MTT, which is normally yellow, is 
transformed in the mitochondria of living cells into the insoluble precipitate formazan, 
that appears blue. After 4 hours MTT incubation at 37°C, 100 µl of cell lysis solution 
(45% dimethylformamide, 10% SDS, pH 4.2) were added to each well. Lysis was 
allowed overnight at room temperature and the day after the plates were read with 
Dynatec microplate reader (Germany) set at a 570 nm wave length. Cell death was 
indicated by a decreased MTT reaction and thus by a decreased absorption at 570 nm. 
Values in the wells where both vehicle (ethanol or DMSO) and H202 were added 
(maximal death) were compared to the values of the wells where only vehicle was added 
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(maximal survival, 100%). The fraction between these values gave the maximal 
percentage of death in the experiment. Only experiments where a maximal cell death 
percentage of >70% (i. e. <30% survival) was obtained, were considered in the Results 
section. In order to compensate any proliferative or antiproliferative effects of the drugs, 
values derived from wells containing the different concentrations of cannabinoids and 
H202 were normalized to the corresponding concentration of drug in the absence of 
H202. To better compare the results of different experiments, data are given as 
percentages of the maximal theoretical protection (100%, corresponding to the value in 
vehicle-treated wells, without toxin), considering as 0% the maximal cellular death. 
Therefore, each value is calculated as follows: 
DS - TCS x 100, 
MP - TCS 
where DS is the drug-induced percent of survival, TCS is the cell survival in the 
presence of H202 alone (with <30% as the limit for the acceptance as a successful 
experiment), and MP is the theoretical maximal protection (100%, corresponding to 
vehicle-treated cells). 
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5.3 Results 
5.3.1 Cannabinoids as antioxidative and neuroprotective agents 
Cannabinoid compounds are generally classified into four different chemical 
groups, based on their structural characteristics (Pertwee, 1997; Fig 1.4). Regarding 
putative neuroprotective properties, cannabinoids can also be classified into three 
groups, based on whether or not they bind to cannabinoid receptors and whether or not 
they have a phenolic structure: i) phenolic compounds that do not bind CB 1 (Fig. 5.1 A); 
ii) non phenolic compounds that bind CBI (Fig 5.113); iii) phenolic compounds that 
bind CB 1 (Fig. 5.1 C). 
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Fig 5.1. Classification of cannabinoids on the basis of CB 1 binding and presence of phenolic 
moieties (in green). A. Phenolic cannabinoids with no or very low affinity for CB 1. B. 
Nonphenolic compounds with high affinity for CB 1. C. Phenolic cannabinoids with high 
affinity for CB 1. 
Accordingly, Fig 5.2A, B and C show the antioxidant properties of various 
cannabinoids and cannabimimetics. Compounds containing a phenolic group, such as 
cannabinol, cannabidiol, AM 404 (not binding CBI, Fig. 5.2A), and A9-THC, 
CP 55,940 and HU 210 (binding CB I, Fig. 5.2C) were shown to be potent antioxidants 
in a brain lipid oxidation assay. On the other hand, cannabinoids not containing a 
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phenolic ring, such as methanandamide (a stable analogue of anandamide), WIN 
55,212-2 and SR 141716A did not show any antioxidant activity in the same assay (Fig 
5.2B). Oxidative stress experiments in HT22 cells generally reflect the chemical 
antioxidant properties of the tested compounds, e. g. oestrogenic drugs (Bernd 
Moosmann, personal communication). Therefore, this notion was tested here for 
cannabinoids. Indeed, the same compounds that showed biochemical antioxidant 
properties resulted also in potent protection for H202-induced oxidative stress in HT22 
cells (Fig. 5.2A', C'), whereas the non phenolic compounds, regardless of whether they 
were CB 1 agonists (methanandamide and WIN 55,212-2) or CB 1 antagonists 
(SR 141716A), were not able to protect the cells from oxidative stress (Fig. 5.2B'). 
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Fig 5.2. Antioxidant properties of cannabinoids and protection against oxidative stress in HT22 
cells. A, B, C, percentages of inhibition of oxidation of brain lipids induced by 50 . tM 
ascorbate. 100% indicates maximal oxidation in the absence of any cannabinoid. A', B', C', 
percentages of protection against oxidative stress in HT22 cells, induced by 120 µM of H202. 
0% indicates the cell death in the absence of cannabinoids. 100% indicates the maximal 
possible protection against oxidative stress. Data are indicated as ± s. e. m. 
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These results seem to indicate the antioxidant properties of cannabinoids as the 
main mean through which they exert neuroprotection in oxidative stress assays. 
However, neither HT22 nor PC 12 cells express CB 1 (see below, Fig. 5.4). Therefore, 
from these results, it cannot be excluded that cannabinoid-mediated neuroprotection is 
dependent in part on a receptor-dependent mechanism. Thus, as a source of CB 1- 
expressing neurons, rat primary cerebellar granule cells cultures were assessed and 
tested in similar oxidative stress paradigms. 
5.3.2 Cannabinoids are neuroprotective in rat cerebellar granule cells 
Neuroprotective properties of cannabinoids were then assessed in oxidative stress 
assays carried out on cultured primary cerebellar granule cells which are known to 
contain CB 1 protein (e. g. Hillard et al., 1999). Four CB 1 agonists were chosen for these 
tests, namely the two non phenolic compounds methanandamide and WIN 55,212-2 and 
the two phenolic antioxidant compounds CP 55,940 and HU 210. Fig. 5.3A and C show 
that CP 55,940 and HU 210 possess similar neuroprotective potentials as in HT22 cells 
(Fig. 5.2C, C'). These results indicate that phenolic cannabinoids are able to protect 
primary granule cells in in vitro oxidative stress assays. In contrast, the results with the 
other two compounds, WIN 55,212-2 and methanandamide, seem to indicate different 
mechanisms of cannabinoid protection in neuronal cell lines and cultured primary 
neurons. These compounds belong to the group of CBI-binding molecules that are 
neither phenolic (Fig 5.1B), nor antioxidant or protecting HT22 cells from oxidative 
stress (Fig 5.2B, B'). Fig. 5.3B shows that methanandamide does not appear to have any 
neuroprotective effect on granular neurons at any of the concentrations tested, whereas 
WIN 55,212-2 seems to be able to protect granular neurons from oxidative stress, as 
protection values of 43±0.5% and 25±0.6% were reached at 1 µM and 10 µM, 
respectively. 
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Fig. 5.3. Cannabinoid-mediated neuroprotection in oxidative stress assays on cultured primary 
rat cerebellar granule cells. A. Neuroprotective effects of CP 55,940 and HU 210 (phenolic 
antioxidant CB 1 agonists). B. Neuroprotective effects of WIN 55,212-2 and methanandamide 
(non phenolic CB1 agonists) C. Phase contrast micrographs showing examples of CP 55,940- 
mediated neuroprotection in cultured primary rat cerebellar granule cells. In A and B, results 
are presented as in Fig. 5.2A', B', C'. 
These results indicate that in oxidative stress assays conducted with primary 
cerebellar granule cells, the protective properties of some cannabinoids cannot be only 
attributed to their biochemical antioxidant actions, and hence, the question remains of 
whether a receptor-mediated mechanism exists. 
5.3.3 Cannabinoid-mediated neuroprotection in neuronal cell lines expressing CB1 
Cerebellar granule cells express CBI (Matsuda et at, 1993; see also Chapter 1). 
Therefore, it is possible to hypothesize that the presence of the receptor may account for 
the differences in in vitro neuroprotective properties of different cannabinoids (i. e. WIN 
55,212-2) observed in neuronal cell lines as compared to primary neuronal cell cultures. 
control +H2O2 +H201+CP 55,940 
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To test this hypothesis, two neuronal cell lines not endogenously expressing CB 1, 
HT22 and PC 12, were stably transfected with an expression vector coding for the mouse 
CB 1. Such an expression vector contains also the cDNA for the neomycin 
phosphotransferase gene, conferring antibiotic resistance to G418 (see also Chapter 4). 
After transfection of the cells and 8 days of selection in 2.5 mg/ml and 3.5 mg/ml G418 
for HT22 and PC 12 cells, respectively, 18 resistant clones were picked for each cell line, 
expanded and checked for the expression of CB 1 mRNA by Northern hybridization. 
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Fig 5.4. Northern blot analysis of HT22 and PC 12 cell clones, after stable transfection with the 
expression vector G160.1, containing the mouse CBI cDNA. Ribosomal RNA was used as 
molecular weight marker (28S, approximately 4.6 kb; 18 S, approximately 1.9 kb). The fragment 
CB 1 HIII (see Chapter 4, Fig. 4.4) was used as probe. Mouse cortex RNA, containing high levels 
of CB 1 RNA (about 6.0 kb), was used as positive control. Negative controls were cell clones 
transfected with the empty expression vector (WT). Positive signals in clones HT22.18, PC 12.17 
and PC 12.18 correspond to a band of about 1.6-1.7 kb, consistent with the expected size. 
Cells transfected with an empty vector were used as negative controls (termed as 
PC 12 WT and HT22 WT). Fig 5.4 shows the results of Northern blots of HT22 and PC 12 
RNA extracts, probed with the fragment CB I HIII (see Chapter 4, Fig. 4.4). The positive 
control was RNA from mouse cortex. Hybridization signals were detected at 
approximately 6.0 kb for cortex RNA, as previously described (Matsuda, 1997) and at 
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approximately 1.6 kb for many G418-resistant CB1-transfected clones. As expected, no 
band was present in G418-resistant clones transfected with the empty vector (PC 12 WT 
and HT22 WT). Clones HT22.18 and PC 12.17 (PC 12 CB 1 in Fig. 5.5) with their 
respective parental negative controls (WT) were used for further experiments (Fig. 5.4). 
Fig. 5.5 shows the neuroprotective effects of four CBI agonists in PC 12 cells either 
expressing (PC 12 CB 1) or not expressing (PC 12 WT) the receptor. 
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Fig. 5.5. Cannabinoid-mediated neuroprotection in in vitro oxidative stress assays on PC 12 cells 
expressing CB 1 (PC 12 CB 1) and not expressing CB 1 (PC 12 WT). Results are presented as in Fig. 
5.2A', B', C'. Note the lack of difference between the two cellular genotypes. 
The four CB 1 agonists to be tested were chosen in light of their previously 
determined effects in the antioxidant assay and in the oxidative stress assays in HT22 cells 
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and primary cerebellar granule cells cultures (Fig. 5.2 and 5.3). A9-THC and CP 55,940 
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were used as prototypes of the phenolic antioxidant group, while methanandamide and 
WIN 55,212-2 represented non phenolic-non antioxidant compounds (Fig. 5.2). As shown 
in Fig 5.5A and B, the two phenolic compounds A9-THC and CP 55,940 were able to 
protect PC 12 cells up to values of 60-70% and 55-60%, respectively. However, no 
difference was observed between the wild type (PC 12 WT) and the CBI-expressing 
(PC 12 CB 1) clones. The dose-response curves were almost identical, thus indicating that 
the presence of CB 1 was altering neither the efficacy nor the potency of the drugs. Once 
again, methanandamide (Fig. 5.5C) showed no ability to protect cells from oxidative 
stress, neither in the absence nor in the presence of CB I. Also WIN 55,212-2 (Fig. 5.5D), 
despite some apparent effect at low concentrations, could not show any reliable and 
significant protective effect even at concentrations as high as 10 µM. Similar experiments 
using HT22 WT and HT22.18 gave very similar values as the ones depicted in Fig. 5.2B' 
and C', and no difference was observed between the two different genotypes (data not 
shown). These observations indicate that CB 1 is not required for the protective effects of 
cannabinoids in in vitro oxidative stress assays in neuronal cell lines. Neither WIN 55,212- 
2, which is able to protect primary cerebellar granule cells, did show any clear effect in 
CB 1-expressing cell lines. 
5.3.4 Cannabinoid-mediated neuroprotection in primary cerebellar granule cells 
from CB1 knock out mice 
WIN 55,212-2 was shown to protect rat primary granule cells from oxidative stress 
(Fig. 5.3B), but not neuronal cell lines regardless the presence of CBI (Fig. 5.2B' and 
Fig. 5.5D). It is possible that in primary cultures, the presence of CBI is associated with 
other factors that are absent in neuronal cell lines. If this is the case, WIN 55,940 should 
not be able to protect cultured primary granule cells that do not contain CB I. In order to 
test this hypothesis, primary cerebellar granule cell cultures were assessed from WT and 
CB I knock-out mice (CBN/CBN, see Chapter 4). 
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Fig. 5.6. Cannabinoid-mediated neuroprotection in in vitro oxidative stress assays on primary 
cerebellar granule cell cultures derived from wild type mice (WT) and homozygous CBN/CBN 
littermates (CB1 KO, see Chapter 4). Results are presented as in Fig. 5.2A', B', C'. Note the lack 
of difference between the two genotypes and the protection caused by WIN 55,212-2. 
CP 55,940 was used as phenolic antioxidant cannabinoid, and its effects were 
compared to WIN 55,212-2. Fig. 5.6A shows that CP 55,940 was able to protect WT and 
CB 1-KO cells as much as 40%, whereas WIN 55,212-2 (Fig. 5.6B) showed a protection to 
almost 60%. However, no difference was observed between WT and CB1-KO cells. These 
results indicate that CB 1 is not necessary for the neuroprotective activity of CP 55,940 and 
WIN 55,212-2 in the in vitro oxidative stress assays using H202. 
5.3.5 Cannabinoid-mediated neuroprotection in differentiated PC12 cells 
Although at high concentrations, WIN 55,212-2 is able to protect primary granule 
cells in a CB 1-independent manner, but not neuronal cell lines. Neuronal cell lines share 
many characteristics with neurons, but have also some important differences. One of the 
most important is that neuroblastoma cell lines consists of proliferating and relatively 
undifferentiated cells, whereas mature neurons do not proliferate. It is, therefore, 
possible that the differentiation state of the cells play a role in the differential protective 
effects of WIN 55,212-2. In order to test this hypothesis, neuronal differentiation was 
induced in PC12 cells by treatment with forskolin (Caillaud et al., 1995). 
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Fig. 5.7. Protection against oxidative stress in undifferentiated (PC 12) and differentiated 
(PC 12 +1 µM forskolin) PC 12 cells. Results are given as in Fig. 5.2 A', B', C'. 
After overnight treatment with 1 µM forskolin, PC 12 cells showed a neuron-like 
morphology (not shown). Fig. 5.7A shows that 19-THC was equally able to protect 
undifferentiated and differentiated PC12 cells. However, WIN 55,212-2 was not able to 
protect either of the two cell types against oxidative stress (Fig. 5.7B). These results 
indicate that the differentiation state is unlikely to account for the differential 
neuroprotective effects of WIN 55,212-2 on PC 12 cell line and on primary neurons. 
5.4 Discussion 
In this Chapter, the neuroprotective properties of cannabinoids were analysed in in 
vitro oxidative stress assays. Oxidative stress represents one of the major events that 
occurs during neurodegeneration in many neurological diseases (Behl, 1999a; Browne et 
al., 1999; Fahn & Cohen, 1992). Therefore, drugs which are able to inhibit these processes 
are ideal candidate for the treatment of such diseases. Chemical antioxidants, e. g. vitamin 
E (Behl, 1999b), are examples of these neuroprotective drugs. However, oxidative stress is 
accompained by a series of complex intracellular events that contribute to the cell death 
and that can be modulated also by means other than a simple chemical antioxidant activity. 
As an example, oxidative stress and excessive activation of glutamate receptors, with the 
THC 
10 1 
consequent excessive intracellular concentration of Ca 
2- represent sequential and 
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interacting processes that provide a final common pathway for cell vulnerability in the 
brain (Coyle & Puttfarcken, 1993). Many cannabinoids have typical structural features 
of antioxidants, and on the other hand, through CB 1 activation, they are able to inhibit 
excitability of the cells, by increasing K+ and decreasing Ca 2+ permeability (see Chapter 
1,1.3.1 "Mechanisms of action" and references therein). Therefore, they could exert 
neuroprotective activities through different mechanisms and thus, possess very 
interesting therapeutic potentials for several neurodegenerative diseases. 
Several cannabinoids were tested in a biochemical antioxidant assay, and, as 
expected, phenolic compounds (09-THC, cannabinol, cannabidiol, CP 55,940, HU 210 
and AM 404), were found to be potent antioxidant. These observations were confirmed 
by in vitro oxidative stress experiments, by using two neuronal cell lines, PC 12 and 
HT22, and primary cerebellar granule cells: antioxidant phenolic cannabinoids were also 
protective against oxidative stress on the cells. However, one compound, WIN 55,212-2, 
a potent CB 1 agonist belonging to the family of aminoalkylindoles, was able to protect 
primary neurons but not cell lines. This observation is interesting, also in view of the 
fact that this compound is not a phenolic antioxidant. Other mechanism(s) should, 
therefore, be triggered by the drug in primary neurons that are not present in cell lines. 
The most obvious candidate for this differential protective mechanism appeared to be 
the presence of CB 1 in cerebellar primary neurons, but not in neuronal cell lines. One 
way to test this hypothesis would be to use the specific CB1 antagonist SR141716A in 
the same neurotoxicity assays, in combination with the CB 1 agonists (Nagayama et at., 
1999). However, SR141716A was shown to exert, both in vivo and in vitro, actions 
different from the simple antagonistic effect at CBI receptors. In CB 1-transfected cells 
and in endogenously CBI-expressing neuronal cell lines, SR 141716A was shown to act 
as an inverse agonist (Shire et al., 1999; Meschler et al., 2000) and, furthermore, in 
primary cerebellar granule cells, SR141716A was recently shown to exert different 
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effects on cannabinoid-mediated inhibition of Ca2+ mobility in different subcellular 
portions of the neurons. A mere antagonistic effect was observed at CB 1 receptors 
located in the neuntes, whereas a paradoxical "agonist-like" inhibition of Ca 
2+ influx 
was observed in the soma of the neurons (Hillard et al., 2000). A direct consequence of 
these observations is that, at least in in vitro experiments, the use of SR141716A cannot 
be considered always a reliable mean to detect receptor-mediated actions of CBI 
agonists. Therefore, the involvement of CB 1 in WIN 55,212-2-mediated 
neuroprotection was checked by two genetic approaches, i. e. in heterologously CB 1- 
expressing cell lines as compared to parental lines and in primary cerebellar neurons 
derived from wild type and CB 1-deficient mice (CBN/CBN, see Chapter 4). However, 
unexpectedly, no differences were observed in the neuroprotective activity of the drug in 
presence or in absence of CB 1. Another difference between primary neurons and 
neuronal cell lines is the differentiation state. It is possible that WIN 55,212-2 exert its 
neuroprotective actions only in differentiated postmitotic neurons and not in 
proliferating cell lines. However, even in forskolin-induced differentiated PC 12 cells, 
WIN 55,212-2 was not able to exert the same neuroprotective actions as observed in 
primary neurons. 
An intriguing hypothesis that could explain the effects of WIN 55,212-2 in 
neuronal protection of primary neurons is that these actions are mediated by another 
receptor, distinct from CB 1. WIN 55,212-2 is a potent agonist of CB 1, but is also able to 
bind and activate the "peripheral" cannabinoid receptor, CB2 (Pertwee, 1997). However, 
despite discordant reports (Skaper et al., 1996), CB2 does not appear to be functionally 
present in cerebellum (Griffin et al., 1999). Interestingly, recent results showed that 
WIN 55,212-2 is able to stimulate G proteins in cerebral membranes derived from CB 1- 
deficient mice, thus strongly suggesting the existence of a novel "cannabinoid receptor" 
(Breivogel et al., 2000). Therefore, it could be argued that this "third" receptor might be 
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the responsible for neuroprotective effects of WIN 55,212-2. However, preliminary 
experiments conducted in our laboratory to test the ability of the drug to inhibit 
forskolin-induced increases in cAMP production in primary cerebellar neurons from 
wild type and CBN/CBN mice, revealed that WIN 55,212-2 is able to inhibit cAMP 
accumulation in presence of CB1 but has no effect in mutant neurons. It appears, 
therefore, unlikely that the "third" receptor uses a similar signal transduction pathway to 
CB 1. However, G proteins can trigger also many other intracellular pathways. 
Experiments in this direction, in relation to the mechanisms underlying the 
neuroprotective properties of WIN 55,212-2 and the existence of a novel signal 
transduction pathway stimulated by the drug, are planned in the laboratories of Dr Lutz 
and Dr Behl. 
H202-induced oxidative stress in vitro is a relatively simple paradigm of 
neurodegeneration that can provide useful information about the neuroprotective aspects 
of several drugs. However, the in vivo situation, during neurodegenerative conditions 
induced by brain damage or diseases, is more complex than any in vitro models. As an 
example, cannabinoids, and WIN 55,212-2 in particular, were shown to act differentially 
in similar neurodegenerative models in vivo or in vitro (Nagayama et al., 1999). 
Therefore, the apparent CB 1-independent mechanism of protection of cannabinoids as 
observed in this in vitro study needs to be confirmed in vivo. In other words, an 
involvement of CB 1 in neuroprotection mechanisms during neurodegeneration, as 
shown, for example, by the increased CBI expression in particular brain areas during 
induced ischaemia in rats (Jin et at., 2000), cannot be excluded. Moreover, it could be 
proposed that the increased mortality observed by Zimmer et al. (1999) in CB 1-deficient 
mice might be due to a general decrease of neuroprotective mechanisms in which CB 1 
might play an important role in vivo. Therefore, experiments of in vivo 
neurodegeneration induced in different ways are planned, using CBN/CBN and/or 
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"conditional" CB 1 mutants (see Chapter 4) mice compared with wild type controls. 
In conclusion, in this Chapter, some aspects of neuroprotective properties of 
cannabinoids were analysed. The most important results are the purely antioxidant and 
CB 1-independent mechanism in neuroprotection in these particular in vitro paradigms 
using neuroblastoma cell lines, and the non antioxidant and CBI-independent 
neuroprotection induced by WIN 55,212-2 in cerebellar granule cells. These results 
would indicate the existence of a novel signal transduction pathway triggered by 
WIN 55,212-2 in cerebellar neurons. 
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Conclusions and future perspectives 
The work described in this thesis was designed to better understand some of the 
physiological functions of the "brain type" cannabinoid receptor CB 1 and of the 
cannabinoid system in the mouse central nervous system. Neurochemical and 
neuroanatomical aspects were analysed in Chapter 2 and 3, with some interesting 
findings regarding the distribution and the expression of CB 1 at cellular level. These 
findings further underline the potential central role of the cannabinoid system as a 
modulator of many of the brain functions in physiological and pathological conditions. 
Neurochemical and neuroanatomical results would indicate that the cannabinoid system 
might potentially influence both excitatory and inhibitory pathways in the brain and might 
establish many functional interactions with other signalling systems. 
A functional analysis of one of these putative interactions is presented in Chapter 3, 
where the effects of A9-THC were analysed in mice with a disrupted neuronal nitric oxide 
synthase (nNOS) gene. Results demonstrated that locomotor and hypothermic effects of 
the cannabinoid drug are absent in the mutant animals as compared to wild type controls, 
thus indicating a central key function of the nitric oxide (NO) pathway in these 
cannabinoid effects. Moreover, mutant animals have a selective reduction of CB 1 mRNA 
expression in particular brain areas, thus revealing a putative cross-talk between NO and 
cannabinoid system also at the level of expression control. These studies are still ongoing 
in Dr. Lutz's laboratory, with the discovery of decreased levels of CBI also in 
hippocampi of nNOS mutant animals. This will open new perspectives in the analysis of 
behavioural effects of cannabinoids in this mutant strain, regarding hippocampal- 
dependent learning and memory paradigms. Moreover, in collaboration with other 
groups in the Institute and outside, experiments are planned to analyse hippocampal 
electrophysiological responses to cannabinoids in nNOS-mutants and to measure 
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endocannabinoid content in several brain areas of the animals, in an attempt to find 
putative mechanisms through which the cross-talk between cannabinoid and NO systems 
are interacting. Another interesting consequence of the results obtained in Chapter 2 is 
the putative existence of a functional cross-talk between the cannabinoid system and 
cholecystokinin (CCK). As discussed in this Chapter, CBI and CCK often have 
counteracting effects. Our group has recently obtained from Prof Linda Samuelson 
(U. S. A. ) mutant mice carrying a deleted CCK gene. In the near future, we will analyse 
the interactions between these two systems by treatment of this CCK-mutant with 
cannabinoids and by treatment of null (CBN) or "conditional" CB 1-mutants with CCK 
receptor agonists. Moreover, we will also analyse the expression pattern of genes 
involved in the cannabinoid and cholecystokinergic systems in these mouse strains, 
respectively. 
The work described in Chapter 4 has occupied my time during the entire duration 
of my thesis and is still ongoing. In this Chapter, a "conditional" gene targeting approach 
is described. Two mouse lines were obtained: "CBN", carrying a null mutation of CB 1, 
and "Floxed CBI",, representing the key element for a future spatio-temporal restricted 
deletion of CB 1. One aspect of the phenotype of the first line is already described in this 
Thesis (Chapter 5), but other experiments are also ongoing in our lab and in our 
Institute. For example, electrophysiological experiments revealed that induced long term 
potentiation is improved in the amygdala of homozygous CBN/CBN mice (Marsicano, 
Rammes & Lutz, unpublished results). This is a very interesting aspect that could 
indicate a central role of CBI in amygdala-dependent forms of learning and memory, 
such as cued fear conditioning. Experiments in this direction are planned in our 
laboratory. The "Floxed CB I" mouse line will be the central tool for the "conditional" 
deletion of the gene. As discussed in Chapter 4, the coexpression data obtained in 
Chapter 2 represent very interesting findings also in view of a spatio-temporal specific 
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deletion of CB 1. In fact, the regulatory sequences of CCK and glutamic acid 
decarboxylase (GAD) might provide a specific spatial restriction to the expression of Cre 
recombinase in transgenic mice. Together with the use of drug-inducible forms of Cre 
(see Chapter 4,4.4 "Discussion"), it will be possible to obtain a very finely regulated 
deletion of the CB 1 in cholecystokinergic and GABAergic neurons, respectively. In 
collaboration with other members of Dr Lutz's laboratory, the generation of these 
specific Cre-expressing transgenic mouse lines is planned for the near future. 
In Chapter 5, neuroprotective effects of cannabinoids were analysed in vitro. The 
involvement of CB 1 in these cannabinoid-mediated effects was analysed by heterologous 
expression in neuronal cell lines and in primary neuronal cultures derived from wild type 
and homozygous CBN/CBN mice. The results would indicate that CB 1 is not necessary 
for cannabinoid-mediated in vitro neuroprotection in oxidative stress assays, as 
protection appears to be principally due to chemical antioxidant properties of 
cannabinoids. However, a non-antioxidant CBI agonist (WIN 55,212-2) seems to exert 
CB 1-independent neuroprotective effects. Also this aspect of the cannabinoid system will 
be further studied in the future, with the aid of CB 1-mutant animals. As an example, it 
will be very interesting to analyse the differential responses of wild type and mutant 
("null" or "conditional") to various neurotoxic conditions in vivo. 
In conclusion, the preparation of this thesis represented a very exciting and 
challenging set of tasks, which allowed me to acquire knowledge of several technical and 
theoretical approaches to neurobiology and to be bewitched by the fascinating world of 
the cannabinoid system. For these reasons, I wish to keep on working on this specialized 
but apparently central aspect of mammalian brain physiology in the future. 
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